 
 
 
Protocol : I8F-MC -GPHL 
 
 Efficacy and Safety of Tirzepatide Once Weekly in Participants with Type 2  
Diabetes Who Have Obesity or Are Overweight: A Randomized, Double -Blind, 
Placebo -Controlled Trial (SURMOUNT- 2) 
  NCT 04657003 
  Approval Date: 23 -Nov-2020 
CONFIDENTIAL I8F-MC-GPHL
1Title Page
Confidential Information
The information contained in this document is confidential and is intended for the use of clinical investigators.  It is the 
property of Eli Lilly and Company or its subsidiaries and should not be copied by or distributed to persons not involved 
in the clinical investigation o ftirzepatide (LY3298176 ), unless such persons are bound by a confidentiality agreement 
with Eli Lilly and Company or its subs idiaries. 
Note to Regulatory Authorities:   This document may contain protected personal data and/or commercially 
confidential information exempt from public disclosure.  Eli Lilly and Company requests consultation regarding 
release/redaction prior to any public release.  In the United States, this document is subject to Freedom of Information 
Act (FOIA) Exemption 4 and may not be reproduced or otherwise disseminated without the written approval of Eli Lilly 
and Company or its subsidiaries .
Protocol Title :Efficacy and Safet y of Tirzepatide Once Weekly in Part icipants with Type 2 
Diabetes Who Have Obesit y or Are Overweight : A Rando mized, Double -Blind, Placebo-
Controlled Trial (SURMOUNT -2)
Protocol Number :I8F-MC-GPHL
Amendment Number: This is the init ial protocol.
Compound :LY3298176
Study Phase: 3
Short Title: Effect of Tirzepat ide versus Placebo in Parti cipants wi th Type 2 Diabetes Who 
Have Obesit y or Are Overweight (SURMOUNT -2)
Acronym:SURMOUNT -2
Sponsor Name: Eli Lilly and Com pany
Legal Registered Address: Indianapo lis, Indiana USA 46285
Regulatory Agency Identifier Number(s)
IND: 139721
Approval Date: ProtocolElectronically Signed and Approved by Lillyondate provi ded below.
Approval Date: 23-Nov-2020 GMT
CONFIDENTIAL I8F-MC-GPHL
2Medical Monitor Name and Contact Informatio n will be provided separately.
CONFIDENTIAL I8F-MC-GPHL
3Table of Contents
1. Protocol Summary ...................................................................................................... 6
1.1. Synopsis....................................................................................................................... 6
1.2. Schema....................................................................................................................... 12
1.3. Schedule of Act ivities (SoA) ...................................................................................... 13
2. Introduction .............................................................................................................. 20
2.1. Study Rationale.......................................................................................................... 20
2.2. Background................................................................................................................ 21
2.3. Benefit/Risk Assessment ............................................................................................ 22
3. Objectives and Endpoints ......................................................................................... 23
4. Study Design ............................................................................................................. 26
4.1. Overall Design............................................................................................................ 26
Overview of Study  Periods......................................................................................... 26
Study Procedures ........................................................................................................ 30
4.2. Scientific Rationale for Study Design ......................................................................... 30
4.3. Justification for Dose .................................................................................................. 31
4.4. End of Study  Definition.............................................................................................. 32
5. Study Population ...................................................................................................... 33
5.1. InclusionCriteria........................................................................................................ 33
5.2. Exclusion Criteria....................................................................................................... 34
5.3. Lifestyle Considerat ions............................................................................................. 39
Meals and Dietary  Restrictions................................................................................... 39
Physical Act ivity........................................................................................................ 40
Diabetes Education ..................................................................................................... 41
5.4. Screen Failures ........................................................................................................... 41
6. Study Intervention .................................................................................................... 42
6.1. Study Intervention(s) Administered ............................................................................ 42
Medical Devices ......................................................................................................... 42
6.2. Preparation/Handling/Storage/Accountabilit y............................................................. 43
6.3. Measures to Minimize Bias: Rando mization and Blinding .......................................... 43
6.4. Study Intervent ion Compliance ................................................................................... 44
6.5. Concomitant Therapy ................................................................................................ .45
Management of T2DM at randomizat ion.................................................................... 45
Initiation of New Ant ihyperglycemic Medicat ion....................................................... 45
Management of T2DM after randomizat ion................................................................ 46
6.6. Dose Modificat ion...................................................................................................... 47
Tirzepatide................................................................................................................. 47
Managem ent of Parti cipants wi th Gastrointestinal Symptoms ..................................... 47
6.7. Intervention after the End of the Study ........................................................................ 47
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal .................................................................................... 48
7.1. Discontinuati on of Study Intervent ion........................................................................ 48
CONFIDENTIAL I8F-MC-GPHL
4
Temporary Study Drug Discontinuati on...................................................................... 50
7.2. Participant Discontinuati on/Withdrawal from  the Study ............................................. 51
Participant disposition and timing of safet y follow-up................................................. 53
Discontinuati on of Inadvertent ly Enrolled Parti cipants............................................... 54
7.3. Lost to Follow- up....................................................................................................... 54
8. Study Assessments and Procedures ......................................................................... 55
8.1. Efficacy Assessments ................................................................................................ .55
Primary Efficacy Assessments .................................................................................... 55
Secondary  Efficacy Assessments ................................................................................ 55
Patient-Reported Outcomes Assessments .................................................................... 55
8.2. Safety Assessments .................................................................................................... 57
Physical Examinat ions................................................................................................ 57
Vital Signs.................................................................................................................. 57
Electrocardiograms ..................................................................................................... 57
Clinical Safety  Laboratory  Assessments ..................................................................... 58
Safety Monitoring....................................................................................................... 59
Depressio n, Suicidal Ideation, and Behavior Risk Monitoring ..................................... 61
8.3. Adverse Events, Serious Adverse Events, and Product 
Complaints................................................................................................................. 61
Timing and Mechanism for Collecting Events ............................................................ 62
Special Safety Topics................................................................................................ .64
8.4. Treatment of Overdose ............................................................................................... 70
8.5. Pharmacokinet ics........................................................................................................ 70
8.6. Pharmacodynamics ..................................................................................................... 70
8.7. Genetics..................................................................................................................... 71
8.8. Biomarkers................................................................................................................. 71
8.9. Immunogenicity Assessments ..................................................................................... 72
8.10. Health Economics ....................................................................................................... 72
9. Statistical Considerations ......................................................................................... 73
9.1. Statistical Hypotheses ................................................................................................ .73
9.2. Sample Size Determinat ion......................................................................................... 74
9.3. Populations for Analyses ............................................................................................ 74
9.4. Statistical Analyses..................................................................................................... 75
General Considerations ............................................................................................... 75
Treatment Group Comparabilit y................................................................................. 76
Efficacy Analyses ....................................................................................................... 76
Safety Analyses .......................................................................................................... 78
Pharmacokinet ic/Pharmacodynamic Analyses ............................................................ 79
Evaluation of Immunogenicit y.................................................................................... 79
Other Analyses ........................................................................................................... 80
9.5. Interim Analyses ......................................................................................................... 80
9.6. Data Monitoring Committee ....................................................................................... 80
10. Supporting Documentation and Operational Considerations ................................ 81
10.1. Appendix 1: Regulatory , Ethical, and Study  Oversight 
Considerations ............................................................................................................ 81
CONFIDENTIAL I8F-MC-GPHL
5
Regulatory  and Ethical Considerat ions........................................................................ 81
Informed Consent Process .......................................................................................... 82
Data Protection ........................................................................................................... 82
Committees Structure ................................................................................................ .83
Dissemination of Clinical Study  Data......................................................................... 83
Data Qualit y Assurance .............................................................................................. 83
Source Documents ...................................................................................................... 84
Study and Site Start and Cl osure................................................................................. 85
Publication Policy....................................................................................................... 85
10.2. Appendix 2: Clinical Laboratory  Tests........................................................................ 86
10.3. Appendix 3: Laboratory  Assessments for Hy persensitivity 
Events........................................................................................................................ 89
10.4. Appendix 4: Adverse Events: Definit ions and Procedures for 
Recording, Evaluat ing, Follow -up, and Reporting ....................................................... 91
Definition of AE......................................................................................................... 91
Definition of SAE....................................................................................................... 92
Definition of Product Complaint ................................................................................. 93
Recording and Fo llow-Up of AE and/or SAE and Product 
Complaints................................................................................................................. 93
Reporting of SAEs ...................................................................................................... 95
Regulatory  Reporting Requi rements........................................................................... 96
10.5. Appendix 5: Contraceptive Guidance and Co llection of 
Pregnancy Information ............................................................................................... 97
10.6. Appendix 6: Liver Safet y: Suggested Actions and Fo llow-up 
Assessments ............................................................................................................. 101
10.7. Appendix 7: Protocol GPHL Standardized Protocols for the 
Measurement of Height, Weight, Waist Circumference, Vital 
Signs, and Electrocardi ogram................................................................................... 103
10.8. Appendix 8: Suggested Visit Structure ...................................................................... 105
10.9. Appendix 9: Management of Gastrointestinal Symptoms .......................................... 106
10.10. Appendix 10: World Healt h Organization Classification of 
Diabetes and Di agnostic Cri teria............................................................................... 107
10.11. Appendix 11:Provisions forChangesinStudy 
ConductDuringExceptionalCircumstances ............................................................. 108
10.12. Appendix 12: Abbreviat ions..................................................................................... 112
11. References ............................................................................................................... 117
CONFIDENTIAL I8F-MC-GPHL
61. Protocol Summary
1.1. Synopsis
Protocol Title: Efficacy and Safet y of Tirzepatide Once Weekly in Part icipants with Type 2 
Diabetes who h ave Obesi ty or are Overweight : A Randomized, Double -Blind, Placebo-
Controlled Trial (SURMOUNT -2)
Short Title: Effect of Tirzepat ide versus Placebo in Parti cipants wi th Type 2 Diabetes Who have 
Obesity or are Overweight (SURMOUNT -2)
Rationale :  
Obesity is a chronic disease whose increasing prevalence is a public health concern associated 
with rising incidence of t ype 2 diabetes mellitus (T2DM) , increased risk for premature death and 
increased risk for some cancers ( AMA 2013 ;Council on Science and Public Healt h2013;
Lauby-Secretan et al. 2016 ).  
For patients with T2DM who have obesit y or are overweight, efforts targeting weight loss, 
including lifest yle, medication, and surgical intervent ions, are recommended (Davies 2018) 
because there is strong and consistent evidence that obesit y management is beneficial in t he 
treatment of type 2 diabetes and weight -related comorbidit ies (ADA 2020). Lifestylechanges 
that result in modest and sustained weight loss produce clinically  meaningful reductions in blood 
glucose(BG), hemoglobin A1c ( HbA1c), and triglycerides. Greater weight loss produces even 
greater benefits , including reduct ions in blood pressure, improvements in low-density 
lipoproteins (LDL) and high-density lipoproteins ( HDL)cholesterol, and reduct ions in the need 
for medications to control BG, blood pressure, and lipids, and may even result in achievement of 
glycemic goals in the absence of glucose -lowering agent use in so me patients (UKPDS Group 
1990; Pastors et al . 2002;Wing et al . 2011;Rothberg et al . 2017;ADA 2020 ). 
The gut incretin hor mones, glucose-dependent insulinotropic po lypeptide (GIP) and 
glucagon-like peptide -1 (GLP-1) are secreted after meal ingestion and mediate the incret in 
effect. Both hormones have effects on endocrine cells in the pancreas, increasing insulin 
biosynthesis and secret ion, and modifying glucagon secret ion (Skow et al. 2016). Based on these 
properties, several GLP -1 receptor (GLP -1R) agonists have been approved for pharmaco logical 
treatment of T2DM ( Tomlinson et al. 2016 ).
In addition to its pancreat ic effects, GLP-1R activation decreases gut motilit y, slows gastric 
emptying, and promotes satiet y (presumably through a combinat ion of GLP-1R activation in the 
central and peripheral nervous system s), thereby  regulating food intake and body  weight(Baggio 
and Drucke r 2007). The US Food and Drug Administration (FDA) and the European Medicines 
Agency(EMA)approved the GLP -1R agonist liraglutide for the treatm ent of overweight and 
obesity (SAXENDA® package insert, 2014; SAXENDA summary of product characteristics , 
2015).
Preclinical data indicate that GIP also exert seffects on appetite regulat ion and food intake, on 
adipose tissue, and on peri pheral energy metabolism. Although studies evaluat ing effects of GIP 
on body weight have yielded equivocal results, GIP receptor (GIPR) activation may play a role 
in body weight regul ation and targeting both the GLP- 1R and the GIPR simultaneously could 
CONFIDENTIAL I8F-MC-GPHL
7potentially result in additive or synergistic effects of the 2 incret ins on body weight (Coskun et 
al.2018).
 
 
 It is administered once- weekly (QW) by subcutaneous (SC) inject ion.
As a dual  GIP/GLP -1R agonist, tirzepatidecould exceed the efficacy  of selective GLP-1R 
agonists by recruit ing metabolicallyactive tissues not targeted by selective GLP-1R agonists (for 
example, adipose tissue as indicated by the observation of increased energy utilization) (Müller
et al. 2018)and has the potential to reachhigher efficacy in target tissues that express both GIPR 
and GLP-1R.Therefore, tirzepat ide has the potential to impact several aspects of energy 
regulation and be a treatment of overw eight and obesit y. 
Compared topeople wit hout diabetes, patients with T2DM and obesity or overweight often 
respond less favorably  to weight-management treatments (Pi-Sunyer, 2005 ) and may face unique 
safety issues such as ri sk for hypoglycemia fo llowing weight loss, if the dose of certain 
background medicat ions for the management of hyperglycemia is not appropriately adjusted. 
Therefore, it is important to conduct a dedicated Phase 3, randomized, double -blind,placebo-
controlled study  in patients with T2DM and obesity or overweight to evaluate the efficacy and 
safety of novel chronic weight management products. In addit ion, weight loss should be 
demonstrated over the course of at least 1 y ear before a product c an be considered as effect ive 
for weight management (FDA 2007).
Study 18F-MC-GPHL is a Phase 3, m ulticenter, rando mized, parallel, placebo -controlled, 
double-blinded, 72-weekstudy that will invest igate the effects of treatment with t irzepatide 
10mg and 15 mg QW com pared with placebo, in conjunction with a reduced -calorie diet and 
increased physical activit y, on weight management in participants with T2DM who have obesit y 
(body mass index [BMI] ≥30 kg/m2)or are overweight (BMI ≥27 kg/m2).  
CCI
CONFIDENTIAL I8F-MC-GPHL
8Objectives and Endpoint s
Objectives Endpoints
Primary
To demonstrate that tirzepatide 10 mg QW is superior 
to placebo at 72 weeks for :
Percent change in body weight 
AND
Proportion of participants with ≥5% 
body weight reduction 
AND/OR
To demonstrate that tirzepatide 15 mg QW is superior 
to placebo at 72 weeks for :
Percent change in body weight
AND
Proportion of participants with ≥5% 
body weight reduction Mean percent change in body weight 
from randomization 
Percentage of study participants who 
achieve ≥5% body weight reduction from 
randomization
Key Secondary (controlled for type I error) , by 
dose analysis
For QW tirzepatide 10 mg and/or 15 mg doses, to 
demonstrate superiority to placebo in change from 
randomization for the following (measured at 
72weeks): 
Body weight Percentage of participants who achieve :
o≥10% body weight reduction
o≥15% body weight reduction 
Glycemic controlMean change in HbA1c (%)
Percentage of participants who achieve 
HbA1c <7%
Mean change in fasting glucose (mg/dL )
Waist circumference Mean change in waist circumference 
(cm)
Key secondary (controlled for type I error), 
pooled dose analysis
CONFIDENTIAL I8F-MC-GPHL
9For QW tirzepatide (all doses combined) , to 
demonstrate superiority to placebo in change from 
randomization for the following (measured at 
72weeks):
Lipid parameters
SBPMean change in fasting
oTotal cholesterol (mg/dL)
oLDL-cholesterol (mg/dL)
oTriglycerides (mg/dL)
Mean change in SBP (mmHg)
Additional Secondary ,by dose analysis
For QW tirzepatide 10 mg and/or 15 mg doses, to 
demonstrate superiority to placebo in change from 
randomization for the following (measured at 
72weeks): 
Body weight Mean change in absolute body weight 
(kg)
Mean change in BMI (kg/m2)
Glycemiccontrol Percentage of study participants who 
achieve HbA1c ≤6.5% 
Percentage of study participants who 
achieve HbA1c <5.7%
Insulin Mean change in fasting insulin (pmol/L)
Patient-Reported Outcomes Mean change in 
oSF-36v2 acute form Physical 
Functioning domainscore
oIWQOL-Lite-CT Phy sical 
Function composite score
Additional Secondary, pooled analysis
CONFIDENTIAL I8F-MC-GPHL
10For QW tirzepatide (all doses combined), to 
demonstrate superiority to placebo in change from 
randomization for the following (measured at 
72weeks):
Lipid parameters
DBPMean change in fasting
oHDL-cholesterol (mg/dL)
oVLDL-cholesterol (mg/dL)
oFree fatty acids (mg/dL)
Mean change in DBP (mmHg) 
Pharmacokinetics/Pharmacodynamics
To characterize the population PK of 
tirzepatide and explore the relationships 
between the tirzepatide concentration and 
efficacy, safety ,and tolerability measuresPopulation PK and PD parameters
Abbreviations : BMI= body mass index ;DBP=diastolic blood pressure ;HbA1c=hemoglobin A1c ;
HDL=high-density lipoprotein ;IWQOL-Lite-CT =Impact of Weight on Quality of Life -Lite-Clinical Trials
Version;LDL=low-density lipoprotein ;PD=pharmacodynamics ;PK=pharmacokinetic s;QW=once weekly ;
SBP=systolic blood pressure ;SF-36v2acute form =Short Form-36Health Survey version 2 acute form ;
VLDL=very low-density lipoprotein.
Overall Design :
Study I8F-MC-GPHL is a Phase 3, mult icenter, rando mized, parallel, placebo -controlled, 
double-blinded 72- week study  that will investigate the safety and efficacy o f treatment with 
tirzepatide 10 mg and 15 mg QW SC compared with placebo QW, in conjunct ion with a 
reduced-calorie diet and increased physical act ivity, on weight m anagement in participants with 
T2DM who have obesit y(BMI ≥30kg/m2)or are overweight (BMI ≥27kg/m2).
Disclosure Statement :  
This is a parallel group treatment study that is participant and invest igator blinded.
Number of Participant s:
A total of approximately  900 participants will be randomized in a 1:1:1 ratio to 10 mg tirzepatide 
(300participants), 15 mg t irzepatide (300 participants), or placebo (300 participants) .An upper 
limit of 70% enrollment of women will be used to ensure a sufficient ly large sample of men. In 
addition, an upper limit of 30% enro llment of participants treated w ith sulfonylureawill be used 
to allowsufficient enrollment of participants treated with other antihyperglycemic medicat ions
(AHMs). 
CONFIDENTIAL I8F-MC-GPHL
11Intervention Groupsand Duration :
Study participants will be randomized in a double-blind 1:1:1 ratio (tirzepat ide 10 mg QW, 
tirzepatide 15 mg QW, and placebo) , stratified by 
country
sex, and 
type of baseline AHMs (classified according to its potential effect on body  weight).  
All participants will undergo a 3 -week screening period, a 72 -week treatment period (including a 
20-week dose escalat ion and a 52 -week dose maint enance period), and a 4-week safet y follow-
up period.
Data Monitoring Committee: No
CONFIDENTIAL I8F-MC-GPHL
121.2.Schema
Abbreviations : QW=once weekly, (T) =telephone visit .

CONFIDENTIAL I8F-MC-GPHL
131.3.Schedule of Activities (SoA)
The Schedule o f Activitiesdescribed below should be followed for all pa rticipants enrolled in Study  GPHL. However, for th ose 
participantswhose participat ion in this study  is affected by  exceptionalcircumstances (such as pandemics or natural disasters), please 
refer to Section 10.11Appendix 11for additional guidance.
Visit 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 99 ED 801
Week of Treatment -3 -2 0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 724 wks 
post 
end of 
TxP
Allowable Interval Tolerance (days) ±3 ±7 ±3 +7 ±3 +7 ±3 ±3 ±3 ±3 +7 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±7 ±7 ±3
Fasting Visit X X X X X X X X X X X X X X X
Telephone Visit X X X X X X X X
Informed consent X
Inclusion and exclusion criteria review X X X
Preexisting conditions and medical history, 
including relevant surgical historyX
Medical history includes assessment ofpreexisting conditions (for example, history ofgallbladder disease, cardiovascular disease,
and medullary thyroid carcinoma) and substance usage (such as alcohol andtobacco).
Concomitant medications X X X X X X X X X X X X X X X X X X X X X X X X
Adverse events and product complaints X X X X X X X X X X X X X X X X X X X X X X X X
Physical Evaluation or Clinical Assessments
Height X
WeightX X X X X X X X X X X X X X X
Weight measurements should be obtained per the detailed protocol guidance in Section 10.7. Body weight must be measured in 
the fasting state. If the participant is not fasting, the participant should be called in for a new visit within the visit wi ndow to 
have the fasting body weight measured.
Waist circumference X X X X X X X X X X X X X X
Vital signs ( systolic and diastolic 
blood pressure, pulse rate )X X X X X X X X X X X X X X
Vital sign measurements should be taken before obtaining an ECG tracing and before collection of blood samples for laboratory
testing, per the instruction in Section 10.7 .
CONFIDENTIAL I8F-MC-GPHL
14Visit 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 99 ED 801
Week of Treatment -3 -2 0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 724 wks 
post 
end of 
TxP
Allowable Interval Tolerance (days) ±3 ±7 ±3 +7 ±3 +7 ±3 ±3 ±3 ±3 +7 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±7 ±7 ±3
Fasting Visit X X X X X X X X X X X X X X X
Telephone Visit X X X X X X X X
Dilated Fundoscopic ExaminationX
For all participants who remain eligible after Visit 1, a dilated fundoscopic examination will be performed by an eye care 
professional (ophthalmologist or optometrist) between Visit 2 and Visit 3 to exclude participants with proliferative diabetic
retinopathy, diabetic macular edema, or nonproliferative diabetic retinopathy that re quires acute treatment. The results from 
this examination will be recorded on a specific eCRF page (Fundoscop y Exam) as a baseline measure of retinopathy. Follow -up 
dilated fundoscopic examination should be performed when clinically indicated, and the resu lts recorded on the specific eCRF
page .
Physical Examination X
ElectrocardiogramX X X X X
ECG measurements should be obtained per the instructions in Section 10.7 .Electrocardiograms should be obtained prior to 
collection of blood samples for laboratory testing, including PK samples.
Participant Education and Assessment
Lifestyle Program instructionX X X X X X X X X X
Counselling on diet and exercise, to be performed by a dietitian or equivalent qualified delegate, to include calculation of 
individualized energy requirement and methods to change dietary composition and amount of physical activity .The Lifestyle 
Program instruction may be delivered on a separate day from the rest of that visit’s study procedures but must occur within the 
visit window. Beginning at Week 8, the consultation may be delivered by phone.
Review diet and exercise goalsX X X X X X X X X X X X X X X X X X X X
All training should be repeated as needed to ensure participant compliance.
Study personnel to provide reinforcement and encouragement for lifestyle modifications.
Diabetes education (includes BG meter
dispensing and SMBG training )X
CONFIDENTIAL I8F-MC-GPHL
15Visit 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 99 ED 801
Week of Treatment -3 -2 0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 724 wks 
post 
end of 
TxP
Allowable Interval Tolerance (days) ±3 ±7 ±3 +7 ±3 +7 ±3 ±3 ±3 ±3 +7 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±7 ±7 ±3
Fasting Visit X X X X X X X X X X X X X X X
Telephone Visit X X X X X X X X
Diabetes education to be performed by personnel who are qualified to educate participants on symptoms and management of 
hyperglycemia and hypoglycemia, SMBG , self -injection ,and diabetes management. Participants are required to measure fasting 
SMBG values weekly and record them in the study diary. It is recommended that participants measure their fasting glucose on 
the same day each week .All training sshould be repeated as needed to ensure participant compliance.
Dispense BG meter/supplies as needed X X X X X X X X X X X X X
Remind participants about 7- point 
SMBGX X X
Participant is required to collect two 7 -point SMBGs on nonconsecutive days within 2 weeks prior to the next visit. A 7 -point 
SMBG consists of measurements before and 2 hours after each of 3 main meals within the same day and at bedtime. 
Injection training with autoinjector 
demonstration deviceX
Participant Diary (paper)
Dispense diary, instruct in useX X X X X X X X X X X X X
All training should be repeated as needed to encourage participant compliance.
Diary review , including hypoglycemia X X X X X X X X X X X X X X X X X X X X X
Review 7 -point SMBG values collected in 
the diaryX X X
Patient Reported Outcomes
PGIsX X X X
SF-36v2 acute formX X X X
CONFIDENTIAL I8F-MC-GPHL
16Visit 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 99 ED 801
Week of Treatment -3 -2 0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 724 wks 
post 
end of 
TxP
Allowable Interval Tolerance (days) ±3 ±7 ±3 +7 ±3 +7 ±3 ±3 ±3 ±3 +7 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±7 ±7 ±3
Fasting Visit X X X X X X X X X X X X X X X
Telephone Visit X X X X X X X X
IWQOL -Lite-CTX X X X
EQ-5D-5LX X X
Mental Health Questionnaires
Patient Health Questionnaire -9 (PHQ -9)X X X X X X X X X X X
PHQ -9 is self -administered and should be completed after assessment of adverse events.
Columbia- Suicide Severity Rating Scale 
(C-SSRS) (Baseline/Screening Version)X
The C -SSRS should be administered after assessment of adverse events. For this study, the C -SSRS is a dapted for the assessment 
of the ideation and behavior categories only. The Intensity of Ideation and Lethality of Behavior sections are removed.
Columbia- Suicide Severity Rating Scale 
(C-SSRS) (Since Last Visit Version)X X X X X X X X X X X X X X X X X X X X X X X
The C -SSRS should be administered after assessment of adverse events and capture information since most recent C -SSRS 
administration. For this study, the C -SSRS is a dapted for the assessment of the ideation and behavior categories only. The 
Intensity of Ideation and Lethality of Behavior section s are removed.
Self-Harm Supplement FormX X X X X X X X X X X X X X X X X X X X X X X X
The Self -Harm Supplement Form should be administered after assessment of adverse events.
Self-Harm Follow -up FormX X X X X X X X X X X X X X X X X X X X X X X X
Self-Harm Follow -up Form is only required if triggered by the Self -Harm Supplement Form, per instructions in the form.
Laboratory Tests and Sample Collections
Hematology X X X X X X
HbA1c X X X X X X X X X X
CONFIDENTIAL I8F-MC-GPHL
17Visit 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 99 ED 801
Week of Treatment -3 -2 0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 724 wks 
post 
end of 
TxP
Allowable Interval Tolerance (days) ±3 ±7 ±3 +7 ±3 +7 ±3 ±3 ±3 ±3 +7 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±7 ±7 ±3
Fasting Visit X X X X X X X X X X X X X X X
Telephone Visit X X X X X X X X
Chemistry panel (includes Creatinine for 
eGFR calculation and glucose)X X X X X X X X X X
The CKD- EPI equation will be used by the central lab to estimate and report eGFR.
Lipid panel X X X X X X
Insulin X X X X X
C-peptide X X X X X
Free fatty acids X X X X X X
Serum pregnancy X
For women of childbearing potential only
Urine pregnancy (local)X X X X X X X X
A urine pregnancy test must be performed at Visit 3with the result available prior to first injection of study drug(s) for women of 
childbearing potential only . Additional pregnancy tests (beyond those required per the S oA) should be performed at any time 
during the trial if a menstrual period is missed, there is clinical suspicion of pregnancy, or as required by local law or regulation.
Follicle -stimulating hormone (FSH)X
Only for postmenopausal women at least 40 years of age with an intact uterus, not on hormone therapy, and who have had 
spontaneous amenorrhea for more than 1 year without an alternative medical cause.
Calcitonin X X X X X X
Pancreatic amylase X X X X X X X
Lipase X X X X X X X
Urinary albumin/creatinine ratio X X X X X
Cystatin -c X X X X X
Thyroid -stimulating hormone (TSH) X
Immunogenicity (includes TZP PK sample)X X X X X X X X
In the event of systemic drug hypersensitivity reactions (immediate or nonimmediate), additional unscheduled samples should 
be collected as detailed in Sectio n8.3.2.7 (Hypersensitivity Reactions). Immunogenicity samples and PK samples for 
immunogenicity must be taken prior to drug administration.
CONFIDENTIAL I8F-MC-GPHL
18Visit 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 99 ED 801
Week of Treatment -3 -2 0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 724 wks 
post 
end of 
TxP
Allowable Interval Tolerance (days) ±3 ±7 ±3 +7 ±3 +7 ±3 ±3 ±3 ±3 +7 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±7 ±7 ±3
Fasting Visit X X X X X X X X X X X X X X X
Telephone Visit X X X X X X X X
TZP PKX X X
PK samples will be collected from a subset of participants at these visits at time windows of 1 to 24 hours ,24 to 96 hours, OR 
120 to 168 hours post dose, as assigned by IWRS. Depending on the time -windows to which a participant gets assigned, they 
may be required to come to site for PK -specific visits.
Stored Samples
Pharmacogenetic sample X
Nonpharmacogenetic sample X X X X X X X
Randomization and Dosing
Randomization X
Dispense study drug X X X X X X X X X X
Observe participant administer study 
drugX
Participants should administer their first dose of study drug at the end of the Visit 3, after other study procedures and 
randomization have been completed .
Participant returns study interventions and 
injection suppliesX X X X X X X X X X X
Assess study intervention(s) compliance X X X X X X X X X X X X X X X X X X X
Abbreviations: BG= blood glucose; CKD-EPI = Chronic Kidney Disease -Epidemiology; ECG=electrocardiogram; eCRF= electronic case report form; 
ED=early treatment discontinuation; eGFR=estimated glomerular filtration rate ; HbA1c= hemoglobin A1c; HR=heart rate; IWQOL-Lite-CT =Impact of 
Weight on Quality of Life -Lite-Clinical Trials Version; IWRS= interactive web -response sy stem;PGIs= Patient Global Impression of status for physical 
activity; PK=pharmacokinetics ; SF-36v2 acute form =Short Form-36 Version 2Health Survey acute form; SMBG= self-monitoring of blood glucose ;
SoA=Schedule of A ctivities;TxP= treatment period; TZP= tirzepatide; wks= weeks. 
Note:  
Visit 3 baseline assessments must be completed before processing the randomization in the IWRS.
The visit date is determined in relation to the date of Visit 3 (randomization) .
CONFIDENTIAL I8F-MC-GPHL
19Visit 99 is only applicable to participants who discontinue the double -blind study  treatment prematurely and decline to complete the remaining 
scheduled study visits .Participants wanting to discontinue the study before Week 72 will be asked to return for Visit 99, 72 weeks ± 7 days after 
randomization, primarily for body weight measurement and assessment of adverse events. If the participant is unwilling to atten d Visit 99, it should be 
documented in the participant medical record that the participant has refused to attend.
Participants who are unable or unwilling to continue the study treatment for any reason will perform an E D visit. If the participant is discontinuing 
during an unscheduled visit or a scheduled visit, that visit should be performed as an ED visit. 
Visit 801 (safety follow -up visit) should be performed 4 weeks after the last visit of the participant’s treatment period (see Section 7.2.1.).
Forall office visits (except for Visit 2), remind participants to report to the site before taking study drug(s) in a fasting condition, after a period of 
approximately 8 hours without eating, drinking (except water), or any significant physical activity. Since some screening pro cedures need to be 
completed in the fasting state, Visit 1 may be conducted over more than 1 day to ensure necessary conditions are met. The participant should not take 
any antihyperglycemic medications prior to the fasting visit.
CONFIDENTIAL I8F-MC-GPHL
202. Introduction
Obesity is a chronic disease whose increasing prevalence is a public healt h concern associated 
with rising incidence of t ype 2 diabetes mellitus (T2DM) , increased risk for premature death ,and 
increased risk for some cancers ( AMA 2013 ;Council on Science and Public Healt h2013;
Lauby-Secretan et al. 2016 ).  
For patients with T2DM who have obesit y or are overweight, efforts targeting weight loss, 
including lifest yle, medication, and surgical intervent ions, are recommended ( Davies 2018) 
because there is strong and consistent evidence that obesit y management is beneficial in the 
treatment of type 2 diabetes and weight -related comorbidit ies(ADA 2020). Lifestylechanges 
that result in modest and sustained weight loss produce clinically  meaningful reductions in blood 
glucose(BG), hemoglobin A1c (HbA1c), and triglycerides. Greater weight loss produces even 
greatermetabolicbenefits, including reductions in blood pressure, improvements in low-density 
lipoprotein (LDL)and high-density lipoprotein (HDL)cholesterol, andreductions in the need for 
medications to control BG, blood pressure, and li pids,and may even result in achievement of 
glycemic goals in the absence of glucose -lowering agent use in so me patients (ADA 2020; 
UKPDS Group 1990 ;Pastors et al . 2002;Wing et al. 2011;Rothberg et al . 2017). 
However, therapeutic weight loss in pat ients with T2DM has been very  difficult to achieve (Pi-
Sunyer et al .2005). Lifestyle therapies fail to achieve sustainable weight loss in the majorit y of 
patients with obesity(Dombrowski etal. 2014). Currently, only a limited number of prescript ion 
drugs are approved by  the Food and Drug Administration (FDA) and other regulatory  agencies 
for chronic weight management in adults. They have rather m odestefficacy (M üller et al. 2018) 
andtheir central nervous system , gastrointestinal ( GI), and cardiovascular side effects
(Srivastava and Apovian 2018 a, 2018b) limit their use for m any people with obesity.Patients 
with T2DM who have obesit y or who are overweight would benefit from greater availabilit y of 
pharmacotherapeutic agents that are effective in lowering body weight . 
2.1. Study Rationale
The incret in hormones, glucose -dependent insulinotropic polypept ide(GIP) and gl ucagon-like 
peptide-1 (GLP-1), are secreted after meal ingestion and mediate the incretin effect. Both 
hormones have effects on endocrine cells in the pancreas, increasing insulin bio synthesis and 
secretion, and modifying glucagon secret ion (Skow et al.2016). Based on these properties, 
several GLP -1 receptor (GLP -1R) agonists have been approved for pharmaco logical treatm ent of 
T2DM (Tomlinso n et al. 2016).
In addition to its pancreat ic effects, GLP -1R activation decreases gut motilit y, slows gastric 
emptying, and promotes satiet y (presumably through a combinat ion of GLP-1R activation in the 
central and peripheral nervous system s), thereby  regulating food intake and body  weight (Baggi o 
and Drucker 2007). The US FDAand the European Medicines Age ncy (EMA) approved the 
GLP-1R agonist liraglutide for the treatm ent of overwei ght and obesit y (SAXENDA package 
insert, 2014; S AXENDA summary of product characteri stics 2015).
Preclinical data indicate that GIP also exert seffects on appetite regulat ion and food intake, on 
adipose tissue, and on peri pheral energy metabolism. Although studies evaluat ing effects of GIP 
CONFIDENTIAL I8F-MC-GPHL
21on body weight have yielded equivocal results, GIP receptor (GIPR) activation may  play a rol e 
in body weightregulation and targeting both the GLP- 1R and the GIPR simultaneously could 
potentially result in additive or synergistic effects of the 2 incret ins on body weight (Coskun et 
al.2018).
 
 
It is administered once -weekly (QW) by subcutaneous (SC) inject ion.As a 
dual GIP/GLP -1R agonist, tirzepatidecould exceed the efficacy of selective GLP- 1R agonists by 
recruiting metabo licallyactive tissues not targeted by selective GLP-1R agonists (for example, 
adipose tissue as indicated by the observat ion of increased energy ut ilization) (Müller et al. 
2018)and has the potential to reachhigher efficacy in target tissues that express both GIPR and 
GLP-1R. Therefore, tirzepat ide has the potential to impact several aspects of energy regulation 
and be a treatment for overweight and obesit y.
Compared topeople wit hout diabetes, patients with T2DM and obesit y or overweight often 
respond less favorably  to weight-management treatments (Pi-Sunyer, 2005 ) and may face unique 
safety issues such as risk for hy poglycemia fo llowing weight loss,if the dose of certain
background medicat ions for the management of hyperglycemia is not appropriately adjusted. 
Therefore, it is important to conduct a dedicated phase 3, randomized, double -blind, placebo-
controlled study  in patients with T2DM and o besity or overweight to evaluate the efficacy and 
safety of novel chronic weight management products . In addition, weight loss should be 
demonstrated over the course of at least 1 y ear before a product can be considered as effect ive 
for weight management (FDA 2007).
Study 18F-MC-GPHL is a Phase 3, m ulticenter, rando mized, parallel, placebo -controlled, 
double-blinded study that will invest igate the effects of treatment with tirzepatide 10 mg and 
15mg QW co mpared with placebo, in conjunction with a reduced -calorie diet and increased 
physical act ivity, on weight management at 72 weeks in participants with T2DM who have 
obesity or are overwei ght.  
2.2. Background
There rem ains an unmet need in the pharmaco logic treatment of obesit y for drugs that are safe, 
efficacious, and well -tolerated. There are currently only a fewmedications FDA-approved for 
long-term use for the treatm ent of obesit y that yield a pl acebo-adjusted average weight loss 
between 3% and 7% (Srivastava and Apovian 2018b , FDA 2020). Al though moderate wei ght 
loss of 5% to 10% in individuals wit h obesity/overwei ght has long been shown to yield 
significant metabolic benefits including improvements in cholesterol, blood pressure, and 
glucose param eters (Gol dstein 1992; Wing et al. 2011), greater w eight loss can maximize these 
benefits and may  be required to realize clinically  meaningful  improvements in other obesit y-
related comorbidities such as sleep apnea, nonalcoho lic steatohepatit is, and cardiovascular 
disease (Ryan et al. 2017). In addit ion tomoderate efficacy, so me centrally -acting weight loss 
agents to-date have had adverse neurocognit ive, psychiatric, or cardiovascular effects, further 
limiting their applicat ion in clinical practice (Srivastava and Apovian 2018 b). 
Weight loss induced by  GLP-1R agonists, while appearing to be centrally-mediated through a 
combination of hormonal inputs to satiet y centers (van Bloemendaal  et al. 2014), has not been 
consistent ly associated with changes in mental healt h or with potential for addict ion in long-term 
CCI
CONFIDENTIAL I8F-MC-GPHL
22studies conducted to establish cardiovascular safety  in patients with diabetes (Marso et al. 2016a, 
2016b; Gerstein et al. 2019). Tirzepat ide, which is both a GLP -1R and GIPR agonist, has been 
associated with predominant ly mild to m oderate GI adverse ef fects similar to currently marketed 
GLP-1Ragonists, but has also demonstrated significant weight loss at both the 10 mg and 15 mg 
doses in Phase 2 studies wit h nearly half o f the participants in both dose arms achieving > 10% 
weight loss (Frias et al . 2018).
Dose selection for obesity treatment has been informed by  3clinical tri als: a Phase 1 study, 
StudyI8F-MC-GPGA (GPGA), and 2Phase 2 studies, Study  I8F-MC-GPGB (GPGB) and 
I8F-MC-GPGF (GPGF).  
Phase 1 Study  GPGA was a combinat ion of single ascending dose (SAD) and mult iple ascending
dose (MAD) study in healthy subjects followed bya multiple dose study in patients with T2DM . 
A total of 142participant s (89 healt hy subjects and 53 patients with T2DM) received at least 
1dose of treatment. Doses of tirzepat ide ranged from :
0.25mg to 8mg in the SAD ( with maximum tolerated dose achi eved at 5 mg) in healthy 
subjects,
multiple doses in the MAD from 0.5mg to 4.5 mg QWand titrated doses up to 10 mg 
QW for 4weeks in healt hy subjects ,and
multiple doses at 0.5 mg and 5 mg QWandtitrated to 15 mg QW for 4 weeks in pat ients 
with T2DM.  
Thesafety and tolerability and pharmacokinet ic/pharmacodynamic (PK/PD)profiles of 
tirzepatide at doses and escalationregimens administered in this Phase 1 study supported further 
development of tirzepat ide for QW dosing in pat ients with T2DM.
Phase 2 studies I8F -MC-GPGB (GPGB) and I8F -MC-GPGF (GPGF) provided initial safety, 
tolerability,and efficacy  data in the ti rzepatide 1 to 15 mg dose-range when used in treatment of 
patients with T2DM. In the dose range of 5 to 15 mg, tirzepatide provided significantly greater 
reductions in HbA1cand body weightcompared wit h placebo.In addition, 10-mg and 15 -mg 
dose arms demonstrated significantly greater weight loss co mpared to the GLP -1Ragonist
dulaglutide 1.5mg QW.The most comm on adverse events ( AEs), which were also dose 
dependent, were mild to moderate nausea, vo miting, and di arrhea. Study  GPGF showed that 
adjustments in the ti rzepatide dose escalat ion algorithm resulted in addit ional reduct ions in the 
frequency  of GI AEs and reduced the frequency of treatment discont inuations due to GI AEs.
2.3. Benefit/Risk Assessment
More detailed informat ion about the known and expected benefits and risks and reasonably 
expected AEsof tirzepatidemay be found in the Investigator’s Brochure (IB).
CONFIDENTIAL I8F-MC-GPHL
233. Objectives and Endpoints
Objectives Endpoints
Primary
To demonstrate that tirzepatide 10 mg QW is superior to 
placebo at 72 weeks for :
Percent change in body weight AND
Proportion of participants with ≥5% body 
weight reduction 
AND/OR
To demonstrate that tirzepatide 15 mg QW is superior to 
placebo at 72 weeks for :
Percent change in body weight AND 
Proportion of participants with ≥5% body 
weight reduction Mean percent change in body 
weight from randomization 
Percentage of study participants 
who achieve ≥5% body weight 
reduction from randomization
Key Secondary (controlled for type I error), by dose 
analysis
For QW tirzepatide 10 mg and/or 15 mg doses, t o 
demonstrate superiority to placebo in change from 
randomization for the following (measured at 72 weeks): 
Body weight Percentage of participants who 
achieve:
o≥10% body weight reduction
o≥15% body weight reduction 
Glycemic controlMean change in HbA1c (%)
Percentage of participants who 
achieve HbA1c <7% 
Mean change in fasting glucose 
(mg/dL)
Waist circumference Mean change in waist 
circumference (cm)
Key secondary (controlled for type I error), pooled dose 
analysis
CONFIDENTIAL I8F-MC-GPHL
24For QW tirzepatide (all doses combined )to demonstrate 
superiority to placebo in change from randomization for the 
following (measured at 72 weeks):
Lipid parameters
SBPMean change in fasting
oTotal cholesterol (mg/dL)
oLDL-cholesterol (mg/dL)
oTriglycerides (mg/dL)
Mean change in SBP (mmHg)
Additional Secondary, by dose analysis
For QW tirzepatide 10 mg and/or 15 mg doses, to 
demonstrate superiority to placebo in change from 
randomization for the following (measured at 72 weeks): 
Body weight Mean change in absolute body 
weight (kg)
Mean change in BMI (kg/m2)
Glycemiccontrol Percentage of study participants 
who achieve HbA1c ≤6.5% 
Percentage of study participants 
who achieve HbA1c <5.7% 
Insulin Mean change in fasting insulin 
(pmol/L)
Patient-Reported Outcomes Mean change in 
oSF-36v2 acute form 
Physical Functioning 
domainscore
oIWQOL-Lite-CT Phy sical 
Function composite score
Additional Secondary, pooled analysis
CONFIDENTIAL I8F-MC-GPHL
25For QW tirzepatide (all doses combined), to demonstrate 
superiority to placebo in change from randomization for the 
following (measured at 72 weeks):
Lipid parameters
DBPMean change in fasting
oHDL-cholesterol (mg/dL)
oVLDL-cholesterol (mg/dL)
oFree fatty acids (mg/dL)
Mean change in DBP (mmHg) 
Pharmacokinetics/Pharmacodynamics
To characterize the population PK of tirzepatide and 
explore the relationships between the tirzepatide 
concentration and efficacy, safety ,and tolerability 
measuresPopulation PK and PD parameters
Abbreviations : BMI= body mass index ;DBP=diastolic blood pressure ;HbA1c=hemoglobin A1c ;
HDL=high-density lipoprotein ;IWQOL-Lite-CT =Impact of Weight on Quality of Life -Lite-Clinical Trials
Version;LDL=low-density lipoprotein ;PD=pharmacodynamics ;PK=pharmacokinetic s;QW=once weekly ;
SBP=systolic blood pressure ;SF-36v2acute form =Short Form-36 version 2 Health Survey acute form ;
VLDL=very low-density lipoprotein.
CONFIDENTIAL I8F-MC-GPHL
264. Study Design
4.1. OverallDesign
Study 18F-MC-GPHL is a Phase 3, m ulticenter, randomized, parallel, placebo -controlled, 
double
-blinded,72-week study  that will invest igate the safet y and efficacy  of treatment with 
tirzepatide 10 mg and 15 mg QW SC compared with placebo QW SC, in conjunct ion with a 
reduced-calorie diet and increased physical act ivity, on weight m anagement in parti cipants wi th 
T2DM who have obesit y(body mass index [ BMI]≥30kg/m2)or are overweight (BMI 
≥27kg/m2).
Study participants will be rando mized in a 1:1:1 ratio (tirzepat ide 10 mg QW, tirzepatide 15 mg 
QW, and placebo). An upper limit of 70% enrollment of women will be used to ensure a 
sufficient ly large sample of men. In addition, an upper limit of 30% enrollment of participants
treated with SU will be used to allowsufficient enrollment of participants treatedwithother 
antihyperglycemic medicat ions(AHMs). 
All participants will undergo a 3 -week screening period, a 72 -week treatment period (including a 
20
-week dose escalat ion and a 52 -week dose maint enance period), and a 4-week safet y follow-
up period.  
Overview of Study Periods
4.1.1.1. Visit Structure for all Office Visits
On all office visit s (other than Visit 2), study participants are required to report to the site in a 
fasting condit ion, after a period of approximately 8 hours without eating, drinking (except 
water), or performing any significant physical act ivity and before taking study drug(s) . The 
participant shoul d not take any  AHMsprior to the visit. If participantsareadversely affected by 
the fasting condit ion, they are allowed to eat; however, specific study procedures need to be 
completed while fasting. See Section 10.8Appendix 8for a suggested order of activit ies that 
occurs at office visits. 
4.1.1.2. MainStudy Period 
4.1.1.2.1. Screening Period
Visit 1
The purpose of screening procedures at Visit 1 is to establish init ial eligibilit yand to obtain 
blood samples for laboratory  assessments needed to confirm eligibilit y. The participant must sign 
the informed consent form (ICF) before the study  procedures are performed, as outlined in the 
Schedule of Act ivities (SoA), Section 1.3.Since some screening procedures need to be 
completed in the fast ing state (approximately 8 hours without eating, drinking [except water], or 
any significant physical activit y), Visit 1 may be conducted over more than 1 day  to ensure 
necessary  conditions are met.  
Patient-reported outcomes(PROs)questionnaires should be administered as early as possible, as 
per Suggested Visit Structure ( Section 10.8). Preferred recommended administration ord er is:  
CONFIDENTIAL I8F-MC-GPHL
271.Patient Global Impression of status for physical activity(PGIs)
2.Short Form -36 version 2 Heal th Survey acute form(SF-36v2acuteform) 
3.Impact of Weight on Qualit y of Life-Lite-Clinical Trials Version (IWQOL-Lite-CT)
Participants who m eet all applicable inclusi on criteria and none of the applicable exclusio n 
criteria at Vi sit 1 will continue to Visit 2. 
Visit 2
At Visit 2, the screening laboratory  results will be reviewed. For all participants who remain 
eligible afte r Visit 1, a dilated fundoscopic examination will be performed by an eye care 
professional (ophthalmo logist or optom etrist) between Visit 2 and Visit 3 to exclude participants 
with proliferat ive diabet ic retinopathy , diabetic macular edema, or nonprolifera tive diabetic 
retinopathy  that requi res acute treatm ent.  
Participants will be provi ded diaries and be trained to record key  study information, as 
appropriate.  
Diabetes educat ion willbe perform ed by personnel who are qualified to educate participants o n 
symptoms and management of hyperglycemia and hypoglycemia, self-monitored BG, self-
injection and diabetes management according to American Diabetes AssociationStandards of 
Medical Care in Diabetes (ADA 2020) or local standards . Participants will be trained on how to 
utilize BG meters and how to collect self-monitoring of blood glucose (SMBG), including 
7-point measurements as appropriate. B lood glucosemeters/supplies will be provided to measure 
SMBG values and participants will be required to record them in the study  diary. 
4.1.1.2.2. Treatment Period
Randomization (Visit 3)
At Visit 3, eligible participants (who meet all applicable inclusio n criteria and none of the 
applicable exclusio n criteria) will perform all required randomizat ion study procedures 
(including the co llection of all baseline laboratory measures, electrocardi ograms (ECGs),and 
questionnaires) prior to randomizat ion and prior to taking the first dose of study drug.  
Participantsshould arrive atthe clinic in the fast ing state (after a period of approximately 8 hours 
without eating, drinking [except water ], or any significant physical activit y and before taking 
AHMs).Patient-reported outcomes questionnaires should be administered as early as possible in 
the visit, as per Suggested Visit Structure ( Section10.8).Preferred administration order:  
1.PGIs
2.SF-36v2 acute form
3.IWQOL-Lite-CT
4.EQ-5D-5L  
The mental health questionnaires (Patient Health Questionnaire-9 [PHQ-9], Columbia-Suicide 
Severity Rating Scale [C-SSRS], and Self -Harm Form) should be com pleted after the assessment 
for AEs.
CONFIDENTIAL I8F-MC-GPHL
28Participants will receive an init ial consultation with a dietician,or equivalent qualified delegate,
according to local standards . Lifestyle goals for caloric intake and physical activity will be set 
(Section5.3).
Following rando mization, study site personnel  will demonstrate use of the autoinjector (also 
referred to as single -dose pen) using the provided demonstration device and observe the study  
participant inject the first dose of tirzepatide or placebo. The date ,time,and location of the first 
dose of study  drug willbe recorded on the electronic case report form (eCRF). Beginning at 
randomization, all part icipants will receive study  drug according to the randomized treatment 
arm for the durati on of the 72-week treatment period including a dose escalat ion period of up to
20weeks.  
Treatment Period (End of Visit 3 to Visit 21)
During the treatment period, office visits will occur monthly through 24 weeks and then every 
12weeks thereafter, to 72 weeks. The parti cipant shoul d be fasting for all office visits. 
Telephone visits will occur at 4- week intervals between the office visits starting at Week 28.  
Office visit procedures should be conducted according to the S oA(Section1.3), andwill include :
weight,waist circumference ,and vital sign smeasurements 
laboratory  testing 
administration of PRO squestionnaires
collection of AEs, product com plaints(PCs),and conco mitant medications
review of SMBG valuesand hypoglycemic events collected in the diary
Mental Heal th questionnaires
review of participantdiary information (to include reinforcement and co mpliance 
assessments for study  drug administrati on and lifestyle goals)
study drug and supplies dispensing
Patient-reported outcomes quest ionnaires should be administered as early as possible in the visit ,
as per Suggested Visit Structure ( Section10.8).Preferred administration order is the same as 
Randomization visit .  
Mental Heal th questionnaires should be co mpleted after the assessment of AEs.  
Lifestyle consultations continue at Weeks 4, 8, 12, and then every 12 weeks thereafter, to 
Week72. Study  drug and inject ion supplies will be returned per the S oA(Section1.3) and 
according to local requirements. New supplies will be dispensed as needed.
Study drug dose escalation is double- blinded and will be managed via the interactive 
web-response system (IWRS). The starting dose is 2.5 mg QW (or matching placebo) for 
4weeks, then the dose is increased by 2.5 mg (or matching placebo) every 4 weeks (2.5 to 5to 
7.5 to 10 mg) for those randomized to 10 mg, continuing to 12.5 to 15 mg for those randomized 
to 15mg. The dose is then maintained for the remainder of the study. In participants who 
experience into lerable GI symptoms , the dose can be changed as described in the Sect ion 6.6.2. 
At each of the 8 scheduled telephone visit s, procedures will include :
collection of AEs, PCs,and concomitant medicat ions
review of SMBG valuesand hypoglycemic events collected in the diar y
CONFIDENTIAL I8F-MC-GPHL
29administration of Mental Healt h questionnaires
review of participantdiary information (to include reinforcement and co mpliance 
assessments for study  drug administrati on and lifestyle goals )
Participants shoul d be instructed to contact the investigative site for assistance as soon as 
possible if they experience any difficult ies administering their study  medication. Participants 
should also be advised about the appropriate course of action in the event that study  drug is not 
taken at the required time (lat e/missing doses) .
Study participants will be permitted to use concomitant medications that they  require during the 
study, except certain excluded medicat ions (see Secti on 5.2)thatmay interfere with the 
assessment of efficacy  and safet y characteri stics of the study  treatments.  
Visit 99
Visit 99is only applicable to participants who discontinue the study treatmen t prematurely 
(before Week 72)and decline to complete the remaining scheduled study visits. These 
participants will be asked to return for Visit 99at 72 weeks ± 7 day s after randomization (See 
Section 7.2.1.). This visit is critical to ensure complete data collect ion for the primary weight 
loss endpoint.  
Participants shoul d attend thi s visit in the fasting state. Procedures to be completed are :
measurement of weight and waist circumference
listing of conco mitant medications
assessment of AEs, and 
completion of the Mental Health questionnaires (after the AE assessment).
For participants unwilling to attend this visit, their refusal to attend sho uld be docum ented in the 
participant medical record. 
4.1.1.2.3. Early Discontinuation of Treatment Visit
Participants unable or unwilling to continue the study  treatment for any reason will  perform an 
early discontinuat ion(ED)of treatmentvisit(Section 7.1). If the participant is discontinuing 
during an unscheduled visit or a scheduled visit, that visit should be performed as an ED visit. 
Procedures should be completed according to the S oA.Patient-reported outcomes quest ionnaires 
should be administered as early as possible, as per Suggested Visit Structure (Section 10.8).
Administrati on of Mental Health questionnaires should fo llowassessment for AEs .
4.1.1.3. Safety Follow -up Period
Visit 801
All participants are required to complete a safet y follow-up visit (Visit 801), according to the 
SoA. Participants discont inuing the study early and performing an ED visit will also be asked to 
perform the safety  follow-up visit. During the safety fo llow-up period, participants will not 
receive study  drug. Parti cipantsmay be treated with another glucose -lowering intervent ionat the 
discretion of the investigator or participant’s usual diabetes care physician (see Secti on 6.5.2). If 
any new AHMis initiated during the safet y follow-up period, it will notbe classified as rescue 
CONFIDENTIAL I8F-MC-GPHL
30therapy(see Section6.5.3.1). Participants are also requi red to return any  remaining study  diaries 
to the study  site at the end of this peri od.
For participants who discont inue or complete the study, Visit 801 (safet y follow-up visit) shoul d 
be performed 4 weeks after the last visitofthe treatment period(Visit 21 or 99) or 4 weeks after 
the EDvisit for those who decline to return for Visit 99.  
Study Procedures
Participants will perform study  procedures listed in the SoA.
Participants will be permitted to use concomitant medicat ions that they  require during the study , 
except certain medicat ions that may interfere with the assessment of efficacy and safet y 
characterist ics of the study  treatments(Section 5.2).
Study governance considerations are described in detail in Sect ion 10.1(Appendix 1).
4.2. Scientific Rationale for Study Design
 
 It is administered QW by  SC injecti on. 
As a dual  GIP/GLP -1R agonist, tirzepatidecould exceed the efficacy  of selective GLP-1R 
analogsby recruiting metabo licallyactive tissues not targeted by sele
ctive GLP-1R analogs(for 
example, adipose tissue as indicated by the observation of increased energy ut ilization) (Müller 
et al. 2018)and has the potential to reachhigher efficacy in target tissues ,such as 
insulin-producing pancreat ic beta-cells that e xpress both GIPR and GLP -1R,before reaching its 
therapeuticlimitation. Results fro m a Phase 2 study (GPGB) demo nstratedthat tirzepatide use in 
participants with T2DMwas associated with a substantial, dose -dependent weight loss, greater 
than the weight change observed wit h dulaglutide, a specific GLP -1R agonist.General safet y 
characterist ics of all studied doses of ti rzepatide were similar to that of the GLP -1Ragonist class, 
consisting mainly of nausea, vo miting, and diarrhea. In general, these events were transient and 
mild or moderate in severit y, with few severe episodes .This suggest sthat tirzepatide has the 
potential to becom e a medicat ion for chronic weight management.
Although GIAEs were more commo n in the15-mg arm of tirzepatidein the Phase 2 study 
(GPGB), thisdose demonstrated the highest efficacy  in terms of weight l oss.An optimized dose 
escalationregimen proposed in the Study GPHL to improve tolerabilit y (and supported by  a dose
escalation algorithm from study GPGFand PK/PD modelling) should enable a use of higher 
doses to maximize effects on body  weight.
Study GPHL is designed t o determine the comparative benefit s and risks of t irzepatide 10mg
and15mg QW versus placebo in participants with T2DM who have obesit y or are overweight.
A double-blind design was selected to minimize participant and invest igator bias in assessments 
for efficacy , safety, and study  drug tolerability.
A placebo com parator was selected for this trial in accordance with regulatory  guidance (FDA 
2007; EMA 2016). In addit ion, all part icipants, regardless of treatment assignment, will receive 
lifestyle modification counselling and diabetes educati onconsistent wi th current gui delines for 
weight management ( Jensen et al. 2014)and T2DM management ( ADA 2020 ). Specifically, 
CCI
CONFIDENTIAL I8F-MC-GPHL
31participants will consult with a diet ician, or equivalent qualified delegate ,throughout the study to 
achieve approximately a 500 kcal /day energy deficit through a combinat ion of caloric restrict ion 
and increased physical act ivity.
The planned durat ion of treatment for the primary endpo int at 72 weeks allows for a 52 -week 
treatment period at the dose achieved fo llowing dose escalat ionto either 10 or 15 mg. This 
duration is considered appropriate to assess the full effects and benefit/risk of each maintenance 
dose of tirzepat ide compared with placebo on body weight and is consistent with regula tory 
guidelines (FDA 2007; EMA 2016).  
The effects of study drug cessati on will be assessed in the 4-weeksafety follow-up/observat ional 
period. To minimize the potential confounding effect of changes to concomitant medicat ions, 
participantswill be permi tted to use concomi tant medicat ions that do not interfere with the 
assessment of efficacy  or safety characteristics of the study  treatments.
4.3. Justification for Dose
Dose selection for the tirzepatide program focused on address ingthe unmet need o f achieving 
greater than 10% weight loss ( Srivastava and Apovian 2018a ; Ganguly et al. 2018)in order to 
provide greater metabolic and functional benefits to people with obesit y. 
Tirzepatide doses of 10 m g and 15 m g QW will be evaluated in this study . These doses and 
associated escalat ion schemes were selected based on assessment of safet y, efficacy (weight 
loss), and GI tol erability datain Phase 1 and 2 studies with T2DM , followed by exposure 
response modeling of the datathat predicted weight loss in patients with overweight or obesi ty.
In a 26-week, Phase 2 study  (GPGB) of participants with T2DM, tirzepat ide reduced body  
weight by 4.8 kg, 8.7 kg, and 11.3 kg at dose levels of 5, 10, and 15 mg, respect ively, whereas 
the weight loss observed in partic ipants on dul aglutide, a selective GLP -1R agonist, used at the 
dose of 1.5 mg, was 2.7 kg (Frias et al. 2018).  
Similar to the GLP -1R agonist class, most of tirzepatide AEs were dose dependent and 
GI-related, consisting mainly of nausea, vo miting, and dia rrhea. In general, these events were 
mild or moderate in severit y, with few severe episodes, and transient. 
Tirzepatide doses of 10 m g and 15 m g were selected based principally  on the foll owing cri teria:
each dose provides robust weight loss relat ive to placebo ,
the percent of patients achieving >10% is higher wit h 15 mg than 10 mg, 
both doses are expected to address the unmet need of achieving greater than 10% weight 
loss, and 
safety and tolerabilit y of 10 mg and 15 m g were supported by  Phase 2 resul ts and/or 
PK/PD m odeling.
Tirzepatide dose of 5 m gis not selected as a m aintenance dose since it is unlikely to help address 
the unmet need of achieving greater than 10% weight loss . This is further supported by  the 
following data fro m the T2DM Phase 2 Study GPGB:
only 16.7% of participants on 5 mg achieved >10% weight loss compared to 45.5% 
and 54.3% of participants on 10 mg and 15 mg, respectively , in the 26 -week on 
treatment analysis
CONFIDENTIAL I8F-MC-GPHL
32patients treated with t irzepatide 5mg demonstrated a placebo -correctedmean body 
weight loss of 4.4 kg and m ean percentage weight loss of 4.7%
oamong the 4 currently FDA -approved medicationsfor chronic weight 
management, placebo -corrected mean body  weight loss and mean 
percentage weight loss fro m baseline range from 2.9 to 8.6 kg and fro m 
2.9% to 8.6%, respectively  (Apovian et al . 2015)
oalthough there were no head-to-head clinical trials comparing tirzepat ide 
with the current FDA -approved medicationsfor chronic weight
management, based on data fromGPGB, it is unlikely that tirzepat ide 5mg 
will demo nstrate significant benefit over exist ing treatment options and 
address the unmet need of achieving greater than 10% weight loss to 
provide greater metabolic and functional benefits to people with obesit y
To address the decrease dtolerabilit y and increased treatment discont inuation in the 15-mg arm 
observed in GPGB, Lilly conducted the Phase 2 study  GPGF to investigate the impact of 
different starting doses and escalat ion regimens on tolerabilit y. Slower dose escal ation and 
smaller dose increments are anticipated to improve tolerabilit y. Dosing algori thms starting at a 
low dose of 2.5 m g accompanied by dose escalat ion of 2.5 m g increments every 4 weeks shoul d 
permit time for development of tolerance to GI events and are predicted to minimize GI 
tolerability concerns. The maximum proposed dose of 15 mg maintains an exposure mult iple of 
1.6 to 2.4 to the no -observed adverse effect level doses in 6 -month monkey and rat toxico logy 
studies.
4.4. End of StudyDefinition
Section 7.2describes the criteria used to determine if a participant has com pleted the study .The 
end of the study  is defined as the date of the last visit of the last participant in the study  or last 
scheduled procedure shown in the SoAfor the last participant in the trial glo bally.
CONFIDENTIAL I8F-MC-GPHL
335. Study Population
Prospective approval o f protocol deviations to recrui tment and enro llment criteria, also known as 
protocol waivers or exempt ions, is not permitted.
5.1. Inclusion Criteria
Participants are eligible to be included in the study only if all o f the following crite ria apply:
Type of Participant and Disease Characteristics
1.Have a BMI ≥27 kg/m2 
2.Have a diagnosis of T2DM according to the World Health Organizat ion 
(WHO)classification or other locally applicable standards (see Section10.10), 
withHbA1c ≥7% (≥53 mmol/mol) to≤10%(86 mmol/mol) at screening , on 
stable therapy  for the last 3 monthsprior to screening . Type 2 diabetes mellitus 
may be treated with diet/exercise alone or anyoral glycemic-lowering agent 
(as per local labeling) EXCEPT dipeptidyl peptidase 4(DPP-4)inhibitors or 
GLP-1Ragonists
3.Have a history  of at least 1self-reported unsuccessful dietary  effort to l ose
body weight 
4.In the invest igator’s opinio n, are well -motivated, capable, and willing to: 
perform fingerstick BG monitoring, including weekly fasting glucose 
measurements and scheduled BG profiles wit h up to 7 measurements in 1 day 
learn how to self- inject study  drug, as requi red for this protocol  (visually impaired 
persons who are not able to perform the inject ions must have the assistance of a 
sighted individual trained to inject the study  drug; persons wi th physical 
limitations who are not able to perform the inject ions must have the assistance of 
an individual trained to inject the study  drug) 
inject study  drug (or receive an inject ion from a trained individual if visually 
impaired or with physical limitat ions)
follow study procedures for the dura tion of the study , including, but not limited to 
follow lifestyle advice (for example, dietary restrictions and exercise plan), 
maintain a study  diary, and complete requi red questi onnaires
Participant Characteristics
5.Are at least 18 yearsof age andage ofmajority per local laws and 
regulations
a.Male parti cipants:
Male parti cipantswith partners of childbearing potent ialshould be 
willing to use reliable contraceptive methods throughout the study  and 
CONFIDENTIAL I8F-MC-GPHL
34for 5 half-lives of study  drug plus 90days, correspondi ng to 4 months 
after the last injection
b.Female participants : 
Female participants not of childbearing potential may participate and 
include those who are: 
oinfertile due to surgical sterilizat ion (hysterectomy, bilateral 
oophorectomy , or tubal ligation), congenital ano maly such as 
Mullerian agenesis; or 
opostmenopausal –defined as eit her:
A woman at least 40 years of age with an intact uterus, not 
on hormone therapy , who has cessat ion of menses for at 
least 1 year without an alternative medical cause, AND a 
follicle-stimulating hormone (FSH)≥ 40mIU/mL; women 
in this category  must test negative in pregnancy  test prior to 
study entry
or
A woman 55 or older not on hormone therapy , who has had 
at least 12 m onths of spontaneous amenorrhe a
or
A woman at least 55 years of age with a diagnosis of 
menopause prior to starting hormone replacement therapy 
(HRT)
Female participants of childbearing potential (not surgically  sterilized 
and between menarche and 1 -year postmenopausal) must:
otest negative for pregnancy  at Visit 1 based on a serum  
pregnancy test ,
oif sexually  active, agree to use 2 forms of effect ive 
contraception, where at least 1 form is highly effective for the 
duration of the trial plus30 days, corresponding to 2 months 
after the last injection, and
onot be breastfeeding
Note:Contraceptive use by men or women should be consistent with local regulat ions 
regarding the methods of contraception for those participat ing in clinical studies.
Informed Consent
6.Capable of giving signed informed co nsent as described in Appendix 1 which 
includes compliance with the requirements and restrictions listed in the ICF 
and in this protocol
5.2. Exclusion Criteria 
Participants are excl uded from  the study  if any of the fo llowing criteria apply:
CONFIDENTIAL I8F-MC-GPHL
35Medical Conditions
Diabetes-related
7.Have type 1 diabetes mellitus (T1DM), history of ketosis or hy perosmolar 
state/com a, or any other types of diabetes except T2DM
8.Have had 1 or more episode of severe hypoglycemia and/or 1 or more episode 
of hypoglycemia unawareness wit hin the 6 months prior to Visit 1
9.Have at least 2 confirmed fasting SMBG value s>270 mg/dL (15.0mmol/L) 
(on 2nonconsecutive days) prior to Visit 3
10.Have history  of:
proliferative diabet ic retinopathy OR
diabetic macular edema OR 
nonproliferative diabet ic retinopathy that requi res acute treatment.
Note:A dilated fundoscopic examinat ion perform ed by an ophthalm ologist or 
optometrist between Visit 2 and Visit 3 is required to confirm eligibilit y.
11.Currentor priortreatment(within 3 months prior to Visit 1) withDPP-4 
inhibitors, oral GLP -1Ragonist, or anyinjectable therapy for T2DM
Obesity-related
12.Have a self -reported change in body  weight >5 kg within 3 mo nths prior to 
screening
13.Have a prior or planned surgical treatment for obesit y (excluding liposuct ionor 
abdominoplast yif performed >1 year prior to screening )
14.Have or plan to have endoscopic and/or device -based therapy  for obesity or 
have had device removal wit hin the last 6 months prior to screening
mucosal ablat ion 
gastric artery embolization 
intragastric balloon 
duodenal-jejunal endoluminal liner
Other medical
15.Have renal impairment measured as est imated glomerular filtrat ion rate 
(eGFR) <30 mL/min/1.73 m2, calculated by  Chronic Kidney  
Disease-Epidemio logy as determined by central laboratory  during screening 
Note:For participants on metformin therapy ,their renal function must be greater than 
the country-specific thresho ld criteria for discont inuing metformin therapy per local 
label.
CONFIDENTIAL I8F-MC-GPHL
3616.Have a known clinically significant gastric empt ying abnormalit y (for 
example, severe gastroparesis or gastric outlet obstruction) or chronically  take 
drugs that direct ly affect GI motility
17.Have a history  of chronic or acute pancreatit is 
18.Have a thy roid-stimulating hormone (TSH) outside of 0.4 to 6.0 mIU/Lat the 
screening visit
Note:Participantsreceiving treatment for hy pothyroidism may be incl uded, provi ded 
their thyroid hormone replacement dose has been stable for at least 3 months and their 
TSH at sc reening falls wit hin the range indicated above .
Note:Participantswith a history ofsubclinical hypothy roidismbut a TSH at screening 
within the range indicated above, may  be included if ,in the invest igator’s opinio n, the 
participant is unlikely  to require initiation of thyroid horm one replacement during the 
course of the study .
19.Have obesit y induced by  other endocrinol ogic disorders (for example Cushing 
syndrome) or diagnosed monogenet ic or syndromic forms of obesit y (for example, 
Melanocorti n 4 Receptor deficiency or Prader Willi Syndrome)
20.Have a history  of significant active or unstable Major Depressive Disorder 
(MDD) or other severe psychiatric disorder (for example, schizophrenia, 
bipolar disorder, or other serious mood or anxiet y disorder) wi thin the last 
2years
Note:Participants wi th MDD or generalized anxiety  disorder whose disease state is 
considered stable for the past 2 y ears and expected to remain stable throughout the 
course of the study , in the opinio n of the invest igator, may be consid ered for inclusio n 
if they are not on excluded medicat ions.
21.Have any lifet ime history of a suicide attem pt
22.Have a PHQ -9 score of 15 or more on or before Visit 3
23.On the C-SSRSat Visits 1, 2, or 3, prior to randomizat ion:
a “yes” answer to Question 4 (Act ive Suicidal Ideation with Some Intent to Act, 
Without Specific Plan) on the “Suicidal Ideat ion” portion of the C-SSRS 
or 
a “yes” answer to Question 5 (Act ive Suicidal Ideation with Specific Plan and 
Intent) on the “Suici dal Ideation” portion of the C -SSRS 
or 
a “yes” answer to any  of the suicide-related behaviors (actual attempt, 
interrupted attem pt, aborted attempt, preparatory  act or behavior) on the 
“Suicidal Behavior” portion of the C -SSRS 
CONFIDENTIAL I8F-MC-GPHL
37and 
the ideation or behav ior occurred wi thin the past month
24.Have uncontrolled hypertensio n (systolic blood pressure [SBP]≥160mmHg 
and/or diastolic blood pressure ≥ 100 mmHg)
25.Have any of the fo llowing cardi ovascular condi tions within 3 months prior to 
randomization: acute myocard ial infarction, cerebrovascular accident (stroke), 
unstable angina, or hospitalizat ion due to congestive heart failure (CHF)
26.Have NYHA Functional Classificat ion class IV CHF
27.Have acute or chronic hepat itis, signs and symptoms of any liver disease other 
than nonalcoho lic fatty liver disease (NAFLD), or any of the fo llowing, as 
determined by the central laboratory  during screening :
alanine aminotransferase (ALT)level >3.0Xthe upper limit of normal ( ULN)for 
the reference range ,
alkaline phosphatase (ALP) level >1.5X the ULN for the reference range, or
total bilirubin level (TBL) >1.2X the ULN for the reference range (except for 
cases of known Gilbert’s Syndrome)
Note:Participants wi th NAFLD are eligible to participate in this trial if their ALT 
level is ≤3.0Xthe ULN for the reference range .
28.Have a serum calcitonin level (at Visit 1) of :
≥20 ng/L, if eGFR ≥60 mL/min/1.73 m2
≥35 ng/L, if eGFR <60 mL/min/1.73 m2 
29.Have a family or personal history  of medullary thyroid carcinoma (MTC) or 
multiple endocrine neoplasia (MEN) syndro me type 2
30.Have a history  of an active or untreated malignancy or are in remissio n from a 
clinically significant malignancy (other than basal or squamous cell skin 
cancer, in situ carcino mas of the cervix, or in situ prostate cancer) fo r less than 
5years
31.Have any other condit ion not listed in this sect ion (for example, 
hypersensit ivity or intolerance) that i s a contraindication to GLP -1Ragonists
32.Have a history  of any other condit ion (such as known drug or alcoho l abuse, 
diagnosed eatin g disorder ,or other psychiatric disorder) that, in the opinio n of 
the investigator, may preclude the participant fro m following and com pleting 
the protocol
33.Have history  of use of marijuana or tetrahydrocannabino l(THC)-containing 
products within 3 months of enro llment or unwillingness to abstain from 
marijuana or THC-containing products use during the trial. 
CONFIDENTIAL I8F-MC-GPHL
38Note:If a participanthas used cannabidio l oil during the past 3 m onths but agrees to 
refrain fro m use for the duration of the study , the participantcan be enro lled.
34. Have had a transplanted organ (corneal transplants [keratoplasty] allowed) or 
awaiting an organ transplant
35.Have any hematological condit ion that may interfere with HbA1c measurement 
(for example, hemo lytic anemias, sickl e cell disease)
Prior/Concomitant Therapy
36.Are receiving or have received wit hin 3 months prior to screening chronic 
(>2weeks or >14 day s) systemic glucocorticoid therapy  (excluding topi cal, 
intraocular, intranasal, intraarticular,or inhaled preparations) or have evidence 
of a significant, active autoimmune abnormalit y (for exam ple, lupus or 
rheumatoi d arthritis) that has required (within the last 3months) or is likely to 
require, in the opinio n of the invest igator, concurrent tre atment with systemic 
glucocorticoids (excluding topical, intraocular, intranasal, intraarticular,or 
inhaled preparations) during the course of the study
37.Have a current or history  of (within 3 months prior to randomizat ion) treatment 
with medications that may cause significant weight gain, including but not 
limited to: tricyclic ant idepressants ,atypical antipsychotic s,and mood 
stabilizers
Examples :
imipramine
amitriptyline
mirtazapine
paroxetine
phenelzine
chlorpromazine
thioridazine
clozapine
olanzapine
valproic acid (and its derivat ives), or
lithium
Note:Selective serotonin reuptake inhibitors (SSRIs) other than paroxetine are 
permitted. Antihyperglycemic medicat ions (for example,sulfonylureas,
thiazolidinediones)for the management of T2DM are permitt ed. 
38.Have taken wit hin 3 months prior to randomizat ion, medications (prescribed or 
over-the-counter) or alternat ive remedies that promote weight loss  
Examples include, but are not limited to:
Saxenda (liraglut ide 3.0 mg)
Xenical®/Alli® (orlistat)
CONFIDENTIAL I8F-MC-GPHL
39Meridia® (sibutramine)
Acutrim® (phenylpropanolamine)
Sanorex® (mazindo l)
Apidex® (phentermine)
BELVIQ® (lorcaserin)
Bontril®(phendimetrazine)
Qsymia™ (phentermine/topiramate combinat ion)
Contrave® (naltrexone/bupropion) 
Note:Antihyperglycemic medications for the management of T2DM (for example,
sodium-glucose cotransporter [SGLT]-2 inhibitors) are permitted. 
39.Have started implantable or injectable contraceptives (such as Depo Provera ®) 
within 18 m onths prior to screening
Prior/Concurrent Clinic al Study Experience
40.Are current ly enrolled in any other clinical study  involving an invest igational 
product (IP) or any other type of medical research judged not to be 
scientifically or medically co mpatible wit h this study
41.Within the last 30 day s, have participated in a clinical study  and received 
treatment, whether acti ve or placebo. If the study  involved an IP, 5half-lives or 
30days, whichever i s longer, shoul d have passed 
42.Have previously co mpleted or withdrawn fro m this study or any other study  
investigat ing tirzepatide after receiving at least 1dose of IP
Other Exclusions
43.Are invest igator site personnel directly affiliated wit h this study  and/or thei r 
immediate family. Immediate family is defined as a spouse, parent, child, or 
sibling, whether bio logical or legally adopted
44.Are Lilly employees
5.3. Lifestyle Considerations 
Per the SoA, participants will consult a dietit ian, or equivalent qualified delegate, according to 
local standards, to receive lifest yle management couns eling at Weeks 0, 4, 8 ,and 12 during dose 
escalation and then at Week 24 and every  12weeks thereafter through 72 weeks.  
Diet and exercise goal s established during the lifestyle consultat ion and the importance of 
adherence to the lifest yle component of the trial will be reinforced at each trial contact by  study 
staff.
Study participants shoul d be instructed not to donate blood or blood products during the study .
Meals and Dietary Restrictions
At Visit 3 and subsequent visit s study participants will receive diet arycounseling by a dietician,
or equivalent qualified delegate, according to l ocal standard. Di etary counseling will consist of 
CONFIDENTIAL I8F-MC-GPHL
40advice on healt hy food choices and focus on cal orie restri ction using a hypocalori c diet with 
macronutrient composi tion of:
maximum 30% of energy  from fat,
approximately  20% of energy from protein,
approximately  50% of energy from carbohydrates, and 
an energy  deficit of approximately 500 kcal/day  compared to the parti cipant’s est imated 
total energy expenditure (TEE). 
To encourage adherence, it is recommended that a 3-day dietand exercise log be completed prior 
to each counseling visit. During each visit, the participant’s diet is reviewed and advice to 
maximize adherence is provided if needed.
The hypocaloric diet is cont inued throughout the treatment period. If a BMI ≤22kg/m2is 
reached,the recommended energy  intake shoul d be recal culated wi th no kcal deficit for the 
remainder of the trial.
Total energy expenditure is calculated by mult iplying the estimated basal 
metabolic rate (BMR) 
(see table below) with a Physical  Activity Level value of 1.3 (FAO/WHO/UNU 2004 ), which 
reflects an inactive lifest yle. This calculat ion provides a conservat ive estimate of caloric 
requirements:
TEE (kcal /day)=BMRX1.3
Equations for estimating BMR in kcal/day*
Sex Age BMR(kcal/day)
Men 18to 30years 15.057 X actual weight in kg+692.2
31to 60years 11.472 Xactual weight in kg + 873.1
>60 years 11.711 Xactual weight in kg + 587.7
Women 18to 30years 14.818 Xactual weight in kg +486.6
31to 60years 8.126 Xactual weight in kg + 845.6
>60 years 9.082 Xactual weight in kg + 658.5
Abbreviation: BMR = basal metabolic rate ; WHO=World Health Organization .
*Revised WHO equations (adapted from: FAO/WHO/UNU 2004) .
Physical Activity
At Visit 3 and all subsequent visits, p articipants will be advised to increase their physical act ivity 
to moderate intensity(for example, brisk walking) for at least 150 minutes per week .
CONFIDENTIAL I8F-MC-GPHL
41
Diabetes Education
Diabetes educat ion willbe performed by  personnel who are qualified to educate participants on 
symptoms and management of hyperglycemia and hypoglycemia, SMBG , self-injection and 
diabetes management . It will be provided to study  participants at Visit 2 according to American 
Diabetes Association Standards of Medical Care in Diabetes (ADA 2020) or local standards . 
Additional trainings may be provided during the study as needed.
5.4. Screen Failures
Screen failures are defined as participants who consent to participate in the clinical studybut are 
not subsequently randomly  assigned to study  intervention. 
A minimal set of screen failure 
information is required to ensure transparent reporting of screen failure participants to meet the 
Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to 
respond to queries from regulatory  authorities. Minimal information includes demography, 
screen failure details, eligibilit y criteria, and any  serious adverse event (SAE).
Individuals who do not meet the criteria for participation in this study  (screen failure) may notbe 
rescreened. 
CONFIDENTIAL I8F-MC-GPHL
426. Study Int ervention
Study intervention is defined as an y investigational intervention(s), marketed product(s), 
placebo,or medical device(s) intended to be administered to /used bya study participant 
according to the study  protocol.
6.1. Study Intervention(s) Administered
ArmName Tirzepatide 10 mg Tirzepatide 15 mg Placebo
Dose 10 mg QW 15 mg QW N/A
Route of 
AdministrationSC
Sourcing Provided centrally  by the Sponsor and dispensed via IWRS
Packaging and 
LabelingStudy intervention will be provided in autoinjectors (single-dose pens) , 
packaged in cartons to be dispensed. Clinical study materials will be 
labeled according to country  regulatory requirements.
Abbreviations: IWRS= interactive web -response sy stem; N/A= not applicable, QW = onceweekly, 
SC=subcutaneous .
There are no restrict ions on the time of day  each weekly dose of study  drug is given, but it is 
advisable to administer the SCinjections on the same day and same time each week. The actual 
date,time
,and inject ion site location of all dose administrati ons will be recorded in the diary by 
the participant. If a dose of study drug is missed, the participant should take it as soon as possible 
unless it i s within 72hours of the next dose, in which case, that dose should be skipped and the 
next dose should be taken at the appropriate time. The day of weekly administration can be 
changed if necessary ,as long as the l ast dose was administered 72 or more hours before.
All participants will inject study  drug subcutaneously in the abdomen or thigh using the injection 
supplies provided; a caregiver may admini ster the inject ion in the participan t’s upper arm . The 
injection site location o f all dose administrations will be recorded by the participant. A new
autoinjector will be used for each injection.If study drug is to always be injected in the same 
body region, participantsshould be advised to rotateinjection siteseach week.
Medical Devices
The combination products provided for use in the study are tirzepatideinvestigational 
autoinject or(or matching placebo). Any AEs resulting from device deficiencies, misuse, or 
malfunctionsmust be detected, documented, and reported by  the invest igator through out the 
study(see Section 10.4.3).
CONFIDENTIAL I8F-MC-GPHL
436.2. Preparation/Handling/Storage/Accountability
The invest igator or designee must confirm appropriate storageconditions have 
been maintained during transit for all study  intervention received and any 
discrepancies are reported and resolved before use of the study  intervention.
Only participants enro lled in the study  may receive study  intervention.Only study  
personnel may supply, prepare, or administer study intervent ion. All study  
intervention must be stored in a secure, environmentally controlled, and 
monitored (manual or automated) area in accordance with the labeled storage 
conditions with access limited to t he investigator and authorized study personnel .
The invest igatoror authori zed study  personnel are responsible for study  
intervention accountabilit y, reconciliat ion, and record maintenance ( in other 
words, receipt, reconciliat ion, and final disposit ion records).
Further gui dance and information for the final disposit ion of unused study  
interventions are provided in the study training m aterials.
6.3. Measures to Minimize Bias: Randomization and Blinding
This is a double -blind, randomized study.
Participants who meet all criteria for en rollment will be rando mized to 1of the study  treatment 
groupsat Visit 3. Assignment to treatment groups will be determined by a co mputer-generated 
random sequence using an IWRS. Participant s will be rando mized in a 1:1: 1 ratio to receive
tirzepatide10 mg, tirzepatide15 mg,or placebo.  
The rando mization will be stratified by  country, sex(female, male), and type of AHMused at 
randomization(classified according to its potential effect on body  weight,see table below ). 
Stratification Based on the Use of Antihyperglycemic Medications
Stratum Potential Body Weight 
EffectParticipants to be Included in the Corresponding Stratum
1 Significant weight loss The use of an SGLT -2 inhibitor alone or in combination with 
any other AHMs except for an SU or TZD
2 Significant weight gain The use of an SU alone or in combination with any other AHMs 
except for an SGLT -2 inhibitor 
OR 
The use of a TZD alone or in combination with any other AHMs 
except for an SGLT -2 inhibitor
3 Weight neutral and others Lifestyle management o nly: no background AHMs
OR
Metformin monotherapy  
OR 
The use of an SGLT -2 inhibitor in combination with an SU 
and/or TZD, with or without other AHMs 
Note: The body weight effect of SGLT -2 inhibitor may be offset 
CONFIDENTIAL I8F-MC-GPHL
44Stratum Potential Body Weight 
EffectParticipants to be Included in the Corresponding Stratum
by SU/TZD, and vice -versa, when used in combination.
OR
All other monotherapy (such as glinides and AGIs) or 
combination therapy which does not fall under stratum 1 or 2
Abbreviations: AGI = alpha-glucosidase inhibitor ; AHM= antihyperglycemic medication; SGLT= sodium-glucose 
cotransporter ; SU= sulfonylurea; TZD= thiazolidinedione .
Investigators, site s taff, clinical monitors ,and participants will remain blinded to the treatment 
assignments unt il the study is complete .
Emergency  unblinding m ay be perform ed through the IWRS.This option may be used ONLY if 
the participant’s well -being requires knowledge of the participant’s treatment assignment. All 
unblinding event sare recorded and reported by  the IWRS.
If aninvestigator,site personnel performing assessments or participant is unblinded, the 
participant must be discontinued from the study. In cases where there are ethical reasons to have 
theparticipant remain on study drug, the invest igator must obtain specific approva l from a Lilly 
clinical research physician (CRP) for the participant to continue in the study .
In case of an emergency , the invest igator has the sole responsibilit y for determining if unblinding 
of a participant’s treatment assignment is warranted for medical management of the event. The 
participant’ssafety must always be the first consideration in making such a determinat ion. If a 
participant’s treatment assignment is unblinded, Lilly  must be notified immediately . If the 
investigator decides that unbl inding is warranted, it is the responsibilit y of the investi gator to 
promptly docum ent the decisio n and rationale and notify Lilly as soon as possible.
6.4. Study Intervention Compliance
Participant compliance wi th study intervention will be assessed at each visit. Compliance will be 
assessed by  direct questi oningandcounting of unused study  drug and/or em pty cartons returned. 
Study drug com pliance will  be determined by  the following: 
Study drug administration data will be recorded by the participantand reviewed 
by the investigator at each study  visit.
The participants will be instructed to return any unused study drug and/or empt y 
cartons at the next visit to the study  site for the purpose of performing drug 
accountabilit y.
Treatment compliance for each vis it interval is defined as taking at least 75% of the required 
doses of study  drug. Similarly, a participantwill be considered significant ly noncompliant if he 
or she is judged by the invest igator to have intent ionally or repeatedly  taken more than the 
prescribed amount of medication (more than 125%) .  
CONFIDENTIAL I8F-MC-GPHL
45In addition to the assessment of a participan t’s compliance wit h the study  drug administration, 
other aspects of compliance with the study treatments will be assessed at each visit based on the 
participant’sadherence to the visit schedule, complet ion of study  diaries, and any other 
parameters the investigator considers necessary.
Participants considered to be poorly co mpliant with their medicat ion and/or the study  procedures 
will receive addit ional training and instructi on, as requi red, and will be reminded of the 
importance of co mplying with the protocol.
6.5. Concomitant Therapy
Participants will be permitted to use concomitant medicat ions that they  require during the study , 
except certain medicat ions (for example,other medi cations for weight management , see
Section5)that may interfere with the assessment of efficacy and safet y characteristics of the 
study treatments.
Investigative site staff will inform participantsthat they must consul t with the inves tigator or a 
designated si te staff member upon being prescribed any  new medicat ions during the study . This 
may not be possible when init iated for treatment of medical emergencies, in which case ,the 
participantwill inform the invest igator or a designated site staff member as soon as possible.  
Nonstudy medications taken by  participantswho are screened but not randomized will not be 
reported to Lilly  unless an SAE or AE occurs that the invest igator believes may have been 
caused by  a study procedure .
Management of T2DM at randomization
Use of conco mitant glucoselowering medicat ions will be permitted at randomization, with the 
exception of GLP- 1Ragonist, DPP-4 inhibitors, or other injectable therapies (for example, 
insulin). To minimize the risk for hypogl ycemia, participants taking insulin secretagogues 
(for example, sulfonylurea )at randomization should have their dose halved (or stopped if 
already on the lowest dose ) at randomization. All other AHMwill be cont inued at their 
current dose at randomizat ion.
Initiation of New Antihyperglycemic Medication
The introduction of new AHMsother than study  drug is expected during the study ONLY in the 
following situat ions: 
Asa rescue therapy  forthe managementof severe, persistent hyperglycemia as defined in 
Section6.5.3.1
In those participants who require permanent discont inuation of study  drug, but r emain in 
the study
During the safet y follow-up period
Amylin analogues/agonists , GLP-1Ragonistand DPP-4 inhibitors are not allowedat any time 
during study , including the situations described above (after permanent discont inuation of study  
drug, as rescue therapy ,and during safet y follow-up).
CONFIDENTIAL I8F-MC-GPHL
46
Management of T2DM after randomization
6.5.3.1. Management of Severe, Persistent Hyperglycemia 
Participants who devel op persistent severe hyperglycemia during the treatment period may  be 
candidates for glycemic rescue and shoul d be considered for addit ion of or dose increase in 
antihyperglycemic therapies. The choice of new antihyperglycemic therapy  (with the except ion 
of amylin analogues/agonists ,GLP-1Ragonists,or DPP-4inhibitors) or amount of dose increase 
will beat the discretion of theinvestigator or the participant’s usual diabetes care physician, 
according to local and internat ional guidelines for individualized treatment of patientswith 
T2DM. Metformin is recommended to be used as a first-linerescue therapy for participants who 
receive diet/exercise alo ne;basal insulin may be consi dered for participants already receiving 
combination therapy of ≥3 AHMsat the time o f study entry.The use of rescue therapy  should be 
recorded on a specific eCRF page.
Glycemic rescue criteria will be primarily determined fro m weekly fasting SMBG values 
recorded in participant diaries. Investigators and/orthe participant’s usual care physician may 
initiate rescue therapy for the management of hyperglycemia if at least 2 confirmed values are :
>270mg/dL (15.0 mmol/L) over at least a consecutive 2-week peri od at any time during 
the first 8weeks post-randomizat ionOR
>240mg/dL (13.3 mmol/L) over at least a consecutive 2-week peri od at any time 9 to 
16weeks post -randomizat ionOR
>200mg/dL (11.1 mmol/L) over at least a consecutive 2-week peri od at any time beyond 
the first 16 weeks post -randomizat ion
OR
HbA1c ≥8.5%(69mmol/mol)on and after Week 24 (only 1 value needed)
Note: Investigators should first confirm t hat the patient is fully co mpliant with the assigned 
therapeutic regimen and that he or she does not have an acute condit ion causing severe 
hyperglycemia .
Short-term treatment with insulin for l ess than 14 days is allowed for certain clinical situat ions 
(for example, elective surgery, during hospitalizat ion, hyperosmolar states,or acute illness). This 
is not considered as rescue therapy and it must be different iated from rescue therapy  when 
reported in the eCRF. 
For participants who discont inue study tr eatment permanent ly and continue to participate in the 
study, doses of background AHMs may be increased and new AHMs may  be initiated at the 
discretion of investigators and/or participant’s usual care physician . This is not considered as 
rescue therapy . Itmust be differentiated from rescue therapy when reported in the eCRF. 
Similarly, during the safet y follow-up period, any increase in the dose of background AHM or 
the initiation of new AHM is not considered as rescue therapy  either and must be different iated 
from rescue therapy  when reported in the eCRF. 
6.5.3.2. Management of Hypoglycemia Risk
Participants will be trained in the signs and symptoms of hypoglycemia and its treatment and 
instructed to record pertinent information about hypoglycemic events in their s tudy diary. 
CONFIDENTIAL I8F-MC-GPHL
47Participants who devel op persistent or recurrent unexplained hypoglycemia during the treatment 
period will be asked to reduce the dose or discont inue any conco mitant AHM, starting preferably 
with the ones commonly associated with hypoglycemia ( for example, sulfo nylurea). Monitoring 
for hypoglycemia includes capture of events as described in Sect ions 8.3.2.1and10.4
Appendix 4.
6.6. Dose Modification
Tirzepatide
Tirzepatide is given QWby SC injection. There are no restrict ions on the time of day each 
weekly dose of tirzepat ide is given, but it is advisable t o administer the SCinjections on the 
same day of the week andsimilartime each week. If a dose of ti rzepatide is missed, the 
participantshould take it as soon as possible unless it is within 72hours of the next dose, in 
which case, that dose should be skipped and the next dose should be taken at the appropriate 
time.  
Study drug dose modificat ion is not permitted, except for management of intolerable GI 
symptoms ( see Section 6.6.2).  
Management of Participants with Gastrointestinal Symptoms
Participants who experi ence intol erable GI symptoms (for example, nausea, vomit ing, or 
diarrhea)at any time during the study  should first be counseled on dietary  behaviors that m ay 
help mitigate nausea and vo miting (for example, eating smaller meals, splitt ing 3daily meals 
into 4 or more smaller ones, and stopping eat ing when they feel full) (see Section 10.9). If 
symptoms persist, the participant should be prescribed, at the invest igator’s discret ion, 
symptomat ic medication (for example, antiemetic or antidiarrheal medication). A temporary 
interruption of study drug for 1 dose is permitted, provided the participant has taken the last 
3weekly doses. Study  treatment should be resumed immediately, either alone or in combination 
with symptomatic medication, which can also be utilized to manage symptoms. Management of 
study drug after interruptions >1 dose is discussed in Section 7.1.1.
If intolerable GI symptoms ( for example, nausea, vomit ing, or diarrhea) persist despite the above 
measures, the invest igator should contact Lilly to consider reinitiating study drug at the next-
lowermaintenance dose in a blinded fashio n (for example, 15 mgand 12.5mgreduced to 10 mg, 
10mg or lower reduced to placebo) .Only 1dose reduction per participant will be permitted 
during the course of the study .  
If intolerable GI symptoms persist despite symptomat ic treatment, temporary drug interruption, 
and resumpt ion at a lower dose of study drug, the participant should be discont inued from the 
study drug. All participants who discontinue study  drug shoul d continue to attend scheduled 
study visits. All dose adjust ments will be managed through IWRS.
6.7. Intervention after the End of the Study
Tirzepatide will not be made available to participants after conclusion o f the study.
CONFIDENTIAL I8F-MC-GPHL
487. Discontinuation of Study Intervention a nd Participant 
Discontinuation/Withdrawal
7.1. Discontinuation of Study Intervention
In rare instances, it may be necessary  for a participant to perm anently discont inue (definit ive 
discontinuat ion) study intervention. If study  intervention is definitively discontinued, the 
participant will remain in the study  to be evaluated for any trial endpo int at the end of the study .
See the SoA for data to be collected at the time of discontinuat ion of study  intervention and 
follow-up and for any  further evaluat ions that need to be completed. 
Possible reasons leading to permanent discontinuatio n of IP:
Participant Decision
oThe participant requests to discontinue IP
Clinical Considerations
oInitiation of open-label GLP -1R agonist, amylin analogues/agonists ,or DPP-4 
inhibitor, if part icipants will not or cannot discont inue them
oIntolerable GI symptoms despite management as described in Section 6.6.2
oBMI ≤18.5kg/m2is reached at any  time during the treatment period 
Note:The invest igator should contact the sponsor CRP to discuss whether it is 
medically appropriate for the participant to continue study  treatment. 
oDiagnosis of T1DM
oDiagnosis of MTC or MEN syndrome t ype 2
oSignificant el evation of serum calcitonin (Section 8.3.2.4)
oDiagnosis of acute or chronic pancreat itis 
oDiagnosis of an active or untreated malignancy  (other than basal  or squam ous cell 
skin cancer, in situ carcino mas of the cervix, or in situ prost ate cancer) 
oIf the investigator, after consultation with the sponsor -designated medical mo nitor, 
determines that a systemichypersensit ivity reaction has occurred related to study 
drug administration, the participant should be permanent lydiscontinuedfrom the 
investigat ional drug
oOnset of pregnancy in a female participant 
oOccurrence of any other treatment-emergent AE ( TEAE), SAE, or clinically 
significant finding for which the invest igator believes that permanent study drug 
discontinuat ion is the approp riate measure to be taken
CONFIDENTIAL I8F-MC-GPHL
49oInadvertent enrollment if cont inued treatment with study  drug woul d not be m edically 
appropriate .
oPHQ-9 score ≥15  
Participants shoul d be referred to a mental health professional (MHP) 
to assist in deciding whether the subject should be discontinued fro m 
study drug. If a parti cipant’s psychiatric disorder can be adequately  
treated with psycho -and/or pharmacotherapy , then the subject, at the 
discretion of the investigator (in agreement with the MHP), may be 
continued in the tria l on rando mized therapy.  
oin addition, study drug may be discont inued if participants:
answered “yes”to Question 4 (Active Sui cidal Ideation with Some 
Intent to Act, Without Specific Plan) on the "Suicidal Ideation" portion 
of the C-SSRS
or
answered “yes”to Question 5 (Active Sui cidal Ideation with Specific 
Plan and Intent) on the "Suicidal Ideation" portion of the C -SSRS 
or 
answered “yes”to any of the suicide -related behaviors ( Actual 
attempt, Interrupted attempt, Aborted attempt, Preparatory  act or 
behavior) on the “Suicidal Behavior” portion of the C-SSRS
Note:A psychiatrist or appropriately trained professio nal may assist in the decisio n to 
discontinue the participant.
Discontinuation due to a hepatic event or liver test abnormality
oParticipants who are di scontinued from IP due to a hepat ic event or liver test 
abnormality should have addi tional hepatic safet y data collected via eCRF
oDiscontinuati on of the IPfor abnormal liver tests should be considered by the 
investigator when a part icipant meets 1of the following condit ions after 
consultation wit h the Lilly designated medical monitor:
ALT or aspartate aminotransferase (AST) >8X ULN
ALT>2X baseline value or≥300U/L, whichever occurs first, if baseline ALT
≥2XULN
ALT or AST >5X ULNfor more than 2 weeks
ALT or AST >3X ULN and TBL >2X ULN or internat ional normalized rati o 
(INR)>1.5 
CONFIDENTIAL I8F-MC-GPHL
50ALT or AST >3X ULN with the appearance of fat igue, nausea, vo miting, 
right-upper-quadrant pain or tenderness, fever, rash, and/or eosinophilia 
(>5%)
ALP>3XULN
ALP >2.5X ULN and TBL >2X ULN
ALP >2.5X ULN with the appearance of fatigue, nausea, vo miting, right-
upper-quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)
Participants who stop the study  drug perm anently shoul d continue to atten d all scheduled study  
visitsto collect all planned efficacy and safet y measurements. Participants who stop the study  
treatment post-randomizat ion and prior to 72 weeks but are unwilling to attend remaining 
scheduled visits should return for Visit 99 for a final weight measurement. If these participants 
are unwilling to attend Visit 99, their refusal to attend shoul d be docum ented in the pati ent 
medical record .
See the SoAfor data to be collected at the time of intervention discontinuation and fo llow-up and 
for any further evaluat ions that need to be completed.
Temporary Study Drug Discontinuation
In certain situat ions, after randomizat ion, the investigator may need to tempo rarily interrupt 
study drug. Every  effort shoul d be made by the investigator to maintain participants on study  
drug and to restart study  drug after any  temporary interruption, as soon as i t is safe to do so. 
Distribution of study  medication at the correct dose will be per IWRS instructions. 
If study drug 
interruption is…then…
2 consecutive doses 
or less participant restarts study  drug at last 
administered dose, as per escalat ion 
schedule.
3 consecutive doses 
or more participant restarts study  drug (at 5mg, 
managed by IWRS) and repeats dose 
escalation scheme.
due to an AE the event is to be documented and fo llowed 
according to the procedures in Sect ion8.3
of this protocol .
due to intol erable 
persistent GI AEparticipantsshould be treated as suggested 
in Section 6.6.2.
Abbreviations: AE = adverse event; GI = gastrointestinal; IWRS = interactive web response service.
CONFIDENTIAL I8F-MC-GPHL
51Investigators should inform the sponsor that study  drug has been temporarily interrupted. The 
data related to temporary  interruption of study treatment will be documented in source 
documents and entered on the eCRF.
7.2. Participant Discontinuation/ Withdrawal from the Study
To minimize the amount of missing data and to enable assessment of study  objectives as planned 
in the study protocol, every attempt will be m ade to keep parti cipants in the study  irrespective of 
the following:
adherence to or discont inuation from study drug
adherence to visit schedule
missing assessments
study drug discontinuation due to AE 
development of como rbidities
development of clinical outcomes
The circumstances listed above are notvalid reasons for discont inuation from the study. 
A participantmay withdraw from  the study :
at any time at his/her own request 
at the request of his/her designee (for example, parents or legal guardian)
at the discretion of the invest igator for safet y, behavioral, compliance, or 
administrative reasons
if enrolledin any other clinical study  involving an IPor enrolledin any other 
type of medical research judged not to be scientifically or medically  
compatible with this study
if the participant, for any reason, requi res treatm ent (pharmaco logical, device 
based or surgical) that has been demonstrated to be effect ive for treatment of 
the study indication, discont inuation from the study  occurs pri or to 
introduction of the new treatment
Female participants will be withdrawn fro m the study if the parti cipant beco mes pregnant.
Participation in the study  can be stopped for medical, safety , regulatory, or other reasons 
consistent with applicable laws, regulat ions, and good clinical pract ice (GCP). Participants who 
agree to provide information relevant to any  trial endpoint at the end of the study  are not 
considered to have discont inued from the study .
At the time of discont inuing from the study , if possible, an EDvisitshould be conducted, as 
shown in the SoA ( Section 1.3)(see also Section 4.1.1).See SoA for data to be collected at the 
time of study  discontinuation and safety follow-up and for any  further evaluat ions that need to be 
CONFIDENTIAL I8F-MC-GPHL
52completed.The participant will be permanent ly discontinued both from the study intervent ion 
and from the study at that time.
If the participantwithdraws consent for disclosure of future inform ation, the sponsor may retain 
and continue to use any data collected before such a withdrawal o f consent.If a participant
withdraws fro m the study, he/she may  request destr uction of any samples taken and not tested ,
and the invest igator must document this in the site study records .
CONFIDENTIAL
53
Participant disposition and timing of safety follow -up 
Abbreviations: ED= early discontinuation , wks= weeks .
I8F-MC-GPHL
CONFIDENTIAL I8F-MC-GPHL
54
Discontinuation of Inadvertently Enrolled Participants
If the sponsor or i nvestigator identifiesa participantwho did not meet enrollment criteria and 
was inadvertently enrolled, the investigator and t he sponsor CRP must agree whether continuing 
the study treatment is medically  appropriate. Continuat ion of inadvertently enro lled participants 
in the study ,with or without study drug treatment, requires docum ented approval fro m the 
sponsor CRP .Safety follow-up should be performed as outlined in Sect ion 1.3(SoA), Section 
8.3(Adverse Events and Serious Adverse Events), and Sect ion8.2(Safety Assessments) of the 
protocol.
7.3. Lost to Follow -up
A participant will  be considered l ost to follow -up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contacted by  the study  site.Site personnel or designeeare 
expected to make diligent attempts to contact participants who fail to return for a scheduled visit 
or were otherwise unable to be fo llowed up by the site.
Site personnel, or an independent third party , will attempt to collect the vital status of the 
participantwithin legal and ethical boundaries for all participantsrandomized, including those 
who did not get IP. Public sources may be searched for vital sta tus informat ion. If vital status is 
determined to be deceased
, this will be documented ,and the participant will not be considered 
lost to follow-up.
Lilly personnel will not be invo lved in any attempts to collect vital status informat ion.
Discontinuati on of specific sites or of the study  as a who le are handled as part of Section10.1
(Appendix 1 ).
CONFIDENTIAL I8F-MC-GPHL
558. Study Assessments and Procedures
Study procedures and their timing are summarized in the SoA (Section1.3) .
Immediatesafety concerns should be discussed wit h the sponsor immediately  
upon occurrence o r awareness to determine if the participant should continue or 
discontinue study intervention.
Adherence to the study  design requi rements, including those specified in the SoA, 
is essential and required for study conduct.
All screening evaluat ions must be completed and reviewed to confirm that
potential participants meet all eligibility criteria. The invest igator will maint ain a 
screening log to record details o f all participants screened and to confirm 
eligibility or record reasons for sc reening failure, as applicable.
8.1. Efficacy Assessments
Primary Efficacy Assessments
The primary  efficacy measurement in this study  isbody weight. Body  weight m easurements will 
be collected at specific clinic visits as summarized in the SoA. Methods for measuring body  
weightare described in Section 10.7(Appendix 7).
Secondary Efficacy Assessments
The following secondary  efficacy measures will be collected at the times shown in the SoA: 
BMI (derived using body  weight in kilograms divided by  the square of height in meters)
Waist circumference (m easuring method is described in Section 10.7)
HbA1c (measured th rough central  lab)
Fasting glucose (measured through central lab)
Fasting insulin (measured through central lab)
Blood pressure (measuring method is described in Section 10.7)
Lipids(measured through central lab)
Patient-Reported Outcomes Assessments
The self-administered questionnaires will be translated into the nat ive language of the region, 
linguistically validated and administered according to the SoA(Section 1.3). At these visits, th e 
questionnaires should be co mpleted before the participant has discussed their medical condit ion 
or progress in the study  with the invest igator and/or site staff ,if the participantis not adversely 
affected by  their fast ing condit ion.
CONFIDENTIAL I8F-MC-GPHL
568.1.3.1. Short Form -36 version 2 Health Survey acute form , 1-week recall version
The SF-36v2 acuteform, 1-week recall versio nis a 36-item generic, pa rticipant-administered 
measure designed to assess the following 8domains:
Physical Funct ioning 
Role-Physical
Bodily Pain
General Health
Vitality
Social Functioning 
Role-Emotional 
Mental Heal th.
The Physical Functioning domain assesses limitations due to health “now” while the remaining 
domains assess funct ioning “in the past week.” Each do main is scored individually  and 
information from these 8 dom ains are further aggregated into 2 health -component summary 
scores: Physical Component Summary  and Mental Com ponent Summary . Items are answered on 
Likert scales of varying lengths (3 -point, 5-point, or 6- point scales). Scoring of each domain and 
both summary  scores are norm -based and presented in the form of T- scores, with a mean of 50 
and standard deviat ion (SD)of 10; higher scores indicate better levels o f function and/or better 
health (Maruish 2011).
8.1.3.2. Impact of Weight on Quality of Life-LiteClinical Trials Version
The IWQOL -Lite-CT is a 20-item, obesity-specific PRO instrument developed for use in obesit y 
clinical trials. It assesses 2primary domains of obesity-related healt h-related quali ty of life
(HRQoL) : Physical (7 items) and Psychosoci al (13 items). A 5 -item subset of the Phy sical 
domain –the Physical Funct ion composite –is also supported. Items in the Physical Funct ion 
composite describe physical impacts related to general and specific physical activit ies. All items 
are rated on either a 5 -point frequency (“never” to “always”) scale or a 5 -point truth (“not at all 
true” to “completely true”) scale (Ko lotkin et al. 2017, 201 9). 
8.1.3.3. EQ-5D-5L
Generic HRQoLwill be assessed using the EQ -5D-5L (EuroQoL Research Foundat ion 2019). 
TheEQ-5D-5L is a standardized 5-item instrument for use as a m easure of healt h outcome. It 
provides a simple descriptive profile and a single index value for health status that can be used in 
the clinical and econo mic evaluat ion of healt hcare as well as pop ulation health surveys. The 
EQ-5D-5L comprises 5 dimensio ns of health (mobilit y, self-care, usual act ivities, 
pain/disco mfort, and anxiet y/depression). The 5L versio n, introduced in 2005, scores each 
dimension at 5 levels (no probl ems, slight problems, mod erate problems, severe problems, 
unable to perform/extreme problems) for a total of 3 125possible healt h states. In addit ion to the 
health profile, a single healt h state index value can be derived based on a formula that attaches 
weights to each of the lev els in each dimensio n. This index value ranges between l ess than 0 
CONFIDENTIAL I8F-MC-GPHL
57(where 0is a health state equivalent to death; negative values are valued as worse than dead) to 1 
(perfect health) (Dolan 1997).In addition, the EuroQolVisual Analog Scale records the 
respondent ’s self-rated heal th status on a verti cal graduated (0 to 100) visual analogscale. In 
conjunction with the health state data ,it provides a com posite picture of the respondent’s healt h 
status.  
The EQ-5D-5L is used worldwide and is available in more than 170 different languages. Details 
on the instrument, scoring, organizing, and presenting the data collected can be found in the 
EQ-5D-5L User Guide ( EuroQoL Research Foundation 2019). 
8.1.3.4. Patient Global Impression of Status for Physical Activity 
Study participants will be asked to complete a PGIsitem specifically  developed for this study. 
This is a pa rticipant-rated assessment of current limitat ion on physical act ivity due to heal th and 
is rated on a 5 -point scale ranging fro m “1-not at all limited ” to “5-extremely limited.”
8.2. Safety Assessments
Planned time po ints for all safet y assessments are provided in the SoA.
Physical Examinations
A complete physical examinat ion will include, at a minimum, assessments of 
the cardiovascular, respiratory, GI,and neurologicalsystems, as well as a
thyroid exam.Height, weight,and waist circumference will also be measured 
and recorded, per Section 10.7.
Investigators should pay special attention to clinical signs related to previous 
serious illnesses.
Vital Signs
For eachparticipant, vital signs measurements shoul d be conducted according to the SoA
(Section1.3) andSection10.7(Appendix 7).
Any clinically  significant findings fro m vital signsmeasurement that result in a diagnosis should 
be reported to Lilly or its designee as an AE via the eCRF.
Electrocardiograms
For each participant, single tracing 12-Lead ECGs should be co llected according to the SoAand 
Section 10.7.
Electrocardiograms will init ially be interpreted by  a qualified physician (the investigator or 
qualified designee) at the site as soon after the time of ECG collection as possible and ideally 
while the participant is still present, for immediate subject ma nagement, should any clinically 
relevant findings be identified. Any clinically  significant findings fro m ECGs that result in a 
diagnosis should be reported to Lilly  or its designee as an AE via the eCRF.
All digital ECGs will be obtained using centrally p rovided ECG m achines and will be 
electronically transmitted to a designated central ECG laboratory . The central  ECG laboratory  
will perform a basic qualit y control check (for example , demographics and study  details) and 
CONFIDENTIAL I8F-MC-GPHL
58then store the ECGs in a database. A t a future time, the stored ECG data may  be overread by a 
cardiologist at the central  ECG laboratory  for further evaluat ion of machine -read measurements 
or to meet regulatory requirements.The machine -read ECG intervals and heart rate may  be used 
for data analysis and report -writing purposes, unless a cardio logyoverreading of the ECGs is 
conducted pri or to com pletion of the final study  report (in which case, the overread data would 
be used).
Clinical Safety Laboratory Assessments
See Section10.2Appendix 2 : “Clinical Laboratory Tests ”for the list of 
clinical laboratory  tests to be performed and to the So A for the timing and 
frequency .
Note:See Section 10.2Appendix 2 : “Clinical Laboratory  Tests”for clinical 
laboratory  tests reported or n ot reported to the investigators 
The invest igator must review the laboratory results, document this review, and 
reportany clinically relevant changes occurring during the study as an AE.
The laboratory  results must be retained with source docum entsunless a 
Source Document Agreement or comparable document cites an electronic 
location that accomm odates the expected retention duration. Clinically 
significant abnormal laboratory  findings are those which are not associated 
with the underlying di sease, unless judged by the investigator to be more 
severe than expected for the participant's cond ition.
All laboratory  tests with values considered clinically significantly abnormal 
during parti cipation in the study or within 4 weeksafter the last dose of study  
intervention should be repeated until the values return to normal or baseline or 
are no longer considered clinically significant by the invest igator or medical 
monitor.
○If such values do not return to normal/baseline within a period of time 
judged reasonable by the invest igator, the etiology should be identified ,
and the sponsor notified.
○ All protocol -required laboratory  assessments, as defined in Section10.2
Appendix 2, must be conducted in accordance wit h theSoA, standard 
collection requirements, and laboratory manual.
If laboratory  values from nonprotocol -specified laboratory  assessments 
performed atan investigator-designated local laboratory  require a change in 
participant management or are considered clinically  significant by  the 
investigator (e .g., SAE or AE or dose modification), then report the 
information as an AE.
Repeat or unscheduled samples m ay be taken for safet y reasons or for technical issues with the 
samples.Unless otherwise stated in the subsect ions below, all samples collected for specified 
laboratory  tests will be destroyed within 60 days of receipt of confirmed test results. Certain 
CONFIDENTIAL I8F-MC-GPHL
59samples may  be retained for a l onger peri od, if necessary , to comply with applicable laws, 
regulations, or laboratory  certificat ion standards .
Safety Monitoring
Lilly will periodically review evo lving aggregate safet y data within the study  by appropriate 
methods. The study  team will review safet y reports in a blinded fashio n according to the 
schedule provided in the Trial -Level Safet y Review plan. Lilly  will also review SAEs within 
time frames mandated by  company procedures. The Lilly CRP will, as appropri ate, consul t with 
the functionally independent Global Pat ient Safety therapeutic area physician or clinical scient ist.
8.2.5.1. Hepatic Safety Monitoring
Close hepatic monitoring 
Laboratory  tests (Section 10.6Appendix 6), including ALT, AST, ALP, TBL,direct bilirubin ,
gamma-glutamyltransferase , and creatine kinase ,should be repeated wi thin 48 to 72 hours to 
confirm the abnormalit y and to determine if it is increasing or decreasing, if 1or more of these 
conditions occur: 
If a participant with baseline results 
of…develops the following elevations:
ALT or AST <1.5X ULN ALT or AST ≥3XULN
ALP <1.5 XULN ALP ≥2XULN 
TBL <1.5 XULN TBL ≥2XULN (except for patients with 
Gilbert’s syndrome)
ALT or AST ≥1.5XULN ALT or AST ≥2Xbaseline 
ALP ≥1.5XULN ALP ≥2Xbaseline 
TBL ≥1.5XULN TBL ≥1.5Xbaseline (except for patients 
with Gilbert’s syndro me)
Abbreviations: ALP = alkaline phosphatase ; ALT = alanine aminotransferase ; AST = aspartate aminotransferase ; 
TBL = total bilirubin level; ULN = upper limit of normal.
If the abnormalit y persists or worsens, clinical and la boratory monitoring and evaluat ion for 
possible causes of abnormal liver tests should be init iated by the invest igator in consultat ion with 
the Lilly-designated m edical monitor. At a minimum, this evaluat ion should include physical 
examination and a thorough medical history , including symptoms, recent illnesses (for example, 
heart failure, systemic infect ion, hypotension, or seizures), recent travel, history of conco mitant 
medications (including over -the
-counter), herbal and dietary  supplements, history  of alcohol 
drinking,and other substance abuse.
Initially, monitoring of symptoms and hepat ic biochemical tests should be done at a frequency o f 
1 to 3 times weekly , based on the parti cipant’s clinical condit ion and hepat ic biochemic al tests. 
Subsequently, the frequency o f monitoring may be lowered to once every  1 to 2 weeks, if the 
participant’s clinical condit ion and lab results stabilize. Moni toring of ALT, AST, ALP, and 
TBL should cont inue until levels normalize or return to appro ximate baseline levels.
Comprehensive hepatic evaluation
CONFIDENTIAL I8F-MC-GPHL
60A comprehensive evaluat ion should be perform ed to search for possible causes of liver injury  if 
1or more of these condit ions occur: 
If a participant with baseline results 
of…develops the following elevations:
ALT or AST <1.5X ULN ALT or AST ≥3XULN with hepat ic 
signs/symptom s*, orALT or AST ≥5X
ULN 
ALP <1.5X ULN ALP ≥3XULN 
TBL <1.5 XULN TBL ≥2XULN (except for patients with 
Gilbert’s syndrome) 
ALT or AST ≥1.5XULN ALT or AST ≥2Xbaseline wit h hepatic 
signs/symptom s*, orALT or AST ≥3X
baseline 
ALP ≥1.5XULN ALP ≥2Xbaseline 
TBL ≥1.5XULN TBL ≥2Xbaseline (except for patients 
with Gilbert’s syndrom e)
Abbreviations: ALP= alkaline phosphatase ; ALT= alanine aminotransferase ; AST= aspartate aminotransferase ; 
TBL= total bilirubin level; ULN= upper limit of normal.
*Hepatic signs/symptoms are severe fatigue, nausea, vomiting, jaundice, right-upper-quadrant abdominal pain, 
fever, rash, and/or eosinophilia >5% . 
At a minimum, this evaluat ion should include physical examinat ion and a thorough medical 
history, as outlined above, as well as tests for prothrombin time-INR; tests for viral hepat itis A, 
B, C, or E; tests for autoimmune hepatit is; and an abdo minal imaging study  (for example, 
ultrasound or computed tomography [ CT]scan).
Based on the patient’s history  and initial results, further testing should be considered in 
consultation wit h the Lilly -designated m edical monitor, including tests for hepatit is D virus, 
cytomegalovirus, Epstein -Barr virus, acetaminophen levels, acetaminophen protein adducts, 
urine toxico logy screen, Wilso n’s disease, blood alcohol levels, urinary ethyl glucuronide, and 
bloodphosphatidylethanol. Based on the circumstances and the inv estigator’s assessment of the 
participant’s clinical condit ion, the invest igator should consider referring the participant for a 
hepatologist or gastroenterologist consultation, magnet ic resonance cho langiopancreatography , 
endoscopi c retrograde cholangiopa ncreatography, cardiac echocardiogram, or a liver biopsy.
Additional hepatic data collection (hepatic safety CRF) in study participants who have 
abnormal liver tests during the study
Additional hepatic safet y data collect ion in hepatic safety case report f orm (CRF)should be 
performed in study  participants who meet 1 or more of the fo llowing 5 condi tions: 
1. Elevation of serum ALT to ≥5XULN on 2 or more consecutive blood tests (if baseline 
ALT <1.5 XULN) 
In participants wi th baseline ALT ≥1.5XULN, the thresho ld is ALT ≥3Xbaseline on 
2 or more consecut ive tests 
CONFIDENTIAL I8F-MC-GPHL
612. Elevated TBL to ≥ 2XULN (if baseline TBL <1.5 XULN) (except for cases of known 
Gilbert’s syndrome) 
In participants wi th baseline TBL ≥1.5XULN, the thresho ld should be TBL ≥2X
baseline 
3. Elevation of serum ALP to ≥2XULN on 2 or more consecutive blood tests (if baseline 
ALP <1.5 XULN) 
In participants wi th baseline ALP ≥1.5XULN, the thresho ld is ALP ≥2Xbaseline on 
2 or more consecut ive blood tests 
4. Hepatic event consider ed to be a nSAE 
5. Discontinuati on of study drug due to a hepati c event
Note:The interval between the 2consecutive blood tests should be at least 2 days. 
Depression, Suicidal Ideation , and Behavior Risk Monitoring
Patientswho have obesit y or are overweightare at increased risk for depression (Luppino et al. 
2010).Depression can increase the risk for suicidal ideation and behavior. Therefore, study  
participants will be screened at trial entry  and monitored during the study  for depressi on,suicidal 
ideation,and behavior.  
Participants should be monitored appropriately  and observed cl osely for sui cidal ideation and 
behavior or any  other unusual changes in behavior, especially at the beginning and end of the 
course of treatment, or at the time of d ose changes, ei ther increases or decreases. Consideration 
should be given to discont inuing the study medicatio n in subjects who experience signs of 
suicidal ideation or behavior, fo llowing a risk assessment (Section 7.1).
Baseline and treatm ent-emergent (TE)assessment of depressio n, suicidal ideation,and behavior 
will be mo nitored during the study using the C -SSRS and PHQ- 9 (Section8.3.2.13).
8.3.Adverse Events ,Serious Adverse Events , and Product Complaints
The definit ions of the fo llowing events can be found in Sect ion 10.4Appendix 4:
Adverse events ( AEs)
Serious adverse events ( SAEs)
Product complaints (PCs)
These events will be reported by  the participant (or, when appropriate, by  a caregiver, surrogate, 
or the participant's legally authorized representative).
The invest igator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet these definit ions and remain responsible for fo llowing up events that 
are serious, considered related to the study intervent ion, study device or devi ce constituent, or 
study procedures, or that caused the participant to discontinue the study intervention (see 
Section7).
CONFIDENTIAL I8F-MC-GPHL
62Care will be taken not to introduce bias when detecting events. Open-ended and nonleading 
verbal quest ioning of the participant is the preferred method to inquire about event occurrences .
After the init ial report, the invest igator is required to proactively fo llow each participant at 
subsequent visits/contacts. All SAEs will be fo llowed until resolution, stabilizat ion, the event is 
otherwise explained, or the participant is lost to fo llow-up (as defined in Sect ion7.3). For 
product complaint s, the investigator is responsible for ensuring the fo llow-up includes any  
supplemental  investigations as indicated to elucidate the nature and/or causalit y. Further 
information on follow-up procedures is providedin Section10.4(Appendix 4).
Timing and Mechanism for Collecting Events
This table describes the timing, deadlines, and mechanism for collect ing events.
Event Collection 
StartCollection Stop Timing for Reporting 
to Sponsor or 
DesigneeMechanism for 
ReportingBack-up 
Method of 
Reporting
Adverse Event
AE signing of 
the informed 
consent form 
(ICF)the safety 
follow-up visit 
OR participation 
in study has 
endedAs soon as possible 
upon site awarenessAE eCRF N/A
Serious Adverse Event
SAE and SAE 
updates –prior 
to start of study 
intervention and
deemed 
reasonably 
possibly related 
with study 
proceduressigning of 
the ICFstart of 
interventionWithin 24 hours of 
awarenessSAE eCRF SAE paper 
form
SAE and SAE 
updates –after 
start of study 
interventionstart of 
interventionThe safety 
follow-up visit
ORparticipation 
in study has 
endedWithin 24 hours of 
awarenessSAE eCRF SAE paper 
form
CONFIDENTIAL I8F-MC-GPHL
63Event Collection 
StartCollection Stop Timing for Reporting 
to Sponsor or 
DesigneeMechanism for 
ReportingBack-up 
Method of 
Reporting
SAE –after 
participant’s 
study 
participation has 
ended andthe 
investigator 
becomes awareAfter 
participant’s 
study 
participation 
has endedN/A Promptly SAE paper form N/A
Pregnancy
Pregnancy in 
female 
participants and 
female partners 
of male 
participantsAfter the 
start of study 
interventio nFour months 
after the last 
injection for 
female partners 
ofmale 
participants and 
2 months after 
the last injection 
for female 
participants Within 24 hours of 
learning of the 
pregnancyeCRF SAE paper 
form
Product Complaints
PC associated 
with an SAE or 
might have led 
to an SAEStart of study 
interventio nEnd of study 
interventio nWithin 24 hours of 
awarenessProduct Complaint
formN/A
PC not 
associated with 
an SAEStart of study 
interventio nEnd of study 
interventio nWithin 1 business day 
of awarenessProduct Complaint
formN/A
Updated PC 
information— — As soon as possible 
upon site awarenessOriginally 
completed Product 
Complaint form 
with all changes 
signed and dated by 
the investigatorN/A
CONFIDENTIAL I8F-MC-GPHL
64Event Collection 
StartCollection Stop Timing for Reporting 
to Sponsor or 
DesigneeMechanism for 
ReportingBack-up 
Method of 
Reporting
PC(after 
participant’s 
study 
participation has 
ended andthe 
investigator 
becomes aware )After 
participant’s 
study 
participation 
has endedN/A Promptly Product Complaint
formN/A
Abbreviations: AE = adverse event; eCRF = electronic case report form; N/A = not applicable; PC =product 
complaint; SAE = serious adverse event.
Special Safety Topics
8.3.2.1. Hypoglycemia 
Upon ICF signing, all participants will be educated about signs and symptoms of hypoglycemia,
how to treat hy poglycemia, and how to collect appropriate informat ion for each episode of
hypoglycemia.
Participants who devel op persistent or recurrent unexplained hypoglycemia during the treatment 
period will be asked to reduce the dose or discont inue any conco mitant AHMscommonly 
associated with hypoglycemia (for example, sulfo nylurea).  
All hypoglycemic episodes will be recorded on a specific eCRF (Hypoglycemic Events eCRF) 
and shoul d not be recorded on the AE eCR F, unless the event meets serious criteria. If a 
hypoglycemic event meets severe criteria (see definit ion below), it should be recorded as serious 
on the AE and SAE eCRFs, and reported to Lilly as an SAE. All post-treatment hypoglycemic 
events collected on the hy poglycemic eCRF will be considered as treatment -emergent and 
included in the analysis o f incidence and rate of hypoglycemic events.
Investigators should use the fo llowing definit ions and criteria when diagnosing and categorizing 
an episode considered to be related to hy poglycemia (the BGvalues in this se ction refer to values 
determined by a laboratory  or Internati onal Federati on of Clinical Chemistry and Laboratory  
Medicine blood -equivalent glucose meters and strips) in accordance with the 2020 American 
Diabetes Association posit ion statement on glycemic targets(ADA 2020):
Glucose alert value (Level 1):
Documented symptomatic hypoglycemia is defined as any time a participant feels 
that he or she is experiencing symptoms and/or signs associated with hypoglycemia 
and has a BG level o f <70 mg/dL (<3.9mmol/L).
CONFIDENTIAL I8F-MC-GPHL
65Documented asymptomatic hypoglycemia is defined as any event not accompanied 
by typical symptoms of hypoglycemia but with a measured BG <70mg/dL 
(<3.9mmol/L).
Documented unspecified hypoglycemia is defined as any event with no inform ation 
about symptoms of hypoglycemia available but with a measured BG <70mg/dL 
(<3.9mmol/L).
Clinically significant hypoglycemia (Level 2):
Documented symptomatic hypoglycemia is defined as any time a participant feels 
that he or she is experiencing symptoms and/or signs associ ated with hypoglycemia 
and has a BG level o f <54 mg/dL (<3.0 mmol/L).
Documented asymptomatic hypoglycemia is defined as any event not accompanied 
by typical symptoms of hypoglycemia but with a measured BG level <54mg/dL 
(<3.0mmol/L).
Documen ted unspecified hypoglycemia is defined as any event with no informat ion 
about symptoms of hypoglycemia available but with a measured BG level <54mg/dL 
(<3.0mmol/L).
Severe hypoglycemia (Level 3):
Severe hypoglycemia is defined as an episode with severe cognitive impairment 
requiring the assistance of another person to actively  administer carbohydrate, 
glucagon, or other resuscitative act ions. These episodes may be associated with 
sufficient neuroglycopenia to induce seizure or coma. Blood glucose measurements 
may not be available during such an event, but neurological recovery attributable to 
the restoration of BG to normal is considered sufficient evidence that the event was 
induced by  a low BG concentrati on.
Nocturnal hypoglycemia:
Nocturnal hypoglycemi ais defined as any hypoglycemic event that occurs between 
bedtime and waking.
To avoid duplicate reporting, all consecutive BG values <70mg/dL (3. 9mmol/L) occurring 
within a 1-hour period may be considered to be a single hypoglycemic event 
(Weinberg etal.2010; Danne et al. 2013).  
8.3.2.2. Pancreatitis 
Diagnosis of acute pancreatitis
Acute pancreat itis is an AE of interest in all studies w ith tirzepatide, including this study . The 
diagnosis of acute pancreat itis requires 2 of the fo llowing 3 features (Banks et al. 2006;Koizumi 
et al. 2006):
abdominal pain, characterist ic of acute pancreat itis (that is, epigastric pain radiat ing 
to the back, often associated with nausea and vo miting)
CONFIDENTIAL I8F-MC-GPHL
66serum amylase (total, pancreat ic, or both) and/or lipase ≥3X ULN
characteri stic findings of acute pancreat itis on CT scan or magnet ic resonance 
imaging (MRI)
If acute pancreat itis is suspected, the invest igator should :
obtain appropriate laboratory  tests, including pancreatic amylase (p -amylase) and 
lipase
perform imaging studies , such as abdo minal CT scan wit h or without contrast, 
abdominal MRI , or gallbladder ultrasound
Note:Abdominal ultrasound may be used as an alternat ive method only if CT and MRI 
cannot be performed
evaluate for possible causes of acute pancreatit is, including alcoho l use, gallstone/gall 
bladder disease, hypertriglyceridemia, and conco mitant medications.
Discontinuation for acute pancreatitis
If acute pancreat itis is diagnosed, the participant must discont inue use o f the IP, but will cont inue 
in the study .
Case adjudication and data entry
An independent clinical endpo int committee (CEC) will adjudicate all suspected cases of acute 
pancreatitis. In addition, AEs of severe or serious abdo minal pain o f unknown et iology will also 
be submitted to the adjudication committee to assess for possible pancreat itis or other pancreatic 
disease. 
Asymptomatic elevation of pancreatic amylase and/or lipase
Serial measures of pancreat ic enzymes have limit ed clinical value for predicting episodes of 
acute pancreatit is in asymptomatic patients (Nauck et al. 201 7; Steinberg et al. 2017a, 2017b). 
Therefore, further diagnostic fo llow-up of cases of asymptom atic elevation of pancreatic 
enzymes (lipase and/or p- amylase ≥3X ULN) is not mandated but may  be perform ed based on 
the investigator’s clinical judgment and assessment of the participant’s overall clinical condit ion.
8.3.2.3. Thyroid Malignancies and C -Cell Hyperplasia 
Individuals with personal or family history  of MTC and/or MEN -2 will be excluded from the 
study. Participants who are d iagnosed with MTC and/or MEN -2 during the study will have study 
drug stopped and should cont inue follow-up with an endocrino logist.
The assessment of thy roid safety during the tri al will include reporting of any  case of thyroid 
malignancy (including MTC ,papillary carcinom a, and others ) and measurements of calcitonin. 
Thesedata will be captured in specific eCRFs. The purpose of calcitonin measurements is to 
assess the potential of t irzepatide to affect thyroid C -cell funct ion, which may  indicate 
developm ent of C-cell hyperplasia and neopl asms. 
CONFIDENTIAL I8F-MC-GPHL
678.3.2.4. Calcitonin Measurements 
If an increased calcitonin value (see definit ions below) is observed in a participan t who has been 
administered a medicat ion that is known to increase serum calcitonin , thenthis medicat ion 
should be stopped ,and calcitonin levels should be measured after an appropriate washout period.
For participan tswho require addit ional endocrine assessment because of increased calcitonin 
concentration as defined in this sect ion, data from the follow-up assessment will be co llected in 
the specific sect ion of the eCRF.
Calcitonin Measurements in Participants with eGFR ≥60 mL/min /1.73 m2
A significant increase in calcitonin for participants with eGFR ≥60 mL/min/1.73 m2is defined 
below. If a participant’s laboratory resultsmeet thesecriteria, these clinically  significant 
laboratory resultsshould be recorded as an AE.  
Serum calcitonin value ≥20 ng/L and <35 ng/L AND ≥50% increase from the screening 
value.These participants will be asked to repeat the measurement within 1 month. If this 
repeat val ue is increas ing (≥10% increase), the study  drug shoul d be stopped, and the 
participantencouraged to undergo addit ional endocrine assessment and longer term,
follow-up by an endocrinol ogistto exclude anyserious adverse effect on the thyroid.
Serum calcitonin value ≥35 ng/L AND ≥50% over the screening value . In these 
participants, study drug shoul d be stopped, and the participant recommended to 
immediately  undergo addi tional endocrine assessments and lo nger term ,follow-up by an 
endocrino logist.  
Calcitonin Measurement in Participants with eGFR <60 mL/min /1.73m2
A significant increase in calcitonin for participants with eGFR <60 mL/min/1.73m2is defined as 
a serum calcitonin value ≥35 ng/L AND ≥50% over the screening value. If a participant’s labs 
meet thesecriteria, these clinically  significant l abs should be recorded as an AE.  
In these participants, study  drug shoul d be discontinued (after first confirming the value) and the 
participant recommended to immediately undergo addit ional endocrine assessments and lo nger-
term follow-up by an endocrinol ogistto exclude any serious  adverse effect on the thyro id.  
8.3.2.5. Major Adverse Cardiovascular Events 
Deaths and nonfatal cardiovascular AEs will be adjudicated by  a committee of physicians 
external to Lilly with cardio logy expertise. This committee will be blinded to treatment 
assignment. The nonfatal cardiovascular AEs to be adjudicated include :
myocardial infarction 
hospitalization for unstable angina
hospitalization for heart failure
coronary interventions (such as coronary  artery bypass graft or percu taneous coronary  
intervention), and 
CONFIDENTIAL I8F-MC-GPHL
68cerebrovascular events, including cerebrovascular accident (stroke) and transient 
ischemic attack.
8.3.2.6. Supraventricular A rrhythmias and Cardiac Conduction Disorders
Treatment -emergent cardiac conduction disorders will be further evaluated. Participantswho 
develop any event from these groups of disorders should undergo an ECG, which should be 
submitted to the cen tral reading center. Additional diagnostic tests to determine exact diagnosis 
should be perform ed, as needed. The specific diagnosis will be recorded as an AE. Events that 
meet criteria for serious conditions as described in Section 10.4mustbe reported as SAEs. 
8.3.2.7. Hypersensitivity Reactions
Many drugs, but parti cularlybiologic agents ,carry the ri sk of systemic hypersensit ivity 
reactions.If such a reacti on occurs, a dditional data describing each symptom should be provide d
to the sponsor in the eCRF.  
Sites should have appropri ately trained medical  staff and appropri ate medical equipment 
available when study participantsare receiving study  drug. It is recommended that participants
who experience a systemic hypersensit ivityreaction be treated per national and internat ional 
guidelines.
In the case of generalized urticaria oranaphylaxis ,additional blood and urine samples should be 
collected as described in Section 10.3Appendix 3 “Recommended Laboratory  Testing for 
Hypersensitivity Events”. L aboratory  results are provi ded to the sponsor via the central 
laboratory .
8.3.2.8. Injection Site Reactions
Symptoms of a local injectionsite reaction may include erythema, indurati on, pain, pruri tus, and 
edema. If an injectionsite event is reported, the AE will be recorded, and additional data will be 
provided to the sponsor in the Injection Site Reaction eCRF.   
At the time of AE occurrence, samples will be co llected for measurement of tirzepatideantidrug 
antibody (ADA)and tirzepatideconcentrati on.
8.3.2.9. Antidrug Antibodies
The occurrence of ADA format ion will be assessed as outlined in Section 8.9.
8.3.2.10. Hepatobiliary Disorders
All events of TE biliary  colic, chol ecystitis, or other suspected events related to gallbladder 
disease shoul d be evaluated and addit ional diagnostic tests performed, as needed. In cases of 
elevated liver m arkers, hepati c monitoring shoul d be initiated as outlined in Sect ion 8.2.5.1.
8.3.2.11. Severe Gastrointestinal Adverse Events 
Tirzepatide may cause severe GI AEs, such as nausea, vomit ing, and diarrhea. Informat ion about 
severe GI AEs as well as ant iemetic/antidiarrheal use will be collected in the eCRF/AE form. For 
detailed informat ion concerning the management of GI AE s, please refer to Section 6.6.2.
CONFIDENTIAL I8F-MC-GPHL
698.3.2.12. Acute Renal Events
Renal safety  will be assessed based on repeated renal funct ion assessment as well as assessment
of AEs suggest ive of acute or worsening of chronic renal failure . Gastrointestinal AEs have been 
reported with tirzepatide, including nausea, di arrhea, and vo miting.This is consistent with other 
GLP-1Ragonists (Aroda and Ratner 2011). The events may lea d to dehydration, which could 
cause a deterioration in renal funct ion, including acute renal failure. Participantsshould be 
advised to notify invest igators in case of severe nausea, frequent vomit ing, or symptoms of 
dehydration.
8.3.2.13. Depression, SuicidalIdeation or Behavior Monitoring
Participants will be m onitored for depressi on and sui cidal ideation or behavior through AE 
collection and by using the C -SSRS and the PHQ -9. Participants will be referred to a MHP if in 
the opinion ofthe investigator it is necessary for the safe ty of the participant or if the participant 
had any of the following:
a PHQ-9 score ≥15
C-SSRS responses of :
oA “yes” answer to Question 4 (Act ive Suicidal Ideation with So me Intent to Act, 
Without Specific Plan) on the “Suicidal Ideation”portion of the C-SSRS
or
oA “yes”answer to Question 5 (Act ive Suicidal Ideation with Specific Plan and Intent) 
on the “Suicidal Ideati on”portion of the C-SSRS 
or 
oA “yes”answer to any  of the suicide-related behaviors (actual attempt, interrupted 
attempt, aborted attempt, preparatory  act,or behavior) on the “Suicidal Behavior”
portion of the C-SSRS
8.3.2.14. Amputation/Peripheral Revascularization 
All cases of amputation and peripheral revascularization should be reported as an AE .
8.3.2.15. Metabolic Acidosis, Including Diabetic Ketoacidosi s
Ketoacidosis, a serious life -threatening condit ion requiring urgent hospitalizat ion, has been 
reported rarely  in patients wi th T2DM. Pa rticipants who present with signs and symptoms 
consistent with severe metabo lic acidosis should be assessed for ketoacidosis regardless of 
presenting BGlevels, as ketoacidosis may be present even if BGlevels are less than 250 mg/dL. 
If ketoacidosis is suspected, SGLT-2 inhibitorshould be discontinued (if used), patients should 
be evaluated, and prompt treatment should be inst ituted. Treatment of ketoacidosis will require 
insulin, and carbohydrate replacement.
Lactic acidosis is a risk forparticipants with T2DM who excessively drink alcoho l, have 
impaired kidney function (eGFR <30 ml/min/m2),and are on m etformin therapy. Routine 
bicarbonate assessment will be performed during the course of the study . If lactic acidosis is 
CONFIDENTIAL I8F-MC-GPHL
70suspected, met formin should temporarily be discontinued (if used) unt il the reso lution of the 
event. 
8.3.2.16. Diabetic Retinopathy Complications
Dilated retinal fundoscopic exam will be performed by  an eye care professio nal (ophthalmo logist 
or optometrist) for all patients between Visit 2 and Visit 3 to excl ude participants with 
proliferative diabet ic retinopathy, diabetic macular edema ,or nonproliferat ive diabet ic 
retinopathy  that requi res acute treatm ent. 
The results from this exam will be recorded on a specific eCRF (Fundoscop yExam) as a 
baseline measure of retinopathy . A follow-up, dilated fundoscopic exam should be performed 
when clinically  indicated by  any AEsuspected of worsening retinopathy , and the findings should 
be recorded on the specificeCRFpage. 
8.4. Treatment of Overdose
Study drug overd ose (more than the specified number of injections) will be reported as an AE. In 
the event of overdose, refer to the IB for tirzepat ide.
8.5. Pharmacokinetics
Pharmacokinet ic samples will be co llected from approximately the first300randomized 
participants, approximately 100 part icipants fro m each treatment arm .
A separate written consent for the PKblood draws will be obtained at the time of the init ial trial 
consent, where applicable .
Plasma tirzepatideconcentrati ons will only be determined from blood sam ples obtained from  
participantsreceiving tirzepatidetreatment .Blood samples for PK assessment will be collected 
at Weeks 8, 16, and 36 followingtirzepatidetreatment per the SoA.At each visit prior to a PK 
assessment, e ach participantwill be assigned via IWRS to 1of the sampling PK time windows of 
1 to 24 hours , 24 to 96 hours, or 120 to 168 hours postdose.
The date and time of the most recent tirzepatide SCinjection administered prior to collect ing the 
PK sample m ust be recorded on the eCRF fro m the study diaries.
The date and time at whicheach sample was drawn must be recorded on the laboratory  accession 
page. 
Concentrations of tirzepatide will be assayed using a validated liquid chro matography mass 
spectrometry  method.Bioanalytical samples collected to measure IPconcentrations will be 
retained for a maximum o f 1 year following last subject visit for the study . During thi s time, 
samples remaining after the bioanalyses may be used for exploratory  analyses such as 
metabolism work, protein binding, and/or bioanalytical method cross -validation.  
8.6. Pharmacodynamics
Samples to assess the PDproperties of tirzepatideare included in the efficacy measures and not 
applicable in this sect ion.
CONFIDENTIAL I8F-MC-GPHL
718.7. Genetics
A whole blood sample will be co llected for pharmacogenet ic analysis as specified in the SoA
(Section1.3) where local regulat ions allow.  
Samples will notbe used to conduct unspecified disease or populat ion genetic research either 
now or in the future. Samples will be used to investigate varia ble response to tirzepat ide and to 
investigate genet ic variants though t to play a role in obesi ty. Assessment of variable response 
may include evaluation o f AEs or differences in efficacy.  
All samples will be coded with the participant number. These samp les and any data generated 
can be linked back to the participantonly by the investi gator site personnel.  
Samples will be retained at a facilit y selected by  Lilly or its designee for a m aximum of 15years 
after the last participant visit for the study , or for a shorter period if local regulat ions and/or 
ethical review boards (ERBs)/in stitutionalreview boards (IRBs) impose shorter time limit s. This 
retention period enables use o f new techno logies, response to regulatory  questions, and 
investigat ion of variable response that may not be observed unt il later in the development of 
tirzepatide or after tirzepatide beco me(s) commercially available.
Molecular techno logies are expected to improve during the 15 -year storage period and therefore 
cannot be specifically  named. However, exi sting approaches include who le genome or exome 
sequencing, geno me wide association studies, and candidate gene studies. Regardless of 
technology, utilized genoty ping data generated will be used only for the specific research scope 
described in this sect ion.
8.8. Biomarkers
Biomarker research is performed to address questions of relevance to drug disposit ion, target 
engagement, PD, mechanism of act ion, variabilit y of participant response (including safet y), and 
clinical outcome. Sample colle ction is incorporated into clinical studies to enable examinat ion of 
these questions through measurement of bio molecules including deoxy ribonucleic acid (DNA), 
proteins, lipids, and other cellular elements.
Serum and plasma samples for bi omarker research ( nonpharmacogenetic stored sample) will be 
collected at the times specified in the SoA(Section 1.3) where local regulat ions allow.
Samples will be used for research on the drug target, disease process, variable response to 
tirzepatide, pathways associated with obesit y, mechanism o f action of tirzepatide, and/or 
research method or in validat ing diagnost ic tools or assay(s) related to o besity.  
All samples will be coded with the participant number. These samples and any data generated 
can be linked back to the participant only by the investigator site personnel.  
Samples will be retained at a facilit y selected by  Lilly or its designee for a maximum 15years
after the last participant visit for the study , or for a shorter peri od if local regulations and ERBs 
impose shorter time limits. This retent ion period enables use of new technologies, response to 
regulatory questions, and invest igation of variable response that may not be observed unt il later 
in the development of tirzepat ide or after tirzepat ide becomes commercially  available.
CONFIDENTIAL I8F-MC-GPHL
728.9. Immunogenicity Assessments
Where local regulat ions and ERBs allow, blood samples for immunogenicit y testingwill be 
collected to determine ant ibody production against tirzepatideas specified in the SoA
(Section1.3).
For immunogenicit y testing, venous blood samples will be co llected from each participant
according to the SoA(Section 1.3) to determine antibody production against ti rzepatide. To 
interpret the resul ts of immunogenicit y, a venous blood sample will be co llected at the same time 
pointsto determine the plasma concentrations of tirzepatide . All samples for immunogenicit y 
should be taken predose when applicable and possible.  
In the eve nt of systemic drug hypersensit ivity reactions (immediate or nonimmediate), addit ional 
unscheduled samples shouldbe collectedas detailed in Sect ion8.3.2.7(Hypersensitivity 
Reactions).Instructions for the collect ion and handling of blood samples will be provided by the 
sponsor. The actual date and time (24- hour clock time) of each sampling will be recorded . 
Sample collected at Visit 801 will assess immunogenicit y at washout of tirzepat ide (5half-lives 
postend of treatment).
Immunogenicity will be assessed by  a validated assay  designed to detect ADAs in the presence 
of tirzepatideat a laboratory approved by the sponsor. Antibodies may be further characterized 
for their ability to neutralize the activit y of tirzepatide on GIP and GLP -1Rs. Positive tirzepatide
ADA samples willbe tested for cross -reactivity with native GIP and GLP-1, and, if posi tive, may 
then be tested for neutralizing antibodies against native GIP and/or GLP-1.In vivo laboratory 
indicators for effect on weight loss and PK will be utilized to detect potential neutralizing effect 
of ADAsagainst tirzepat ide.
Treatment -emergent ADAsare defined in Section9.4.6.  
Samples will be retained for a m aximum of 15 years after the last participant visit, or for a 
shorter period i f local regulations and ERBs allow, at a facilit y selected by  the sponsor. The 
duration allows the sponsor to respond to future regulatory  requests related to tirzepat ide. Any 
samples remaining after 15 y ears will be destroyed. 
Concentrations of tirzepat ide will be assayed using a validated liquid chro matography mass 
spectrometry  method. Bioanalytical samples collected to m easure tirzepatide concentrations will 
be retained for a maximum o f 1 year following last subject visit for the study . During this t ime, 
samples remaining after the bioanalyses may be used for exploratory  analyses such as 
metabolism work, protein binding, and/or bioanalyticalmethodcross-validation.
8.10. Health Economic s
Health Economics parametersare not evaluated in this study .
CONFIDENTIAL I8F-MC-GPHL
739. Statistical Considerations
9.1. Statistical Hypotheses
The alternative hypotheses for the primary objective are the fo llowing: 
H10,1: QW tirzepatide 10 mg is superior to placebo for mean percent change in body  
weight from randomization AND proportion of partic ipants who achieve ≥5%body 
weight reducti on at 72 weeks.
H15,1: QW tirzepatide 15 mg is superior to placebo for percent change in body weight 
from randomization AND proportion of participants who achieve ≥5% body weight 
reduction at 72 weeks.
The above 2hypotheses will be tested in parallel, each at a 2- sided significance level o f 0.025.
The alternative hypotheses for the key  secondary object ive controlling for type 1 error rate are 
the following:
H10,2:QW tirzepatide 10 mg is superior to placebo for pro portion of participants who 
achieve ≥10% body  weight reducti on at 72 weeks.
H15,2: QW tirzepatide 15 mg is superior to placebo for proportion of participants who 
achieve ≥10% body  weight reducti on at 72 weeks.
H10,3:QW tirzepatide 10 mg is superior to placebo for proportion of participants who 
achieve ≥15% body  weight reducti on at 72 weeks.
H15,3: QW tirzepatide 15 mg is superior to placebo for proportion of participants who 
achieve ≥15% body  weight reducti on at 72 we eks.
H10,4: QW tirzepatide 10 mg is superior to placebo for change fro m randomization in 
HbA1c(%)at 72 weeks.
H15,4: QW tirzepatide 15 mg is superior to placebo for change fro m randomization in 
HbA1c(%) at 72 weeks.
H10,5: QW tirzepatide 10 mg is superi or to placebo for proportion of participants who 
achieve the target value of HbA1c <7% at 72 weeks.
H15,5: QW tirzepatide 15 mg is superior to placebo for proportion of participants who 
achieve the target value of HbA1c <7% at 72 weeks.
H10,6: QW tirzepati de 10 mg is superi or to placebo for change from randomizat ion in 
waist circumference (cm) at 72 weeks.
H15,6: QW tirzepatide 15 mg is superior to placebo for change fro m randomization in 
waist circumference (cm) at 72 weeks.
CONFIDENTIAL I8F-MC-GPHL
74H10,7: QW tirzepatide 10 mg is superior to placebo for change from randomizat ion in 
Fasting Glucose (mg/dL) at 72 weeks.
H15,7: QW tirzepatide 15 mg is superior to placebo for change fro m randomization in 
Fasting Glucose (mg/dL) at 72 weeks.
Hp,8: tirzepatide (all tirzepatide doses combined) is superior to placebo for change in 
triglycerides (mg/dL) from  randomization at 72 weeks.
Hp,9: tirzepatide (all doses combined) is superior to placebo for change in LDL 
cholesterol (mg/dL) from randomization at 72 weeks.
Hp,10: tirzepatide (alldoses combined) is superior to placebo for change in total 
cholesterol (mg/dL) from randomization at 72 weeks.
Hp,11: tirzepatide (all doses co mbined) is superior to placebo for change in SBP (mmHg) 
from randomization at 72 weeks.
The details o f type 1 error rate control strategy  for the above key  secondary  objectives will be 
provided in the statistical analysis plan (SAP).
9.2. Sample Size Determination
Approximately 1300 participants will be screened to achieve 900randomly assigned to study 
intervention(300participants per intervent ion group).
The sample size determinat ion assumes that evaluation of superiorit y of tirzepatide 10mg and 
tirzepatide 15 mg to placebo will be conducted in parallel, each at a 2 -sided significance level of 
0.025 using a 2- sample t-test. Addit ionally, a difference of at least 11% mean body  weight 
percentage reduction from rando mization at 72 weeks for tirzepat ide 10 mg and/or tirzepat ide 
15mg compared to placebo, a commo n SD of 10%, and a dropout rate of 25% are assumed for 
statistical power cal culations. Under the assumpt ions above, rando mizing 900 participants in a 
1:1:1 ratio to tirzepat ide 10 mg (300), tirzepat ide 15 mg (300), and placebo (300) provides more 
than 90% power to demonstrate superiorit y of each tirzepatide dose to placebo. 
The chosen sample size and randomization ratio also provides >90% power to establish 
superiority of 10 mg tirzepatide and 15 mg tirzepatide dose to placebo in term sof proportion of 
participants achieving at least 5% body  weight reducti on at 72 w eeks, conducted in parallel using 
a Chi-square test, each at a 2 -sided significance level of 0.025, assuming 25% placebo treated 
participants and 90% tirzepatide treated participants achieving the goal and a dropout rate of 
25%.
9.3. Populations for Analyses
For purposes of analysis, the following analysis sets are defined:
Analysis Set Description
EnteredParticipants All participants who sign informed consent
Randomized Participants All participants who are randomly assigned a study treatment
Modified Intent-to-Treat 
(mITT)All randomly assigned participants who are exposed to at least 1dose of study 
drug.Participants will be included in the treatment group they were randomized 
CONFIDENTIAL I8F-MC-GPHL
75to.
Efficacy A nalysis Set(EAS) Data obtained during treatment period from mITT, excluding data after 
initiating rescue antihyperglycemic medication or stopping study drug 
prematurely (last dose + 7 days).
FullAnalysis Set (FAS) Data obtained during treatment period from mITT, regardless of adherence to 
study drug or initiation of rescue antihyperglycemic medication . 
SafetyAnalysis Set(SS) Data obtained during the treatment period plus safety follow up from mITT, 
regardless of adherence to study drug or initiation of rescue antihyperglycemic 
medication . 
9.4. Statistical Analyses
General Considerations
Statistical analysis o f this study  will be the responsibilit y ofLilly or its designee.Any change to 
the data analysis methods described in the protocol will require an amendment ONLY if it 
changes a principal f eature of the protocol. Any other change to the data analysis methods 
described in the protocol, and the just ification for making the change, will be described in the 
SAP or the clinical study  report (CSR). Addit ional exploratory  data analyses may  be conducted 
as deemed appropriate.
Unless otherwise noted, all tests of treatment effects will be conducted at a 2 -sided alpha level o f 
0.05, and the confidence interval will be given at a 2 -sided 95% level.In statistical summaries 
and analyses, datawill be analyzed as rando mized.
Unless specified otherwise, efficacy analyses will  be conducted using efficacy analysis set (EAS) 
and safety analyses will be conducted using safety  analysis set (SS). Baseline is defined as the 
last nonmissing data collect ed prior to or at randomizat ion.  
Summary  statistics for con tinuous m easures will  include sample size, mean, SD, median, 
minimum, and maximum. T heanalysis model to make comparisons among treatment groups 
relative to continuous measurements assessed over time will be a mixed model for repeated 
measures (MMRM), with terms of treatment, visit, treatment -by-visit interaction, stratificat ion 
factorsand baseline measurement as a covariate. An unstructured covariance structure will 
model relationship of within-patient errors.
Kaplan-Meier method will be used for estimation of cumulat ive event-free survival rates over 
time, and cox proportional hazards regression analysis will be used to compare hazard rates 
among treatm ents.
Summary  statistics for categorical me asures (including categorized continuous measures) will 
include sample size, frequency, and percentages. Logistic regressio n will be used to examine the 
treatment difference in binary  efficacy outcomes if there i s a need to adj ust for covari ates. 
Otherwise, Fisher’s exact test will be used to examine the treatment difference in categorical 
outcomes.  
Summary  statistics for discrete coun t measures will include sample size, mean, SD, median, 
minimum, and maximum. The negat ive binomial regressio n model will be used for the treatment 
comparison of discrete count measures. 
CONFIDENTIAL I8F-MC-GPHL
76Other stati stical methods may be used, as appropriate, and details will be described in the SAP.
Treatment Group Comparability
9.4.2.1. ParticipantDisposition
A detailed description o f participant disposition will be provided at the end of the study. 
Frequency counts and percentages of all part icipants screened, randomized, and receiving at least 
1dose of study  drug will  be presented by  treatment groups. Of therandomized populat ion,
frequency  counts and percentages of participants who completed the study orprematurely 
discontinued the study  (and/or study  drug), including reason for premature discont inuation, will 
be presented by  treatment groups.
A Kaplan-Meier analysis o f time from randomizationto premature discontinuat ion from study
and/or treatment by treatment group will be provided. 
9.4.2.2. Participant Character istics
Demographics and other baseline characteristics ( including years of educat ion)will be 
summarized by  treatment group for all rando mized participants.
9.4.2.3. Concomitant Therapy 
Concomitant medicat ions, including previous therapy , will be summarized by  treatment armfor 
FAS.
9.4.2.4. Treatment Compliance 
Frequency counts and percentages of participants compliant to study  drug will be summarized by 
treatment arms and visits for FAS. 
Efficacy Analyses
9.4.3.1. Primary Analyses
There will be 2 estimands o f interest in comparing efficacy o f tirzepatide doses wi th placebo. 
For the FDA, the primary  efficacy analysis will  be guided by the “hybrid” estimand and 
conducted using the FAS. This assessment will analyze percent change in body  weight obtained 
at 72 weeks visit using an analysis o f covariance (ANCOVA) and the proporti on of participants 
achieving at least 5% body  weight reducti on obtained at 72 weeks visit us ing logistic regressio n 
model.Both models(ANCOVA and l ogistic regressio n model)will include terms o f treatment, 
stratificat ion factors, and baseline body weight as a covariate. Missing data of the primary 
outcome measurement due to all other Intercurren t Events (ICEs) will be imputed based on 
retrieved dropouts i n the same treatment arm, defined as observed primary outcome 
measurements fro m participants in the same treatment group who had their efficacy assessed 
after early discontinuat ion of study  drug.In cases where there are not enough retrieved dropouts 
to provide a reliable imputation model (for example, the model implemented by  the SAS 
program does not converge), an alternat ive multiple imputation method with reference to the 
placebo group (pl acebomultiple imputation) will be used. Analysis will be conducted with 
multiple imputations. Since the mean percent change in body weight and percentage of 
CONFIDENTIAL I8F-MC-GPHL
77participants wi th ≥5% body weight reducti on needsto be achieved at the same time, no 
multiplicity adjustment is planned for these 2 tests.
For all other purposes, t he primary efficacy assessment will beguided by the “efficacy” 
estimand, which represents efficacy prior to discontinuat ion of study  drug without confounding 
effects of ant ihyperglycemic rescue therapy,and conducted using the EAS. The primary analysis 
model will be a MMRM for body  weight percent change over time and longitudinal logist ic 
regression for proportion of participants achieving at least 5% body  weight reducti on over time. 
The respons e variable of MMRM will be the percent change in body  weight from randomization 
values obtained at each scheduled postbaseline visit. The response variable o f longitudinal 
logistic regressio n will be the proportion of participants achieving at least 5% bod y weight 
reduction at each scheduled post -randomizat ion visit. The independent variables of both analysis 
models are treatm ent group (ti rzepatide 10 mg, tirzepatide 15 mg, and placebo), visit, and 
treatment-by-visit interaction, stratificat ion factors,andbaseline body  weight as covari ate. An 
unstructured covariance structure will model relat ionship of wit hin-patient errors. The Kenward -
Roger approximat ion will be used to estimate denominator degrees of freedo m. 
9.4.3.2. Key Secondary Analyses
Superiority of each tirzepatide dose to pl acebo for the proportion of participants who 
achieve≥10% body  weight reducti on at 72 weeks 
Superiority of each tirzepatide dose to pl acebo for the proportion of participants who 
achieve≥15% body  weight reducti on at 72 weeks 
Superiority of each tirzepatide dose to pl acebo for the change fro m randomization in 
HbA1c(%)values at 72 weeks 
Superiority of each tirzepatide dose to pl acebo for the proportion of participants who 
achieve the target value of HbA1c <7% at 72 weeks 
Superiority of each tirzepatide dose to pl acebo for the change fro m randomization in 
waist circumference (cm) at 72 weeks 
Superiority of each tirzepatide dose to pl acebo for the change fro m randomization in 
fasting glucose (mg/dL) at 72 weeks 
Superiority of tirzepatide (all dosescombined) to placebo for change fro m randomization 
in triglycerides (m g/dL) at 72 weeks visit
Superiority of tirzepatide (all dosescombined) to placebo for change fro m randomization 
in LDL cholesterol (mg/dL) at 72 weeks visit 
Superiority of tirzepatide (all dosescombined) to placebo for change fro m randomization 
in total cholesterol(mg/dL) at 72 weeks visit
Superiority of tirzepatide (all dosescombined) to placebo for change fro m randomization 
in SBP (mmHg) at 72 weeks visit
CONFIDENTIAL I8F-MC-GPHL
78Additional details, including analysis methods for key secondary endpo ints and the strategy  for 
controlling overall t ype 1 error rate at a 2 -sided alpha of 0.05 of primary and key  secondary  
endpoint evaluation, will be provided in the SAP. 
Safety Analyses
Unless specified otherwise, s afety assessments will be guided by  an estimand comparing safety  
of tirzepatide doses with placeboirrespective of adherence to study  drugor initiation of rescue 
AHM. Thus, safet y analysis will be conducted using SS. 
9.4.4.1. Study Drug Exposure
Exposure to each study  treatment will be calculated for each participant and summarized by 
treatment group.
9.4.4.2. Adverse Events
Adverse events will be coded from the actual term using the Medical Dict ionary for Regulatory 
Activities (MedDRA) and reported wi th preferred terms and system organ class. Counts and 
proportions of participants experiencing events will be reported for each treatment group, and 
Fisher’s exact test will be used to compare the treatment groups.
The proporti on of participantsexperiencing TEAE , SAE, and discontinuation due to AE will be 
summarized by treatment group.
9.4.4.3. Special Safety Topics
This section includes areas of interest whether due to observed safet y findings, potential findings 
based on drug class, or agreed upon cons ultation with regulatory agencies for the reasons 
previously mentioned.
The following AEs are AEs of special interest (AE SIs)for this study:
Severe hypoglycemia
Major adverse cardi ovascular events (adj udicated). Includes, but not limited to 
cardiovascular death, nonfatal myo cardial infarction, nonfatal  stroke, and hospitalization 
for heart failure
TE Supraventricular arrhyt hmias and Cardiac Conduction Disorders
Hepatobiliary disorders. Includes biliary co lic, cholecyst itis, and other gallbladder disease
Severe GIevents
Acute renal events
MDD/Suicidal Behavi or and Ideation  
Pancreatitis(adjudicated)
C-Cell Hyperplasia and thy roid malignancies
Allergic/Hypersensit ivity Reactions. Includes injecti on site reactions and ADAformation
Diabetic retinopathy co mplications
Metabolic acidosis, including diabet ic ketoacidosis
Amputati on/peripheral revasculari zation.
Summaries and analyses for incidence of AESIs will be provided by treatment. The details of 
analysis of AESI will be provided in SAP.
CONFIDENTIAL I8F-MC-GPHL
799.4.4.4. Other Adverse Event Assessments 
9.4.4.4.1. Gastrointestinal Events
Summaries and analyses for incidence and severit y of nausea, vo miting,and diarrhea will be 
provided by each treatment.  
9.4.4.4.2. Events Related to Potential Abuse Liability
Summaries and analyses for incide nce of potential abuse liabilit y TEAEs will be provided by
treatment. The details will be provided in SAP.
9.4.4.4.3. Depression, Suicidal Ideation and Behavior
In addition to the summary  of TEAEs, s uicidal ideation andbehaviorwill be assessed by 
C-SSRS, and depression related symptoms will be assessed using PHQ -9. 
The analysis details will be provided in the SAP .
9.4.4.4.4. Central Laboratory Measures, Vital Signs, and Electrocardiograms
Actual values and change fro m randomizationto post-randomizat ionvalues of central laboratory  
measures, vital signs, and se lected ECG parameters will be summarized at each scheduled visit. 
Change from randomizat ionto post-randomizat ionvalue will be summarized for participants
who have both a randomization and at least1 post-randomizationresult.  
The percentages of participantswith TEabnormal, high, or low measures (including laboratory , 
vital, and ECG param eters) at any time will  be summarized and compa red between treatment 
groups using Fisher’s exact test.  
Theanalysis d etails will be provided in SAP.
9.4.4.4.5. Hypoglycemic Events 
Incidence and rateof documented symptom atic hypoglycemic events and severe hypoglycemia 
will be summarized and compared between tirzepatide doses and placebo. 
Pharmacokinetic/Pharmacodynamic Analyses
Tirzepatideconcentration data will be analyzed using a populat ion PK approach via nonlinear 
mixed-effects modeling wi th the NONMEM® software . The relat ionship between t irzepatide 
dose and/or concentration and efficacy, tolerability, and safet y endpoints will be characterized . 
Additionally, the impact of intrinsic and extrinsic participantfactors such as age, weight, sex,
and renal funct ion on PK and/or PD parameters may be examined as needed . If ADAtiters are 
detected from immunogenicit y testing, then the impact of immunogenicit y titers on tirzepatide 
PK or any  relevant PD parameters may  also be examined. 
Evaluation of Immunogenicity
The frequency and percentage of participantswith preexisting ADA and with 
treatment-emergent antidrug ant ibodypositive (TE ADA+ )to tirzepatide will be tabulated. 
Treatment -emergent ADA sare defined as those with a titer 2- fold (1 dilution) greater than the 
minimum required dilut ion (1:10) of the ADA assay if no ADAs were detected at baseline 
(treatment -induced A DA) or those wi th a 4-fold (2 dilut ions) increase in t iter compared with 
CONFIDENTIAL I8F-MC-GPHL
80baseline if ADAs were detected at baseline (treatment- boosted ADA). For the TE ADA+ 
participants, the distribution of maximum titers will be described. The frequency o f neutralizing 
antibodies, if assessed, and cross reactivit y to native GIP and GLP -1 mayalso betabulated in TE 
ADA+ participants.
The relationship between the presence of ant ibodies and the PKparameters and PDresponse
including safet y and efficacy to tirzepatidemay be assessed.
Other Analyses
9.4.7.1. Health Outcomes
Analyses of actual and change fro m randomizationin thedomains and/or summary  scores of 
PROsquestionnaires will be conducted using EAS. The details on quest ionnaire-specific 
analyses will be provided in the SA P.
9.4.7.2. Subgroup Analyses for Primary Analysis
Details of the subgroup analyses will be shown in the SAP.  
The following subgroup variables will be considered (but not limited to) :
Age(<65 years and ≥65years)
Sex (female and male)
Baseline BMI (<30, ≥30 and<35,≥35 and <40, ≥40 kg/m2)
Race 
Ethnicity 
Type of antihyperglycemic agent used at randomization (associated weight gain , weight 
loss, and weight neutral )
Baseline HbA1c (
≤8.5% [≤69 mmol/mol] and >8.5% [>69 mmol/mol])
The outcome measures for the subgroup analyses will include:
percentchange in body  weight from randomizat ion at 72 weeks
proportion of participants achieving at least 5% body weight reduction at 72 weeks.
9.5.Interim Analyses 
No interim analyses are planned for this study . If an unplann ed interim analysis is deemed 
necessary  for reasons other than a safet y concern, the protocol must be amended.
9.6.Data Monitoring Committee 
Not applicable .
CONFIDENTIAL I8F-MC-GPHL
8110. Supporting Documentation and Operational Considerations
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations
Regulatory and Ethical Considerations
This study  will be conducted in accordance wit h the protocol and with the 
following:
○Consensus ethical principles derived from international guidelines 
including the Declarat ion of Helsinki a nd Council for International 
Organizat ions of Medical Sciences (CIOMS) Internat ional Ethical 
Guidelines
○Applicable International Council for Harmonization of Technical 
Requirements for Pharmaceut icals for Human Use(ICH)GCP Guidelines
○Applicable laws and regulati ons
The protocol, protocol amendments, ICF, IB, and other relevant documents 
(for example , advertisements) must be submitted to an IRB/ Independent 
Ethics Co mmittees (IEC)by the invest igator and reviewed and approved by 
the IRB/IEC before the study is init iated.
Any amendments to the protocol will require health authorityapproval before 
implementati on of changes made to the study  design, except for changes 
necessary  to eliminate an immediate hazard to study  participants.
Protocols and any substantial amendments to the protocol will require healt h 
authority approval prior to initiation except for changes necessary  to eliminate an 
immediate hazard to study  participants.
The invest igator will be responsible for the fo llowing:
○Providing written summaries of the status of the study  to the IRB/IEC 
annually or more frequently in accordance with the requirements, policies, 
and procedures established by the IRB/IEC
○Notifying the IRB/IEC of SAEs or other si gnificant safet y findings as 
required by IRB/IEC procedures
○Providing oversight of study conductfor participants under thei r 
responsibilit y and adherence to requirements of 21 Code of Federal 
Regulations (CFR) , ICH gui delines, the IRB/IEC, European regulat ion 
536/2014 for clinical stu dies (if applicable), and all other applicable local 
regulations
CONFIDENTIAL I8F-MC-GPHL
82Investigator sites are compensated for participat ion in the studyas detailed in 
the Clinical TrialAgreement (CTA).
Informed Consent Process
The invest igator or his/her representative will e xplain the nature of the study , 
including the risks and benefit s,to the participant or his/her legally authorized 
representative and answer all questions regarding the study .
Participants must be inform ed that thei r participation is voluntary. Participants 
or their legally authorized representative will be required to sign a statement 
of informed consent that m eets the requi rements of 21 CFR 50, local 
regulations, ICH guidelines, Health Insurance Portabilit y and Accountabilit y 
Act (HIPAA) requir ements, where applicable, and the I RB/IEC or study 
center.
The medical record m ust include a statement that written informed consent 
was obtained before the participant was entered in the study  and the date the 
written consent was ob tained. The authori zed person obtaining the informed 
consent must also sign the ICF.
Participants must be reconsented to the most current versio n of the ICF(s) 
during their participation in the study .
A copy of the ICF(s) m ust be provi ded to the participant or the participant’s 
legally authorized representati veand is kept on file .
Data Protection
Participants will be assi gned a unique i dentifier by the sponsor. Any 
participant records ,datasetsor tissue samples that are transferred to the 
sponsor will contain the identifier on ly; participant names or any informat ion 
which woul d make the parti cipant identifiable will not be transferred.
The participant must be inform ed that his/her personal  study-related data will  
be used by  the sponsor in accordance with local data protection l aw. The level 
of disclosure must also b e explained to the participant who will be required to 
give consent for his/her data to be used as described in the informed consent .
The participant must be inform ed that his/her medical records m ay be 
examined by  Clinical Qualit y Assurance auditors or other authorized 
personnel appo inted by the sponsor, by  appropriate IRB/IEC m embers, and by  
inspectors from regulatory  authorities.
The sponsor has processes in place to ensure data protection, informat ion 
security,and data integri ty. These processes include appropriate contingency 
plan(s) for appropri ate and timely  response in the event of a data security  
breach.
CONFIDENTIAL I8F-MC-GPHL
83
Committees Structure
Prospective adjudicat ion of major adverse cardio vascular events and pancreat ic AEswill be 
performed for this study . Sections8.3.2.2, and 8.3.2.5outlines addit ional information on 
pancreatic and cardiovascular adjudicat ion commit tees. 
Dissemination of Clinical Study Data
Required clinical  trial registries (for example, ClinicalTrials.gov) will be updated with the results 
from registered clinical trials regardless of the research outcome in accordance wit h local laws 
and regulations. 
All CSRs, amendments ,and addenda will be submitted to external regulatory authorit ies, 
external partners (as applicable) ,and sites. 
The publicat ion policy for Study I8F-MC-GPHLis outlinedin Section 10.1.9and further 
described in the CTA.
Data Quality Assurance
All participant data rel ating to the study  will be recorded on printed or eCRF 
unlesstransmitted to the sponsor or designee electronically ( for example, 
laboratory  data). The investi gator is responsible for verifying that data entries are 
accurate and correct by  physically  or electronically si gning the CRF.
The invest igator must maintain accurate documentation (source data) that 
supports the informat ion entered in the CRF.
The invest igator must permit study -related monitoring, audi ts, IRB/IEC revi ew, 
and regulatory  agency inspect ions and provide direct a ccess to source data 
documents.
Monitoring details describing strategy  (for example , risk-based init iatives in 
operations and qualit y such as risk management and mitigation strategies and 
analytical risk-based monitoring), methods, responsibilit ies,and requirements, 
including handling of no ncompliance issues and monitoring techniques ,are 
provided in the Monitoring Plan.
The sponsor or designee is responsible for the data management of this study ,
including quality checking of the data.
The sponsor assumes accountabilit y for actions delegated to other individuals ( for 
example, contract research organizations).
Study monitors will perform  ongoing source data verification to confirm that data 
entered into the eCRFby authorized site personnel are accurate, complete, and 
verifiable fro m source docum ents; that the safet y and rights of participants are 
being protected; and that the study  is being conducted in accordance with the 
currently approved protocol and any other study agreements, ICH GCP, and all 
applicable regu latory requirements.
CONFIDENTIAL I8F-MC-GPHL
84Records and documents, including signed ICFs, pertaining to the conduct of this 
study must be retained by  the invest igator for the time period outlined in the CTA
unless local regulat ions or institutional policies requi re a longer retenti on period. 
No records may be destroy ed during the retention period without the written 
approval of the sponsor. No records may  be transferred to another l ocation or 
party without written notificat ion to the sponsor .
In addition, the sponsoror its representatives will perio dically check a sample of 
the participant data recorded against source documents at the study  site. The study  
may be audited by the sponsoror its representatives, and/or regulatory  agencies at 
any time. Invest igators will be given notice before an audit o ccurs.
Data Capture System
The invest igator is responsible for ensuring the accuracy, completeness, legibilit y, and timeliness 
of the data reported to the sponsor.
An electronic data capture sy stem (EDC) will be used in this study  for the collect ion of CRF 
data. The invest igator maintains a separate source for the data entered by the invest igator or 
designee into the sponsor provided EDC system. The investigator is responsible for the 
identification of any data to be considered source and for the confirmat ion that data reported are 
accurate and complete by  signing the eCRF.
Additionally, clinical outcome assessment (COA) data (participant -focused outcome instrument ) 
and other data (for example, diary) will be collected by  the participant,caregiver, orauthorized 
studypersonnel , via a paper source document and will be transcribed by  the authorized study  
personnel into the EDC sy stem.
Data collected via the sponsor -provided data capture system (s)will bestored at third- parties. The 
investigator will have cont inuous access to the data during the study and unt il decommissioning 
of the data capture sy stem(s).Prior to decommissioning, the invest igator will receive an archival 
copy of pertinent data for retention.
Data managed by  a central vendor, such as laboratory  test data, will be stored electronically in 
the central vendor’s database system .Data will subsequent ly be transferred fro m the central 
vendor to the sponsordata warehouse.
Data from co mplaint forms submitted to sponsorwill be encoded and st ored in the global PC
management system.
Source Documents
Source documents provide evidence for the existence of the participant and 
substantiate the integrity  of the data collected. Source documents are filed at 
the investigator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed from 
source documents must be consistent with the source documents or the 
discrepancies must be explained. The invest igator may need to request 
previous medical records or transfer records, depending on t he study. Also, 
current medical records must be available.
CONFIDENTIAL I8F-MC-GPHL
85Definition of what constitutes source data can be found in study training 
material
Study and Site Start and Closure
The study  start date is the date on which the clinical study  will be open for re cruitment of 
participants.
The sponsor or designee reserves the right to close the study  site or terminate the study  at any 
time for any  reason at the sol e discretion of the sponsor. Study  sites will be cl osed upon study  
completion. A study  site is considered closed when all required documents and study  supplies 
have been co llected and a study -site closure visi t has been performed.
The invest igator may init iate study -site closure at any  time, provi ded there i s reasonable cause 
and sufficient notice i s given in advance of the intended terminat ion.
Reasons for the early closure of a study  site by the sponsor or investigator may  include but are 
not limited to:
Failure of the invest igator to comply wit h the protocol, the requirements of the 
IRB/IEC or loc al health authorities, the sponsor's procedures, or GCP 
guidelines
Inadequate recruit ment of participants by  the investi gator
Discontinuati on of further study  intervention development .
If the study  is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the IECs/IRBs, the regulatory  authorities, and any contract research organizat ion(s) 
used in the study  of the reason for terminat ion or suspensio n, as specified by the applicable 
regulatory requirements. The investigator shall prompt ly inform the participantand assure s
appropriate participant therapy and/or foll ow-up.
Publication Policy
In accordance with the sponsor’s publication po licy,the results of this study  will be submitted 
for publicat ion by a peer -reviewed journ al:
The sponsor will co mply with the requi rements for publication o f study 
results. 
Authorship will be determined by mutual agreement and in line wit h 
International Co mmittee of Medical Journal Editors authorship requirements.
The publicat ion policy for Study I8F-MC-GPHLis described in the CTA.
CONFIDENTIAL I8F-MC-GPHL
8610.2. Appendix 2: Clinical Laboratory Tests
The tests detailed below will be performed by a central lab unless designated 
as local in the SoA and in the table below.
In circumstances where the sponsor approves local laboratory  testing in lieu of central 
laboratory  testing (in the table below), the local laboratory  must be qualified in 
accordance with applicable local regulat ions.
Protocol-specific requirements for inclusio n or exclusio n of participants are 
detailed inSect ion5of the protocol.
Additional tests may be performed at any  time during the study  as determined 
necessary  by the invest igator or required b y local regulations.
Pregnancy testing (refer to Section 5.1Inclusion Criteria for screening 
pregnancy criteria ).  
Investigators must document their review of the laboratory  safety results.
Laboratory  resultsthat could unblind the study  will not be reported to invest igative 
sites or other blinded personnel and are denoted in the table below .
CONFIDENTIAL I8F-MC-GPHL
87Clinical Laboratory Tests
HematologyaClinical Chemistrya
Hemoglobin Bicarbonate
Hematocrit Sodium
Erythrocyte count (RBC) Potassium
Mean cell volume Total bilirubin
Mean cell hemoglobin concentration Direct bilirubin
Leukocytes (WBC) Alkaline phosphatase
Neutrophils, segmented Alanine aminotransferase (ALT)
Lymphocytes Aspartate aminotransferase (AST)
Monocytes Blood urea nitrogen (BUN)
Eosinophils Creatinine
Basophils Uric acid
Platelets Calcium
Glucose
Urine ChemistriesaAlbumin
Albumin Creatine kinase (CK)
Creatinine
Cystatin-CaHormones (females)
Pregnancy Test serumaand/or urine (local)
Follicle-stimulating hormone (FSH)a
HbA1ca
Endocrinea
Calcitonin Pancreas (exocrine)a
Thyroid-stimulating hormone (TSH) Pancreatic amylase
Lipase
Nonpharmacogenetic Stored Samplesa,b
Serum
EDTA plasma
P800 plasmaImmunogenicitya,b
Anti-tirzepatide antibodies
Anti-tirzepatide antibody neutralization
Pharmacokinetic Sample for Immunogenicity
Lipid Panela
Pharmacogen etics Samplea,b
Whole blood (EDTA)Triglycerides
VLDL-C
HDL-C
LDL-Cc
Total cholesterol
Free Fatty Acidsa
Insulina
C-peptideaCalculationsa
eGFR(calculated by CKD -EPI equation)
UACR
Abbreviations: CKD-EPI=Chronic Kidney Disease -Epidemiology; EDTA=ethylenediaminetetraacetic acid ;
eGFR=estimated glomerular filtration rate; HbA1c =hemoglobin A1c; HDL -C =high-density lipoprotein 
cholesterol; LDL-C=low-density lipoprotein cholesterol; RBC=red blood cells ;UACR = urine 
albumin/creatinine ratio; VLDL-C =very low-density lipoprotein cholesterol; WBC= white blood cells .
CONFIDENTIAL I8F-MC-GPHL
88aAll tests will be performed by a Lilly -designated central laboratory, u nless otherwise noted.
bResults will not be provided to the investigative sites.
cThis value will be calculated. If triglycerides are >400 mg/dL, the direct LDL will be assayed.
CONFIDENTIAL I8F-MC-GPHL
8910.3. Appendix 3: Laboratory Assessments for Hypersensitivity Events
Laboratory assessments should be performed if the participant experiences 
generalized urticaria or if anaphylaxis is suspected .
Collect sample after the participant has been stabilized, and within 1 to 2 hours of 
the event; however, samples may be obtained as late a s 12 hours after the event as 
analytes can remain altered for an extended period of time. Record the time at 
which the sample was co llected.
Obtain a fo llow-up sample at the next regularly scheduled visit or after 4 weeks, 
whichever i s later.
The table below summarizes the laboratory  parameters that will be evaluated. These laboratory  
tests are bundled in the hypersensit ivity laboratory  testing kit.
CONFIDENTIAL I8F-MC-GPHL
90Clinical Lab Tests for Hypersensitivity Events
Hypersensitivity Tests Notes
Selected test may be obtained in the event of anaphylaxis or systemic 
allergic/hypersensitivity reactions.
Tirzepatide ADAs 
(immunogenicity/ADA)Assayed by Lilly -designated laboratory. Results will not be provided to the 
investigative sites.
Tirzepatide 
concentrations (PK)Assayed by Lilly -designated laboratory. Results will not be provided to the 
investigative sites.
Tryptase Assayed by Lilly -designated laboratory. Results will not be provided to the 
investigative sites.
Note:If a tryptase sample is obtained more than 2 hours after the event (that is, 
within 2 to 12 hours), or is not obtained because more than 12 hours have lapsed 
since the event, obtain urine sample for N -methylhistamine testing. Note that for 
tryptase serum samples obtained within 2 to 12 hours of the event, urine 
N-methylhistamine testing is performed in addition to tryptase testing. Collect the 
first void urin esamplefollowing the event. Obtain a follow -up urine samplefor 
N-methylhistamine te sting at the next regularly scheduled visit or after 4 weeks, 
whichever is later.
N-methylhistamine Assayed by Lilly -designated laboratory. Results will not be provided to the 
investigative sites.
Drug-specific IgE Will be performed if a validated assay is available.
Assayed by Lilly -designated laboratory. Results will not be provided to the 
investigative sites.
Basophil activation test Will be performed if a validated assay is available.
Assayed by Lilly -designated laboratory. Results will not be provided to the 
investigative sites.
Note:The basophil activation test is an in vitro cell based assay that only requires a 
serum sample. It is a surrogate assay for drug specific IgE, but is not specific for 
IgE.
Complement ( C3, C3a, 
and C5a)Assayed by Lilly -designated laboratory. Results will not be provided to the 
investigative sites.
Cytokine panel (IL ‐6, 
IL-1β, IL‐10)Assayed by Lilly -designated laboratory. Results will not be provided to the 
investigative sites.
Abbreviations: ADA = antidrug antibody; IgE = immunoglobulin E; IL = interleukin; PK = pharmacokinetic.
CONFIDENTIAL I8F-MC-GPHL
9110.4.Appendix 4: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting
Definition of AE
AE Definition
An AE is any untoward m edical occurrence in a participant administered a 
pharmaceutical product and which does not necessarily have a causal relat ionship 
with the study  intervention. An AE can therefore be any  unfavourable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease 
(new or exacerbated) temporally associated with the use of a m edicinal 
(investigational) product, whether or not related to the medicinal (invest igational) 
product.
Events Meeting the AE D efinition
Any abnormal laboratory  test resul ts (hematol ogy, clinical chemistry , or 
urinalysis) or other safet y assessments ( for example , ECG, radi ological scans, 
vital signs measurements), including those that worsen fro m baseline, considered 
clinically significant in the medical and scient ific judgment of the investigator 
(that is, not related to progression of un derlying disease).
Exacerbat ion of a chronic or intermittent pre -existing condit ion including either 
an increase in frequency and/or intensit y of the condit ion.
New condi tions detected or di agnosed after study  intervent ion administration 
even though theymay have been present before the start of the study .
Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, symptoms, or the clinical sequelae of a suspected overdose of either study  
intervention or a concomitant medicat ion.
“Lack of efficacy ”or “failure of expected pharmacological act ion”per se will not 
be reported as an AE or SAE. Such instances will be captured in the efficacy 
assessments. However, the signs, symptoms, and/or clinical sequelae result ing 
from lack of effi cacy will be reported as AE or SAE if they fulfil lthe definition 
of an AE or SAE.
Events NOTMeeting the AE D efinition
Any clinically  significant abnormal  laboratory  findings or other abnormal safet y 
assessments which are associated with the underlying disease, unless judged by 
the investigator to be more severe than expected for the participant’s condit ion.
The disease/disorder being studied or expected progressio n, signs, or symptom s 
of the disease/disorder being studied, unless more severe than expected for the 
CONFIDENTIAL I8F-MC-GPHL
92participant’s condit ion.
Medical or surgical procedure ( for example, endoscopy , appendectomy ): the 
condition that leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admissio n to a hospital).
Anticipated day -to-day fluctuations of pre- existing disease(s) or condit ion(s) 
present or detected at the start of the study  that do not worsen.
Definition of SAE
If an event is not an AE per definit ion above, then it cannot be an SAE even if serious condit ions 
are met (for example, hospi talization for signs/symptoms of the disease under study , death due to 
progression of disease).
SAE is defined as any untoward medical occurrence that, at any dose:
a.Results in death
b.Is life-threatening
The term ‘life-threatening’in the definit ion of ‘serious’refers to an event in which the 
participant was at ri sk of death at the time o f the event. It does not refer to an event, 
which hypothetically  might have caused death, if it  were more severe.
c.Requires inpatient hospitalization or prolongation of existing hospitalization
In general, hospitalizat ion signifies that the participant has been admitted to
hospitalfor observat ion and/or treatment that would not have been appropriate in 
the physician’s office or outpatient setting. Complications that occur during 
hospitalization are AEs. If a complicat ion prolongs hospi talization or fulfills any 
other serious criter ia, the event is serious. When in doubt as to whether 
“hospitalizat ion” occurred or was necessary, the AE should be considered 
serious.
Hospitalization for elective treatment of a pre -existing condit ion that did not 
worsen from baseline is not considered a n AE.
d.Results in persistent disability/incapacity
The term disabilit y means a substant ial disruption of a person’s abilit y to conduct 
normal life functions.
This definit ion is not intended to include experiences of relat ively minor medical 
significance such as unco mplicated headache, nausea, vomit ing, diarrhea, 
influenza, and accidental trauma ( for example , sprained ankle) which may  
interfere with or prevent everyday  life functions but do not const itute a 
substantial disruption.
e.Is a congenital anomaly/bi rth defect
CONFIDENTIAL I8F-MC-GPHL
93Abnormal pregnancy outcom es (for example , spontaneous abortion, fetal death, 
stillbirth, congenital ano malies, ectopi c pregnancy) are considered SAEs
f.Other situations:
Medical or scient ific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that 
may not be immediately  life-threatening or resul t in death or hospi talization but 
may jeopardize t he participant or may require medical or surgical intervent ion to 
prevent 1of the other outcomes listed in the above definit ion. These events 
should usually be considered serious.
Examples of such events include invasive or malignant cancers, intensive 
treatment in an emergency room or at home for allergic bronchospasm, blood 
dyscrasias or convulsio ns that do not result in hospitalizat ion
,or development of 
drug dependency or drug abuse .
g.Resulted in medical or surgical intervent ion to prevent life -threatening illness or 
injury or permanent impairment to a body  structure or a body  function.  
Definition of Product Complaint
Product Complaint
A product complaint is any written, electronic, or oral communicat ion that alleges 
deficiencies related to the identity, quality, durability , reliabilit y, safety, 
effectiveness,or performance of a studyintervention .When the abilit y to use the 
study intervention safely is impacted, the fo llowing are also PCs:
oDeficiencies in labeling informat ion, and
oUse errors for device or drug -device co mbination products due to 
ergonomic design elements of the product.
Product complaints related to study  interventions used in clinical trials are 
collected in order to ensure the safet y of participants, monitor qualit y, and to 
facilitate process and product improvements.
Investigators will instruct p articipants to contact the siteas soon as possible if he 
or she has a product complaintor problem wit h the study interventionso that the 
situation can be assessed.
An event may mee t the defini tion of both a product complaint and an AE/SAE. In 
such cases, it should be reported as both a product complaint and as an AE/SAE.
Recording and Follow -Up of AE and/or SAE and Product Complaints
AE, SAEand Product Complaint Recording
When an AE/SAE/product com plaint occurs, it is the responsibilit y of the 
investigator to review all documentation ( for example, hospi tal progress notes, 
laboratory  reports, and diagnost ics reports) related to the event.
CONFIDENTIAL I8F-MC-GPHL
94The invest igator will then record all relev ant AE/SAE/product com plaint 
information in the participant’s medical records, in accordance with the 
investigator’s normal clinical pract ice. AE/SAE informat ion is reported o n the 
appropriate (e)CRFpage and product complaintinformation is reported on the 
product complaint Form .
Note: An event may meet the definit ion of both a product complaint and an 
AE/SAE. In such cases, it should be reported as both a product complaint and as 
an AE/SAE.
It is notacceptable for the invest igator to send photocopies of the participant’s 
medical records to sponsor or designee in lieu of complet ion ofthe (e)CRF page
for AE/SAE and the Product Complaint form for product complaint s.
There may be instances when copies o f medical records for certain cases are 
requested by  sponsor or desi gnee. In this case, all participant ident ifiers, with the 
exception of the participant number, will be redacted on the copies o f the medical 
records before submissio n to sponsor or designe e.
The invest igator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical informat ion. Whenever possible, the diagnosis 
(not the individual signs/symptoms) will be documented as the AE/SAE .
Assessment of Inten sity
The invest igator will make an assessment of intensit y for each AE and SAE reported 
during the study and assign it to 1of the following categori es:
Mild:A type of AEthat is easily tolerated by the participant, causing usually 
transient and m ay require only minimal discomfort and treatment or therapeuti c 
intervention. The event does not interferinggenerally interfere with everyday
usual activities of daily living.
Moderate: A type of AEthat causes suffic ient discomfort andis usually alleviated 
with additional specific therapeut ic intervention. The event interferes wit h normal 
everyday usual activities of daily living, causing disco mfort but poses no 
significant or permanent risk of harm to the research participant .
Severe: A type of AEthat prevents normal everyday interrupts usual act ivities of 
daily living, or si gnificantly affects clinical status, or may require intensive 
therapeutic intervent ion. An AE that is assessed as severe should not be confused 
with a SAE. Se vere is a category  utilized for rating the intensit y of an event; and 
both AEs and SAEs can be assessed as severe.
An event is defined as ‘serious’ when it meets at least 1of the predefined 
outcomes as described in the definit ion of an SAE, NOT when it is rated as 
severe.
Assessment of Causality
CONFIDENTIAL I8F-MC-GPHL
95The invest igator is obligated to assess the relationship between study intervent ion 
and each occurrence of each AE/SAE.
A “reasonable possibilit y”of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relat ionship, rather than a relat ionship 
cannot be ruled out.
The invest igator will use clinical judgment to determine the relat ionship.
Alternative causes, suc h as underlying disease(s), concomitant therapy, and other 
risk factors, as well as the temporal relat ionship of the event to study  intervention 
administration will be considered and invest igated.
The invest igator will also consult the IB and/or Product In formation, for 
marketed products, in his/her assessment.
For each AE/SAE, the invest igator mustdocument in the medical notes that 
he/she has reviewed the AE/SAE and has provided an assessment of causalit y.
There may be situations in which an SAE has occur red and the invest igator has 
minimal informat ion to include in the init ial report to sponsor or designee . 
However, it is very  important that the invest igator always make an assessment of 
causality for every event before the init ial transmission of the SAE data to 
sponsor or desi gnee.
The invest igator may change his/her opinio n of causalit y in light of fo llow-up 
information and send a SAE follow -up report wi th the updated causalit y 
assessment.
The causalit y assessment i s 1of the criteria used when determining regulatory  
reporting requirements.
Follow-up of AEs and SAEs
The invest igator is obligated to perform or arrange for the conduct of 
supplemental  measurements and/or evaluat ions as medically indicated or as 
requested by  sponsor or desi gneeto elucidate the nature and/or causalit y of the 
AE or SAE as fully as possible . This may  include addi tional laboratory  tests or 
investigat ions, histopathological examinations, or consultation wit h other healt h 
care professio nals.
If a participant dies during participation in the study or during a recognized 
follow-up period, the inv estigator will provide sponsor or desi gnee with a copy of 
any postmortem findings including histopathology .
Reporting of SAEs
SAE Reporting via an Electronic Data Collection Tool
The primary  mechanism  for reporting an SAE will be the electronic data 
collection tool.
If the electronic system is unavailable, then the site will use the paper SAE data 
CONFIDENTIAL I8F-MC-GPHL
96collection tool (see next secti on) in order to report the event within 24 hours.
The site will enter the SAE data into the electronic sy stem as soon as i t becomes 
available.
After the study  is completed at a given site, the electronic data collect ion tool will 
be taken off -line to prevent the entry  of new data or changes to existing data.
If a site receives a report of a new SAE fro m a study participant or receives 
updated data on a previously reported SAE after the electronic data collect ion 
tool has been taken off -line, then the site can report this informat ion on a paper 
SAE form (see next section) or to the sponsor contact for SAE reporting by 
telephone.
Contacts for SAE reporting can be found in study training m aterial. 
SAE Reporting via Paper CRF
Facsimile transmissio n of the SAE paper CRF is the preferred method to transmit 
this informat ion to thesponsor contact for SAE reporting .
Initial notification via telephone does not replace the need for the invest igator to 
complete and sign the SAE CRF pages within the designated reporting time 
frames.
Contacts for SAE reporting can be found in study training m aterial.
Regulatory Reporting Requirem ents
SAE Regulatory Reporting
Prompt notificat ion by the invest igator to the sponsor of a SAE is essent ial 
so that legal obligat ions and ethical responsibilit ies towards the safet y of 
participants and the safet y of a study intervention under clinical 
investigat ion are met.
●The sponsor has a legal responsibilit y to notify both the l ocal regulatory  
authority and other regul atory agencies about the safet y of a study 
intervention under clinical investigat ion. The sponsor will co mply with 
country-specificregulatory requirements relating to safet y reporting to the 
regulatory authority, IRB/IEC, and invest igators.
●An investigator who receives an invest igator safety report describing a 
SAE or other specific safet y information (for example, summary or list ing 
of SAEs) from the sponsor will review and then file it along with th e IB
and will notify the IRB/IEC, if appropriate according to local 
requirements.
CONFIDENTIAL I8F-MC-GPHL
9710.5. Appendix 5: Contraceptive Guidance and Collection of Pregnancy 
Information
Definitions
Woman of Childbearing Potential :
A woman is considered fertile fo llowing menarche and unt il becoming postmenopausal unless 
permanently sterile (see below).
If fertility is unclear ( for example , amenorrhea in adolescents or athletes) and a menstrual cy cle 
cannot be confirmed before first dose of study  intervention, additional evaluation should be 
considered.
Women in the following categori es are not considered women of childbearing potential :
Article I. Premenarchal
Article II. Premenopausal female wit h1 of the following:
Documented hysterectomy
Documented bilateral  salpingectomy
Documented bilateral  oophorectomy
For individuals wit h permanent infert ility due to an alternate medical cause other than the 
above, (for example , Mullerian agenesis, androgen insensitivity), investigator discretion 
should be applied to determining study  entry.
Note:Determinat ioncan come from the site personnel’s :review of the participant’s 
medical records, medical examinat ion, or medical history  interview.
Article III. Postmenopausal female :
A postmenopausal  state is defined as either:
oA woman at least 40 years of age with an intact uterus, not on hormone 
therapy, who has cessat ion of menses for at least 1 year without an 
alternative medical cause, AND a FSH≥40 mIU/mL; or 
oA woman 55 or older not on hormone therapy , who has had at l east 
12months of spontaneous amenorrhea; or 
oA woman at least 55 years of age with a diagnosis of menopause prior to 
starting HRT. 
Females on HRT and whose menopausal status is in doubt will be required to use 
1of the nonestrogen horm onal highly effect ive contraception methods if they 
wish to continue their HRT during the study . Otherwi se, they must discontinue 
HRT to allow confirmat ion of postmenopausal status before study enro llment.
CONFIDENTIAL I8F-MC-GPHL
98Contraception Guidance
Contraceptive use by men and wo men should be consistent with local regulat ions regarding the 
methods of contraception for those participat ing in clinical studies .
Two forms of effect ive contraception, where at least 1form is highly effective, will be used. 
Effective contraception may be used as the second therapy . Barrier protection methods wi thout 
concomitant use of a spermicide are not a reliable or acceptable method. The use of male and 
female condo ms as a double barrier method is not considered acceptable due to the high failure 
rate when these methods are combined. 
Highly Effective Methods of Contraception:
Combined oral contraceptive pill and mini pill
NuvaRing
Implantable contraceptives
Injectable contraceptives (such as Depo -Provera®)
Intrauterine device (such as Mirena®and ParaGard®)
Contraceptive patch –ONLY women <198 pounds or 90 kg
Total abstinence (if this is their preferred and usual lifestyle) or in a sa me-sex 
relationship with no sexual relationship with males (as part of their preferred and 
usual lifest yle), and agrees to maintain this status throughout trial fo llow-up 
Note:Periodic abst inence (for example , calendar, ovul ation, symptothermal, and 
postovulation methods), declarat ion of abstinence just for the duration of a trial, and 
withdrawal are not acceptabl e methods of contraception .
Vasectomy  –for men in clinical studies
Note:Implantable contraceptives and injectable contraceptives (such as Depo Provera) 
are only permitted if started more than18 months prior to screening. Participants should 
not start these methods of contraception after being enrolled in the study .
Effective Methods of Contraception (must use combination of 2 methods):
Male condom with spermicide
Female condo m with spermicide
Diaphragm with spermicide
Cervical sponge
Cervical cap wit h spermicide
Men, regardless of their fertilit y status, with nonpregnant WOCBP partners must agreeto either 
remain abstinent (if this is their pref erred and usual lifest yle) or use condoms plus 1additional 
highly effective (less than 1% failure rate) method of contraception (such as co mbination oral 
contraceptives, implanted contraceptives ,or intrauterine device) or effective method of 
CONFIDENTIAL I8F-MC-GPHL
99contraceptio n (such as diaphragms with spermicide or cervical sponge) for the duration of the 
study and for 5 half-lives of study  drug plus 90days, which is approximately  4 monthsafter the 
lastinjection. Periodic abstinence ( for example , calendar, ovul ation, symptothermal, and 
postovulat ion methods), declarat ion of abstinence just for the duration of a trial, and withdrawal 
are not acceptable methods of contraception .
Men with pregnant partners should use condoms during intercourse for t he duration of the study  
and until the end of est imated relevant potential exposure in women of childbearing potential.
Men who are abstinent (if this is co mplete abstinence, as their preferred and usual lifest yle) or in 
a same-sex relationship (as part of their preferred and usual lifestyle) must agree to either remain 
abstinent or stay  in a same-sex relationship wi thout sexual relat ionships with females. In these 
situations, menare not required to use contraception. 
Men should refrain fro m sperm donation for the durati on of the study  and for 5 half-lives of 
study drug plus 90 days after the last dose of study drug, corresponding to 4 months after the last 
injection. 
Collection of Pregnancy Information
Male participants wi th partners who become pregnant
The invest igator will attempt to collect pregnancy informat ion on any male 
participant’s female partner who beco mes pregnant while the male parti cipant 
is in this study . 
After obtaining the necessary  signed informed consent from the pregnant 
female partner direct ly, the invest igator will record pregnancy informat ion on 
the appropriate form and submit it to the sponsor within 24 hoursof learning 
of the partner’s pregnancy. The female partner will also be followed to 
determine the outcome of the pregnancy. Informat ion on the status of the 
mother and child will be forwarded to the sponsor. Generally , the follow-up 
will be no longer tha n 6 to 8weeks following the estimated delivery  date. Any  
termination o f the pregnancy  will be reported regardless of fetal status 
(presence or absence of ano malies) or indication for the procedure. 
Female Participants who become pregnant
The invest igatorwill collect pregnancy information on any female participant 
who beco mes pregnant while part icipating in this study . The initial 
information will be recorded on the appropriate form and submitted to the 
sponsor within 24 hoursof learning of a participant's pregnancy. 
CONFIDENTIAL I8F-MC-GPHL
100The participant will be fo llowed to determine the outcome of the pregnancy . 
The invest igator will co llect follow-up informati on on the parti cipant and the 
neonate and the informat ion will be forwarded to the spons or. Generally, 
follow-up will not be required for longer than 6 to 8 weeks beyo nd the 
estimated delivery  date. Any  termination of pregnancy will be reported, 
regardless of fetal status (presence or absence of ano malies) or indicat ion for 
the procedure.
While pregnancy  itself is not considered to be an AE or SAE, any  pregnancy  
complication or elective terminat ion of a pregnancy  for medical reasons will 
be reported as an AE or SAE. 
A spontaneous abortion (occurring at <2 0weeks gestational age) or still birt h 
(occurring at > 20weeks gestational age) is always considered to be an SAE 
and will be reported as such. 
Any poststudy  pregnancy related SAE consi dered reasonably  related to the 
study intervention by the invest igator will be reported to the sponsor as 
described in protocol Section8.3.1. While the investigator is not obligated to 
actively seek this informat ion in former study participants, he or she may 
learn of an SAE through spontaneous reporting.
Any female part icipant who becomes pregnant while participat ing in the study  
will discont inue study  interventionandbe withdrawn fro m the study.
CONFIDENTIAL I8F-MC-GPHL
10110.6. Appendix 6: Liver Safety: Suggested Actions and Follow-up 
Assessments 
For testing selected, analysis is required to be completed by the Lilly designated 
central laboratory , except for microbio logy.
Local testing m ay be performed in addition to central testing when required for 
immediate participant man agement.
Results will be reported if a validated test or calculation is available.
Hepatic Evaluation Labs
Hematology Clinical Chemistry
Hemoglobin Total bilirubin
Hematocrit Direct bilirubin
Erythrocytes (RBCs -red blood cells) Alkaline phosphatase (ALP)
Leukocytes (WBCs -white blood cells) Alanine aminotransferase (ALT)
Differential: Aspartate aminotransferase (AST)
Neutrophils, segmented Gamma -glutamyl transferase (GGT)
Lymphocytes Creatine kinase (CK)
Monocytes Other Chemistry
Basophils Acetaminophen
Eosinophils Acetaminophen protein adducts
Platelets Alkaline phosphatase isoenzymes
Cell morphology (RBC and WBC) Ceruloplasmin
Coagulation Copper
Prothrombin Time, INR (PT -INR) Ethyl Alcohol
Serology Haptoglobin
Hepatitis A Virus (HAV) testing: Immunoglobulin IgA (Quantitative)
HAV total antibody Immunoglobulin IgG (Quantitative)
HAV IgM antibody Immunoglobulin IgM (Quantitative)
Hepati tis B Virus (HBV) Testing: Phosphatidylethanol (PEth)
Hepatitis B surface antigen (HBsAg) Urine Chemistry
Hepatitis B surface antibody (Anti -HBs) Drug Screen
Hepatitis B core total antibody (Anti -HBc) Ethyl glucuronide (EtG)
Hepatitis B core IgM antibody Other Serology
Hepatitis B core IgG antibody Anti-nuclear antibody (ANA)
CONFIDENTIAL I8F-MC-GPHL
102HBV DNAaAnti-smooth muscle antibody (ASMA) b
Hepatis C Virus (HCV) Testing: Anti-actin antibodyc
HCV antibody Epstein -Barr Virus (EBV) Testing:
HCV RNAaEBV antibody
Hepatitis D Virus (HDV) Testing: EBV DNAa
HDV antibody Cytomegalovirus (CMV) Testing:
Hepatitis E Virus (HEV) Testing: CMV antibody
HEV IgG antibody CMV DNAa
HEV IgM antibody Herpes Simplex Virus (HSV) Testing:
HEV RNAaHSV (Type 1 and 2) antibody
MicrobiologydHSV (Type 1 and 2) DNAa
Culture: Liver Kidney Microsomal Type 1 (LKM -1) Antibody
Blood
Urine
Abbreviations: Ig = i mmunoglobulin; INR = internatio nal normalized ratio; PT = prothrombin time.
aReflex/confirmation dependent on regulatory requirements, testing availability, or both.
bThis is not required if anti -actin antibody is tested.
cThis is not required if anti -smooth muscle antibody is tested.
dAssayed by investigator-designated local laboratory ONLY. No central testing available.
CONFIDENTIAL I8F-MC-GPHL
10310.7. Appendix 7: Protocol GPH LStandardized Protocols for the 
Measurement of Height, Weight, Waist Circumference, Vital Signs ,
and Electrocardiogra m
The following inform ation has been adapted fro m standardized physical measurement protoco ls 
for the WHO’sSTEPwise approach to Surveillance (STEPS) (WHO 2017) .
Measuring Height
Step 1.Ask the participant to remove their footwear and any headgear (light headgear worn for 
religious reasons can remain, but this should be worn by the participant at every clinic visit when 
their height is m easured).
Step 2.Ask the participant to stand on the calibrated height measuring board (stadio meter) or 
against a wall wit h their feet together and their knees straight with their heels against the 
backboard, t he stadiometer,or the wall.
Step 3.Ask the participant to look straight ahead without tilt ing their head up.
Step 4.Ask the participant to breathe in and stand tall. Measure and record the participant’s 
height in cent imeters to 1 decimal place. 
Measuring Weight
Body weight m easurements shoul d be done in a consistent manner using a calibrated 
electronic scale capable of measuring weight in kilograms to 1 decimal place.
All weights for a given participant should be measured using the same scale, whenever 
possible, at approximately the same time in the morning after evacuat ion of bladder 
contents.  
Body weight m ust be measured in fasting state. If the participant is not fast ing, the 
participant shoul d be called in for a new visit wit hin the visit window to have the fast ing 
body weight m easured.
Step 1.Ask the participant to empt y their pockets, rem ove their footwear, outerwear (coat, 
jacket, etc.), and any  headgear (li ght headgear worn for religious reasons can remain, but this 
should be worn by  the partic ipant at every  clinic visi t when weight i s measured).
Step 2.Make sure the scale is placed on a firm, flat, even surface (not on carpet, on a sloping 
surface, or a rough, uneven surface).
Step 3.Ask the participant to step onto the scale wit h 1 foot on e ach side of the scale.
Step 4.Ask the participant to stand still wit h arms by sides and then record wei ght in kilograms 
to the nearest one- tenth kilogram.
Measuring Waist Circumference
Waist circumference should be measured in the horizontal plane and at the midpoint 
between the lower margin o f the last palpable rib and the top of the iliac crest .
CONFIDENTIAL I8F-MC-GPHL
104Measurements should be taken at the end of a normal expirat ion using a nonstretchable 
measuring tape. The tape should lie flat against the skin without compressi ng the soft 
tissue.
The waist circumference should be measured twice, rounded to the nearest 0.5 cm. The 
measuring tape should be removed between the 2 measurements. Both measurements 
will be recorded in the eCRF. If the difference between the 2 measuremen ts exceeds 
1cm, this set of measurements should be discarded and the 2 measurements repeated.
Step 1: Ask the participant to wear litt le clothing (if available, garments could also be used).
Step 2: Ask the participant to stand with their feet close toget her, arms at their side, body  weight 
evenly distributed.
Step 3: Ask the participant to relax and measure the participant’s waist circumference.
Vital Sign Measurements
Vital sign measurements (blood pressure and heart rate, measured by pulse) should be 
taken before obtaining an ECG tracing and before collect ion of blood samples for 
laboratory  testing.
The participant shoul d sit quietly for 5 minutes before vital signs measurements are 
taken.
For each parameter, 2 measurements will be taken using the same a rm, preferably the 
nondominant arm .
The recordings should be taken at least 1 minute apart. Each measurement of sitting pulse 
and BP needs to be recorded in the eCRF.
BPmust be taken with an automated blood pressure instrument .
If blood pressure and pulse measurements are taken separately, pulse should be taken 
prior to blood pressure .
Note:In the event pulse measurement cannot be taken via an automated blood pressure 
instrument, the preferred location for measurement of pulse is the radial artery . 
Electrocardiogram
All digital ECGs will be obtained using centrally provided ECG machines and will be 
electronically transmitted to a designated central ECG laboratory .
12-lead ECGs should be obtained after the subject has rested in a supine posit ion for at 
least 10 minutes.
Electrocardiograms should be co llected at least 30 minutes prior to collection of blood 
samples for laboratory  testing, including PK samples.
CONFIDENTIAL I8F-MC-GPHL
10510.8. Appendix 8: Suggested Visit Structure
Abbreviations: AE = adverse event; ECG = electrocardiogram; PRO = patient reported outcome; SOA = schedule of 
activities.

CONFIDENTIAL I8F-MC-GPHL
10610.9.Appendix 9: Management of Gastrointestinal Symptoms
Abbreviations: GI = gastrointestinal; IWRS = interactive web -response sy stem

CONFIDENTIAL I8F-MC-GPHL
10710.10.Appendix 10: World Health Organization Classification of Diabetes 
and Diagnostic Criteria
Type 1 Diabetes: Type 1 diabetes i s judged to be present when the classical symptoms of 
diabetes (thi rst, polyuri a, wasting and stupor, or coma) are associated with readily detectable 
concentrations of glucose and ketone bodi es in the blood and urine. Insulin treatment is 
necessary  not only to control  hyperglycemia but also to prevent spontaneous ketosis and death.
Type 2 Diabetes: Type 2 diabetes, although often asymptomat ic, may also present with classica l 
hyperglycemic symptoms (thirst, polyuria, weight loss), but despite hyperglycemia, ketone 
bodies are present in only  low concentrati ons in the blood and urine. Coma is rare in t ype2 
diabetes, but m ay result from extreme hyperglycemia and hyperosmo larity; lactic acidosis or 
ketoacidosis can also occur in fulminat ing illness (for example, severe infect ion or mesenteric 
artery thrombosis) due to an acute increase in insulin requirements, but spontaneous ketosis does 
not occur. Some pat ients with type 2 diabetes later progress to a state of absolute insulin 
deficiency (Albert i and Zimmet 1998). 
CONFIDENTIAL I8F-MC-GPHL
10810.11.Appendix 11:Provisions for Changes inStudy 
Conduct DuringExceptional Circumstances
Implementation of this appendix
The changes to procedures described in this appendix are temporary  measures intended to be 
used only during specific time periods as directed by the sponsor in partnership wit h 
theinvestigator.
Exceptional circumstances
Exceptionalcircumstances are rare events thatmay cause disruptions to the conduct of the 
study.Examples include pandemics or natural disasters. These disruptions may limit the abilit y 
of the invest igators, participants, or both to attend onsite visits or to conduct planned study 
procedures.
Implementing changes under excep tional circumstances
In an except ional circumstance, after receiving the sponsor’s written approval, sites may  
implement changes if permitted by local regulat ions.
After approval by local ERBs, regulatory bodies,and any other relevant local authorities, 
implementation of these except ional circumstance changes will not ty pically requi re additional 
notification to these groups, unless they  have specific condi tions in which notificati on is requi red. 
To protect the safet y of study participants, urgent chang es may be implemented before approval 
but need to be reported as soon as possible. All approvals must be retained in the study  records.
If the sponsor grants written approval for changes in study  conduct, the sponsor will also provide 
additional written guidance, if needed.
Considerations for making a change
Theprevailing considerat ionfor making a change is ensuring the safet y of study 
participants.Additional important considerat ionsfor making a change are compliance wi th GCP, 
enabling participants to continue safely  in the study  and maintaining the integrity  of the study .
Informed Consent
Additional consent fro m the participant will be obtained, ifrequired, for:
participation in remote visits, as defined in Section “Remote Visits,”
dispensation ofadditional studyinterventionduringanextended treatment period,
alternatedelivery ofstudy interventionandancillary supplies, and
provision oftheirpersonalor medical information requiredprior to implementation of 
these activit ies.
Changes in Study Conduct During Exceptional circumstances
Changes in study  conduct not described in this appendix or not consistent with applicable local 
regulations, are not allowed.
The following changes in study  conduct will not be considered pro tocol deviations.
1.Remote visits
CONFIDENTIAL I8F-MC-GPHL
109In source documents andthe eCRF, the study  site should capture the visit method, with a 
specific explanat ion for the reason of conducting a remote visit instead of an onsite visit and 
for any data missing because o f missed in-person site visits .
Telemedicine:
Telephone or technology-assistedvirtual visits, orboth,are acceptable to 
completeappropriate assessments. Assessments to be co mpleted in this manner include, 
but are not limited to ,concomitantmedications, review of study  participant diary 
(including study  drug com pliance), review diet and exercise goals, C -SSRS (Since Last 
Visit Version), Self-Harm Supplement For m, Self-Harm Follow-up Form (if applicable), 
and PHQ-9.
Mobile healthcare:
Healthcarevisitsmay be performed by a mobile heal thcare provi deratlocations other 
than thestudy sitewhen parti cipants cannot travel to the site due toan except ional 
circumstance if written approval is provided by the sponsor. Procedures performed at
such visit sinclude, but are not limited to, weight and waist measurement s, physical 
assessments, vital signs , ECG, Patient Reported Outcome questionnaires administration , 
collection of blood samples and healt h information. 
Otheralternative locations:
Laboratory  draws may be doneat an alternate location in except ional circumstances .
Regardless of the ty pe of remote visits implemented, theprotocol requirements regarding the 
reporting of AEs, SAEs, and product complaints remain unchanged. Furthermore,every 
effort should be made to enable participantsto return to on -site visits as soon as reasonably  
possible, while ensuring the safet y ofboththe participants andthesitestaff.
2.Local laboratory testingoption
Locallaboratory testing m ay be conducted in lieu of central laboratory testing. The local 
laboratory  must be qualified in accordance with applicable local regulations.
3.Study intervention and ancillary supplies (including participant diaries)
When aparticipantisunable to gotothesite to receive studysuppliesduring norm al on-site 
visits, the site should work with the sponsor to determine appropriate actions. These 
actionsmayinclude:
askingtheparticipant togotothe siteandreceivestudysuppliesfromsite staff 
without completion of afull studyvisit
askingtheparticipant’s designee togotothe siteandreceivestudysupplies on 
aparticipant’s behalf,and
arranging deliveryof study supplies.
CONFIDENTIAL I8F-MC-GPHL
110Theserequirements m ustbe metbefore action is taken:
Alternatedelivery ofstudy interventionshould be perform ed in a manner that does 
not compromise treatm ent blinding and ensures product integrit y.The existing 
protocol requirements for product accountabilit y remain unchanged, including 
verification o f participant’s receipt of study  supplies.
Whendelivering supplies to a location other than the study  site (for 
example, participant’s hom e),theinvestigator,sponsor, or both should ensure 
oversight of the shipping process toensureaccountability and product qualit y (that is, 
storage condit ionsmaintained and intact packaging upon receipt).
Instructionsmaybe provided to the particip antor designee onthe final disposit ion 
ofanyunused or completedstudysupplies.
4.Screening period guidance
To ensure safet y of study participants, l aboratory values and other eligibilit y assessments 
takenprior to Visit 3are valid for a maximum of 90days.The following rules will be applied 
foractive, nonrando mizedparticipants whose participat ionin the study  must bepauseddue 
toexceptional circumstances:
If paused for less than90daysfromVisit 1 to Visit 3: The participant willproceed to 
the next study  visit per theusualSoA, provided thatVisit 3must be conducted 
within90days fromVisit 1.
oThe site should conductthe next visit ifthe participant’seligibility 
criteriaareconfirmed, andthe site shoulddocument thereason for delayin 
theCRF.
oDue to the pause in screening, sites should also reconfirm the impacted 
participant’s consent and document this confirmat ion in the source 
documentation.
If paused for more than 90days from Visit 1 to Visi t 3: The participant must be 
discontinued because of screening interruption due to an except ional circumstance.   
This is documented as a screen fail urein the CRF .The participant can reconsent and 
be rescreened as a new participant. The screening procedures per the usual SoA 
should be followed,starting at Visit 1to ensure parti cipant eligibilit y byVisit 3.
5.Adjustments to Visit Windows
Whenever possible and safe to do so, as determined by the investigator’s discretion, 
participants shoul dcomplete the usual SoA.Tomaximize the possibility that these visits can 
be conducted as on-site visits, the windows for visitsmay beadjusted,uponfurtherguidance 
from the sponsor. This minimizes missing data and preserves the intended conduct of the 
study.
Primary endpo int visit (Visit 21 or 99) shoul d be completed as per ori ginal schedule 
whenever possible and safe to do so. However, the visit windows may be brought forward no 
sooner than 14 day s or extended up to 28 day srelative to the target visit date .
Forparticipants whose visits have extended windows, additional study interventionmay need 
tobe provided to avoidinterruption and maintainoverall integrity of thestudy.
CONFIDENTIAL I8F-MC-GPHL
111Documentation
Changes to study  conduct will be docum ented:
Sites will ident ify and document the details o f how participants, visits t ypes, and 
conducted activit ies were affected by except ional circumstances. 
Dispensing/shipment records of study  intervention and relevant communicat ions, 
including delegat ion, should be filed with site study records .
Source documents generated at a location other than the study site should be part of 
the investigator’s source doc umentation and should be transferred to the site in 
asecure and timely manner.
CONFIDENTIAL I8F-MC-GPHL
11210.12. Appendix 12: Abbreviations
Term Definition
ADA antidrug antibod y
AE adverse event : Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relationship with this treatment . An adverse event can therefore be any unfavorable and 
unintended sign (including an ab normal laboratory finding), symptom, or disease 
temporally  associated with the use of a medicinal (investigational) product, whether or 
not related to the medicinal (investigational) product.
AESI adverse event of special interest
AHM antihyperglycemicmedications
ALP alkaline phosphatase
ALT alanine aminotransferase
ANCOVA analysis of covariance
AST aspartate aminotransferase
BG blood glucose
BMI body mass index
BMR basal metabolic rate
CEC clinical endpoint committee
CFR Code of Federal Regulations
CHF congestive heart failure
CIOMS CouncilforInternational Organizations ofMedicalSciences
CK creatine kinase
CKD-EPI Chronic Kidney Disease-Epidemiology
CONSORT Consolidated Standards of Reporting Trials 
complaint A complaint is any written, electro nic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
compliance Adherence to all study -related, GCP, and applicable regulatory requirements.
CONSORT Consolidated Standards of Reporting Trials
CONFIDENTIAL I8F-MC-GPHL
113CRF case report form
CRP clinical research physician : Individual responsible for the medical conduct of the study . 
Responsibilities of the CRP may be performed by a physician, clinical research 
scientist, global safety physician or other medical officer.
CSR clinical study report
C-SSRS Columbia -Suicide Severity Rating Scale
CT computed tomography
CTA Clinical Tr ial Agreement
DNA deoxyribonucleic acid
DPP-4 dipeptidyl-peptidase -4
EAS efficacy analysis set
ECG electrocardiogram
eCRF electronic case report form
ED early discontinuation
EDC electronic data capture
eGFR estimated glomerular filtration rate
EMA European Medicines Agency
enroll The act of assigning a participant to a treatment . Participantswho are enrolled in the 
study are those who have been assigned to a treatment.
enter Participantsentered into a study are those who sign the informed consent form directly 
or through their l egally acceptable representatives.
ERB ethical review board
FAS full analy sis set
FDA Food and Drug Administration
FSH follicle-stimulating hormone
GCP good clinical practice
GGT gamma-glutamyltransferase 
GI gastrointestinal
GIP glucose-dependent insulinotropic polypeptide
CONFIDENTIAL I8F-MC-GPHL
114GIPR glucose-dependent insulinotropic polypeptide receptor
GLP-1 glucagon-like peptide -1
GLP-1R glucagon-like peptide -1 receptor
HbA1c hemoglobin A1c
HDL high-density lipoprotein
HIPAA Health Insurance Portability and Accountability Act
HRT hormonal replacement therapy
HRQoL health-related quality of life
IB Investigator’s Brochure
ICF informed consent form
ICH The International Council for Harmoni zation of Technical Requirements for 
Pharmaceuticals for Human Use
informed consent A process by which a patientvoluntarily confirms his or her willingness to participate 
in a particular study, after having been informed of all aspects of the study that are 
relevant to the patient’sdecision to participate . Informed consent is documented by 
means of a written, signed and dated informed consent form .
INR internatio nal normalized ratio
interim analysis An interim analysis is an analysis of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is created/locked.
IP Investigational product; a pharmaceutical form of an active ingredient or placebo being 
tested or used as a reference in a clinical trial, including products already on the market 
when used or assembled (formulated or packaged) in a way different from the 
authorized form, or market ed products used for an unauthorized indication, or marketed 
products used to gain further information about the authorized form.
IRB/IEC Institutional Review Boards /Independent Ethics Committees 
IWQOL-Lite-CT Impact of Weight on Quality of Life -Lite-Clinical Trials Version
IWRS interactive web -response sy stem
LDL low-density lipoprotein
MAD multiple ascending dose
MDD Major Depressive Disorder
MedDRA Medical Dictionary for Regulatory Activities
MEN multiple endocrine neoplasia
CONFIDENTIAL I8F-MC-GPHL
115MHP mental health professional
mITT modified intent -to-treat
MMRM mixedmodel for repeated measures
MRI magnetic resonance imaging
MTC medullary thyroid carcinoma
NAFLD nonalcoholic fatty liver disease
NYHA New York Heart Association
p-amylase pancreatic amylase
PC product complaint
PGIs Patient Global Impression of status for physical activity
PHQ-9 Patient Health Questionnaire -9
PK/PD pharmacokinetics/pharmacodynamics
PRO patient-reported outcome
QW once weekly
SAD single ascending dose
SAE serious adverse event
SAP statistical analysis plan
SBP systolic blood pressure
SC subcutaneous
screen The act of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study. 
SD standard deviation
SF-36 v2 ShortForm-36 Health Survey (SF -36), version 2 acute form
SGLT sodium-glucose cotransporter
SMBG self-monitoring of blood glucose
SoA Schedule of Activities
SS safety analysis set
SSRI selective serotonin reuptake inhibitor
CONFIDENTIAL I8F-MC-GPHL
116T1DM Type 1 diabetes mellitus
T2DM Type 2 diabetes mellitus
TBL total bilirubin level
TE treatment-emergent
TE ADA+ treatment -emergent antidrug antibody positive
TEAE treatment-emergent adverse event : An untoward medical occurrence that emerges 
during a defined treatment period, having been absent pretreatment, or worsens relative 
to the pretreatment state, and does not necessarily have to have a causal relationship 
with this treatment.
TEE total energy expenditure
THC tetrahydrocannabinol
TSH thyroid-stimulating hormone
ULN upper limit of normal
WHO World Health Organization
CONFIDENTIAL I8F-MC-GPHL
11711. References
[ADA]. Glycemic targets: s tandards of medical care in diabetes -2020. Diabetes Care .
2020;43(suppl 1):S66 –S76.https://doi.org/10.2337/dc20 -S006
Alberti, K.G. and Zimmet, P.Z. (1998) Definit ion, Diagnosis and Classificat ion of Diabetes 
Mellitus and Its Complications. Part 1: Diagnosis and Classification o f Diabetes Mellitus 
Provisional Report of a WHO Consultat ion. Diabetic Medicine, 15, 539 -553.
http://doi.org/ 10.1002/(SICI)1096- 9136(199807)15:7<539::AID -DIA668>3.0.CO;2 -S
[AMA].American Medical Association House of Delegates resolution: 420 (A -13):
recognition of obesity as a disease. May 2013. Accessed May 21, 2020. 
https://media.npr.org/documents/2013/jun/ama -resolution-obesity.pdf
Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmaco logical management of obesit y: an 
endocrine societ y clinical pract ice guideline . J Clin Endocrinol Meta b. 2015;100(2):342 -362.
https://doi.org/10.1210/j c.2014-3415
Aroda VR, Ratner R. The safety and tolerability of GLP-1 receptor agonists in the treatment of 
type 2 diabetes: a review. Diabetes Metab Res Rev . 2011;27(6):528 -542. 
https://doi.org/10.1002/dmrr.1202
Baggio LL, Drucker DJ. Bi ology of incretins: GLP -1 and GIP. Gastroenterol ogy. 
2007;132(6):2131 -2157. https://doi.org/ 10.1053/j.gastro.2007.03.054
Banks PA, Freeman ML , Practice Parameters Committee of the American Co llege of 
Gastroenterology. Practice guidelines in acute pancreatit is. Am J Gastroenterol.
2006;101(10):2379 -2400.https://doi.org/10.1111/j.1572 -0241.2006.00856.x
Coskun T, Sl oop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP -1 receptor 
agonist for the treatme nt of type 2 diabetes mellitus: from discovery  to clinical  proof of 
concept. Mol Metab . 2018;18:3-14.https://doi.org/10.1016/j .molmet.2018.09.009
Council on Science and Public Health. Report of the Council on Science and Public Healt h:is 
obesity a disease? ( Resolution 115-A-12): R eport number: 3 -A-13. 2013. Accessed May 21, 
2020.https://www.ama -assn.org/si tes/ama-assn.org/files/corp/media -browser/public/about-
ama/councils/Council%20Reports/council -on-science-public-health/a13csaph3.pd f. 
Danne T, Philotheou A, Goldman D, et al. A randomized trial co mparing the rate of 
hypoglycemia –assessed using continuous glucose monitoring –in 125 preschool children 
with type 1 diabetes treated with insulin glargine or NPH insulin (the PRESCHOOL s tudy). 
Pediatr Diabetes . 2013;14(8):593 -601. https://doi/ 10.1111/pedi.12051
DaviesMJ,D’Alessio DA,FradkinJ,etal.Managem ent of hyperglycemia in type 2 diabetes, 
2018. A consensus report by the American Diabetes Associat ion (ADA) and the European 
Association for the Study  of Diabetes (EASD). Diabetes Care2018;41(12):2669-2701.
https://doi.org/10.2337/dci18-0033
Dolan P. Modeling valuations for EuroQol healt h states. Med Care .1997;35(11):1095 -1108. 
https://doi/10.1097/00005650-199711000-00002
CONFIDENTIAL I8F-MC-GPHL
118Dombrowski SU, Knittle K, Avenell A , et al.Long-term maintenance of weight loss wit h non-
surgical interventi ons in obese adults: systemat ic review and meta -analyses of rando mised 
controlled trials. BMJ. 2014;348:g2646. https://doi.org/ 10.1136/bmj.g2646
[EMA].Guideline on clinical evaluation of medicinal products used in weight management.
EMA/CHMP/311805/2014. Published June 23, 2016. Accessed May 22, 
2020https://www.ema.europa.eu/en/docu ments/scientific-guideline/guideline -clinical-
evaluation-medicinal -products-used-weight-management -revision-1_en.pdf. Published 23 June 
2016.
EuroQol Research Foundat ion. EQ-5D-5L User Guide, Version 3.0. Updated September 2019. 
Accessed March 13, 2020. https://euroqol.org/publicat ions/user-guides.
[FAO/WHO/UNU] Food and Agriculture Organization of the United Nat ions/World Health 
Organizat ion/United Nations Universit y. Human energy  requirements: report of a joint 
FAO/WHO/UN Uexpert consul tation. Published October 2004 Accessed May 21, 
2020.http://www.fao.org/3/y5686e/y5686e00.ht m. 
[FDA]. Guidance for industry : developing products for weight management. Published February 
2007. Accessed May 22, 2020. https://www.fda.gov/media/71252/download .
[FDA].FDA requests the wi thdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) 
from the market: potential risk of cancer outweighs the benefit s. Published 14January 2020. 
Accessed June 5, 2020.  https://www.fda.gov/media/135189/download . 
Frias JP, Nauck MA, Van J, et al. Efficacy and safety  of LY3298176, a novel dual GIP and 
GLP-1 receptor agonist, in pat ients with type 2 diabetes: a randomized, placebo -controlled and 
active comparator-controlled phase 2 trial. Lancet.2018;392 (10160):2180-2193.
https://doi.org/10.1016/S0140 -6736(18)32260-8
Ganguly R, Tian Y, Kong SX, et al. Persistence of newer ant i-obesity medications in a real -
world setting. Diabetes Res Clin Pract. 2018;143:348-356. 
https://doi.org/10.1016/j .diabres.2018.07.017
Gerstein HC, Co lhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 
2 diabetes (REWIND): a double -blind, randomized placebo -controlled trial. Lancet. 
2019;394(10193):121 -130. https://doi.org/ 10.1016/S0140 -6736(19)31149 -3
Goldstein DJ. Beneficial healt h effects of modest weight loss. Int J Obes Relat Metab Disord . 
1992;16(6):397 ‐415. 
Jensen MD, Ryan DH, Donato KA, et al. Executive summary: guidelines (2013) for the 
management of overweight and obesit y in adults: a report of the American College of 
Cardiology/American Heart Associat ion Task Force on Practice Guidelines and the Obesit y 
Society published by the Obesit y Society and Ameri can College of Cardio logy/American 
Heart Associ ation Task Force on Practice Guidelines. based on a systemat ic review from the 
Obesity Expert Panel , 2013. Obesity.2014;22(suppl 2):S5 -S39. 
https://doi.org/10.1002/oby .20821
Koizumi M, Takada T, Ka warada Y, et al.JPN guidelines for the management of acute 
pancreatitis: diagnostic criteria for acute pancreatitis. J Hepatobiliary Pancreat Surg . 
2006;13(1):25 -32.https://doi.org/10.1007/s00534 -005-1048-2
CONFIDENTIAL I8F-MC-GPHL
119Kolotkin RL, Ervin CM, Meincke HH, et al. Development of a clinical trials versio n of the 
impact of weight on qualit y of life-lite questionnaire (IWQOL -Lite clinical tri als version): 
results from two qualitat ive studies. Clin Obes. 2017;7(5):290 -299. 
https://doi.org/10.1111/cob.12197
Kolotkin RL, Williams VSL, Ervin CM, et al. Validation of a new measure of qualit y of life in 
obesity trials: impact of weight on qualit y of life-lite clinical trials versio n. Clin Obes. 
2019;9(3):e12310. https://doi.org/10.1111/cob.12310
Lauby-Secretan, B, Scocci anti C, Loomis D, et al. ; Internati onal Agency for Research on Cancer 
Handbook Working Group. Body fatness and cancer -viewpoint of the IARC Wor king Group. 
N Engl J Med. 2016;375 (8):794-798. https://doi.org/10.1056/NEJMsr1606602
Luppino FS, de Wit LM, Bouvy  PF, et al. Overweight, obesit y, and depressio n: a systemat ic 
review and meta -analysis of lo ngitudinal studies. Arch Gen Psychiatry. 2010;67(3):220 -229.
https://doi.org/10.1001/archgenpsychiatry .2010.2.
Marso SP, Bain SC, Conso li A, et al. Semaglutide and cardi ovascular outcom es in patients with 
type 2 diabetes. N Engl J Med .2016a;375(19):1834 -1844. 
https://doi.org/10.1056/NEJMoa1607141
Marso SP, Daniels GH, Brown -Frandsen K, et al. Liraglut ide and cardiovascular outcomes in 
type 2 diabetes. N Engl J Med .2016b;375(4):311- 322. https://doi.org/
10.1056/NEJMoa1603827
Maruish ME, ed. User’s Manual for the SF -36v2 Health Survey . 3rd ed. Lincoln, RI: Qualit y 
Metric Incorporated; 201 1.
Müller TD, Clemmensen C, Finan B, et al. Anti-obesity therapy: from rainbow pills to 
polyagonists. Pharmacol Rev . 2018;70(4):712 ‐746. https://doi.org/10.1124/pr.117.014803
Nauck MA, Meier JJ, Schmidt WE. Incretin -based glucose -lowering medicat ions and the risk o f 
acute pancreatit is and/or pancreati c cancer: reassuring data from ca rdio-vascular outcome 
trials. Diabetes Obes Metab . 2017;19(9):1327- 1328.https://doi.org/10.1111/dom.12981
PastorsJG, Warshaw H,DalyA,et al. The evidence for the effectiveness of medical nutrition 
therapy in diabetes management. Diabetes Care.2002;25(3):608 -613.
https://doi.org/10.2337/diacare.25.3.608
Pi-SunyerFX.Weight loss in type 2 diabetic patients. Diabetes Care.2005;28(6):1526 -1527.
https://doi.org/10.2337/diacare.28.6.1526
Rothberg AE, McEwen LN, Kraftson AT, et al. Impact of weight loss on waist circumference 
and the components of the metabo lic syndro me. BMJ Open Diabetes Res Care . 
2017;5(1):e000341. https://doi.org/10.1136/bmjdrc -2016-000341
Ryan DH, Yockey  SR. Weight l ossand improvement in co morbidity: differences at 5%, 10%, 
15%, and over. Curr Obes Rep .2017;6(2):187 -194. https://doi.org/ 10.1007/s13679-017-
0262-y
SAXENDA [summary of product characterist ics].Bagsværd, Denmark: Novo Nordi sk, 2015. 
SAXENDA  [package insert].Bagsvaerd, Denmark: Novo Nordisk; 2014 .
CONFIDENTIAL I8F-MC-GPHL
120Skow MA, Bergman NC, Knop FK. Diabetes and obesit y treatment based on dual incretin 
receptor acti vation: “twincret ins”. Diabetes Obesity Metab. 2016;18(9):847-854.
https://doi.org/10.1111/dom.12685
Srivastava G, Apovian C. Future pharmacotherapy for obesit y: new ant i-obesity drugs on the 
horizon.Curr Obes Rep. 2018a;7(2):147-161. https://doi.org/ 10.1007/s13679-018-0300-4 
Srivastava G, Apovian CM. Current pharmacotherapy  for obesity. Nat Rev Endocrinol. 
2018b;14(1):12 -24. https://doi.org/10.1038/nrendo.2017.122
Steinberg WM, Buse JB, Ghorbani MLM, et al.Amylase, lipase, and acute pancreat itis in people 
with type 2 diabetes treated with liraglut ide: result s from the LEADER randomized trial. 
Diabetes Care. 2017a;40(7):966 -972.https://doi.org/10.2337/dc16 -2747
Steinberg WM, Rosenstock J, Wadden TA, et al. Impact of liraglut ide on amylase, lipase, and 
acute pancreatit is in participants with overweight/obesity and norm oglycemia, predi abetes, or 
type 2 diabetes: secondary  analyses of pooled data fro m the SCALE clinical development 
program. Diabetes Care. 2017b;40(7):839 -848.https://doi.org/10.2337/dc16 -2684
Tomlinso n B, Hu M, Zhang Y, et al. An overview of new GLP -1 receptor agonists for ty pe 2 
diabetes. Expert Opin Investig Drugs . 2016;25(2):145 -158. 
https://doi.org/10.1517/13543784.2016.1123249
van Bloemendaal L, Ten Kulve JS, la Fleur SE, et al. Effects of glucagon -like peptide 1 on 
appetite and body  weight: focus on the CNS. J Endocrinol. 2014;221(1):T 1-T16. 
https://doi.org/10.1530/JOE -13-0414
UKPDS Group. UK Prospective Diabetes Study 7: response of fasting plasma glucose to diet 
therapy in newly present ing type II diabet ic patients. Metabolism. 1990;39(9):905 –912.
https://doi.org/10.1016/0026 -0495(90)90299-R
Weinberg ME, Bacchetti P, Rushakoff RJ. Frequent ly repeated glucose measurements 
overestimate the incidence of inpatient hy poglycemia and severe hyperglycemia. J Diabetes 
Sci Techno l. 2010;4(3):577 -582. https://doi .org/10.1177/193229681000400311
[WHO]. WHO STEPS surveillance manual: the WHO STEP wise approach to noncommunicable 
disease risk factor surveillance. Updated 26 January 2017. Accessed May 4, 2020. 
https://www.who.int/ncds/surveillance/steps/STEPS_Manual.pdf . 
Wing RR, Lang W, Wadden TA, e t al.; Look AHEAD Research Group. B enefits of modest 
weight loss in improving cardiovascular risk factors in overweight and obese individuals with 
type 2 diabetes. Diabetes Care . 2011; 34(7):1481‐ 1486. https://doi.org/ 10.2337/dc10 -2415 
Leo Document ID = 19b74ae5-962b-4a66-aa8c-fc057d6b206c
Approver: 
Approval Date & Time: 23-Nov-2020 21:00:11 GMT
Signature meaning: Approved
Approver: 
Approval Date & Time: 23-Nov-2020 21:39:12 GMT
Signature meaning: Approved
PPD
PPD